| Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents | Phase 3 | AstraZeneca | <1 mi |
| Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML | Phase 2 | Bio-Path Holdings, Inc. | <1 mi |
| E-Mindfulness Approaches for Living After Breast Cancer | Phase 3 | NRG Oncology | <1 mi |
| Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial | Phase 2 | NRG Oncology | <1 mi |
| Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease | Phase 2/3 | NRG Oncology | <1 mi |
| Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study | Phase 2/3 | National Cancer Institute (NCI) | <1 mi |
| Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab | Phase 3 | Alliance for Clinical Trials in Oncology | <1 mi |
| Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 | Phase 3 | NRG Oncology | <1 mi |
| Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer | Phase 2/3 | SWOG Cancer Research Network | <1 mi |
| Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer | Phase 3 | NRG Oncology | <1 mi |
| A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. | Phase 3 | Epizyme, Inc. | <1 mi |
| A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer | Phase 1/2 | Hoffmann-La Roche | <1 mi |
| Project: Every Child for Younger Patients With Cancer | — | Children's Oncology Group | <1 mi |
| ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study) | Phase 3 | Jazz Pharmaceuticals | <1 mi |
| The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study | Phase 1/2 | PedAL BCU, LLC | <1 mi |
| Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery | Phase 3 | NRG Oncology | <1 mi |
| Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy | Phase 3 | Children's Oncology Group | <1 mi |
| Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors | Phase 3 | Children's Oncology Group | <1 mi |
| Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma | Phase 3 | Karyopharm Therapeutics Inc | <1 mi |
| A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas | Phase 2 | Alliance for Clinical Trials in Oncology | <1 mi |
| Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT) | Phase 3 | Children's Oncology Group | <1 mi |
| Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma | Phase 3 | European Organisation for Research and Treatment of Cancer - EORTC | <1 mi |
| A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression | N/A | LivaNova | <1 mi |
| Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure | N/A | Procyrion | <1 mi |
| PROGRESS: Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVR | N/A | Edwards Lifesciences | <1 mi |
| REdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuRE | — | Medtronic Cardiovascular | <1 mi |
| Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG | Phase 3 | Icahn School of Medicine at Mount Sinai | <1 mi |
| Pivotal Study for the Cardiac Performance System (CPS) | — | Sensydia Corporation | <1 mi |
| Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation. | N/A | Medtronic Cardiovascular | <1 mi |
| A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS) | — | TG Therapeutics, Inc. | <1 mi |
| Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain | Phase 3 | NRG Oncology | <1 mi |
| A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer | Phase 3 | Daiichi Sankyo | <1 mi |
| JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer | Phase 3 | University of Texas Southwestern Medical Center | <1 mi |
| A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC | Phase 2 | Eikon Therapeutics | <1 mi |
| Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma | Phase 3 | Children's Oncology Group | <1 mi |
| Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer | Phase 2/3 | National Cancer Institute (NCI) | <1 mi |
| Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer | Phase 3 | NRG Oncology | <1 mi |
| Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial | Phase 3 | NRG Oncology | <1 mi |
| Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer | Phase 3 | Alliance for Clinical Trials in Oncology | <1 mi |
| Study of ABX-002 for the Adjunctive Treatment of Depressive Episodes Associated With Bipolar Disorder in Adults | Phase 2 | Autobahn Therapeutics, Inc. | <1 mi |
| OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events | Phase 3 | Amgen | <1 mi |
| Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer | Phase 3 | Canadian Cancer Trials Group | <1 mi |
| S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cell Lung Cancer | Phase 3 | SWOG Cancer Research Network | <1 mi |
| A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart | Phase 3 | Boehringer Ingelheim | <1 mi |
| A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure | Phase 3 | Boehringer Ingelheim | <1 mi |
| GORE® CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients With Patent Foramen Ovale (PFO): the REDUCE Post Approval Study | N/A | W.L.Gore & Associates | <1 mi |
| Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection | — | Alliance for Clinical Trials in Oncology | <1 mi |
| A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis) | Phase 3 | 89bio, Inc. | <1 mi |
| A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) | Phase 3 | Eli Lilly and Company | <1 mi |
| A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease | Phase 3 | AstraZeneca | <1 mi |
| A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD | Phase 3 | Annovis Bio Inc. | <1 mi |
| Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis | Phase 3 | Novartis Pharmaceuticals | <1 mi |
| A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA) | Phase 2 | atai Therapeutics, Inc. | <1 mi |
| Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products | — | Medtronic | <1 mi |
| Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction | Phase 3 | Cytokinetics | <1 mi |
| Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol | Phase 1 | NRG Oncology | <1 mi |
| Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial) | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer | Phase 3 | NRG Oncology | <1 mi |
| Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial) | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery | Phase 2 | ECOG-ACRIN Cancer Research Group | <1 mi |
| MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer | Phase 1/2 | National Cancer Institute (NCI) | <1 mi |
| Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer | Phase 4 | Takeda | <1 mi |
| A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer | N/A | NRG Oncology | <1 mi |
| Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin | Phase 3 | AstraZeneca | <1 mi |
| De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA) | Phase 3 | NRG Oncology | <1 mi |
| Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial | Phase 2/3 | National Cancer Institute (NCI) | <1 mi |
| Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer | Phase 3 | SWOG Cancer Research Network | <1 mi |
| Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer | Phase 3 | Curium US LLC | <1 mi |
| "A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder" | Phase 3 | Cybin IRL Limited | <1 mi |
| Study to Assess the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder | Phase 3 | Neumora Therapeutics, Inc. | <1 mi |
| Study to Assess the Safety and Effectiveness of NMRA-335140-501 | Phase 3 | Neumora Therapeutics, Inc. | <1 mi |
| A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3) | Phase 3 | Xenon Pharmaceuticals Inc. | <1 mi |
| Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder | Phase 3 | Vanda Pharmaceuticals | <1 mi |
| To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications | Phase 3 | Cerevance | <1 mi |
| Dose Reduction of Postoperative Radiation for Soft Tissue Sarcoma of the Arms and Legs | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Second Look Laparoscopy (SLL) in People With Ovarian Cancer Who Have Completed Their First Course of Chemotherapy | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study to Identify Barriers to Cellular Therapies for People With Plasma Cell Disorders | — | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma | Phase 1 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma | Phase 1 | Pfizer | <1 mi |
| A Study on Pain After Breast Reconstruction | N/A | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors | Phase 2 | AstraZeneca | <1 mi |
| A Study of Pembrolizumab and Radiation Therapy in People With Mesothelioma | Phase 1 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Photobiomodulation (PBM) Therapy in People With Oral Graft-Versus-Host Disease (GVHD) After Stem Cell Transplant | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Reduced Radiation Therapy With Chemotherapy in People With HPV-Positive Throat Cancer | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of ERAS-601 in People With Chordoma | Phase 1/2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Tucatinib and Trastuzumab in People With Rectal Cancer | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Tongue Strength and Endurance Using the Iowa Oral Performance Instrument (IOPI) Tongue Strength Trainer in People With Oral Tongue Cance | N/A | Memorial Sloan Kettering Cancer Center | <1 mi |
| Measuring Cell-Free DNA (cfDNA) Levels in People With Follicular Lymphoma | Phase 1 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Revumenib and Mezigdomide in People With Leukemia | Phase 1/2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| COBRA: Cancer, Older Adults, Balance and Resistance Activities | N/A | Memorial Sloan Kettering Cancer Center | <1 mi |
| Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of SER-155 to Treat Diarrhea in People on Immunotherapy | Phase 1 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Study of a Support Program for Quality of Life in Chinese Cancer Patients and Survivors | N/A | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Questionnaires in Adolescents and Young Adults With Cancer | — | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL) | Phase 1 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery | Phase 2 | ECOG-ACRIN Cancer Research Group | <1 mi |
| A Study of BV-AVD in People With Bulky Hodgkin Lymphoma | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC) | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Botensilimab and Balstilimab for Colorectal Cancer With ctDNA+ After Surgery and Chemotherapy | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Groningen International Study on Sentinel Nodes in Vulvar Cancer-III | Phase 2 | University Medical Center Groningen | <1 mi |
| A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC) | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of the Use of 3D Technology to Guide Head and Neck Surgery | N/A | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study Comparing Two Optical Coherence Tomography Devices in People With Ocular Tumors | N/A | Memorial Sloan Kettering Cancer Center | <1 mi |
| Using a Blood Test and Software Tool to Guide Treatment for Venous Thromboembolism | N/A | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Enfortumab Vedotin in People With Urothelial Carcinoma of the Upper Urinary Tract | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Imaging Acquisition and Analysis Methods for Optimization of MRI Radiation Oncology Simulation and Response Assessment | — | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST) | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Reduced Dose Radiation Therapy for People With B-Cell Lymphomas | Phase 3 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma | Phase 1 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Pasireotide in People With Prolactinoma | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Natural Killer Cells in Combination With Atezolizumab in People With Acute Myelogenous Leukemia | Phase 1 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Fluorescein Sodium in People Undergoing Vulvectomy for Extramammary Paget's Disease (EMPD) | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer | Phase 2/3 | NRG Oncology | <1 mi |
| Genomic Profiling in Cancer Patients | — | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Response to Standard Treatment Before Surgery in People With Rectal Cancer | N/A | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of ADCLEC.syn1 in People With Acute Myeloid Leukemia | Phase 1 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Open-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic Hematopoietic Cell Transplantation | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial | Phase 3 | Alliance for Clinical Trials in Oncology | <1 mi |
| A Study of Blood Based Biomarkers for Pancreas Adenocarcinoma | — | Memorial Sloan Kettering Cancer Center | <1 mi |
| Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy | Phase 3 | Alliance for Clinical Trials in Oncology | <1 mi |
| Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma | Phase 1/2 | Alliance for Clinical Trials in Oncology | <1 mi |
| Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study | Phase 3 | NRG Oncology | <1 mi |
| A Study of Stereotactic Body Radiotherapy and 177Lu-PSMA-617 for the Treatment of Prostate Cancer | Phase 1 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Acupuncture for People Experiencing Period Loss Due to Chemotherapy | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL) | Phase 1 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma | Phase 1/2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC) | Phase 1/2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Dara-RVd and Teclistamab-RVd in People With Multiple Myeloma | Phase 1/2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of MB-CART19.1 Cellular Therapy for People With Central Nervous System Lymphoma (CNSL) | Phase 1 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell Lymphoma | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| ctDNA Testing to Inform Standard-of-Care Treatment Decisions in People With Endometrial Cancer | N/A | Memorial Sloan Kettering Cancer Center | <1 mi |
| Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease | — | Memorial Sloan Kettering Cancer Center | <1 mi |
| Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL) | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial | Phase 3 | NRG Oncology | <1 mi |
| Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Germ Cell Tumor and Testicular Tumor DNA Registry | — | Memorial Sloan Kettering Cancer Center | <1 mi |
| Hyperpolarized C Pyruvate Magnetic Resonance Imaging, and Blood-Based Biomarkers for Early Detection of Pancreatic Adenocarcinoma in Patients With Intraductal Papillary Mucinous Neoplasms | — | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Multiparametric Ultrasound Imaging Methods | N/A | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE) | N/A | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer | Phase 1/2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, The ERASur Study | Phase 3 | Alliance for Clinical Trials in Oncology | <1 mi |
| Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies | Phase 1/2 | Effector Therapeutics | <1 mi |
| Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer | Phase 3 | NRG Oncology | <1 mi |
| A Study Collecting Health Information to Understand and Prevent Gastric Cancer | — | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study Evaluating the Use of an Indoor Air Quality Monitor to Promote a Smoke-free Home | N/A | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Herbal Supplements in Cancer Survivors With Constipation | N/A | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Tarlatamab for People With Prostate Cancer | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Botensilimab and Balstilimab for Rectal Adenocarcinoma | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study Testing Topical Pain-Relieving Herbal Plasters in People Who Are Using Opioids for Their Pain | Phase 1 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer | Phase 3 | Seagen, a wholly owned subsidiary of Pfizer | <1 mi |
| A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes | Phase 1 | National Cancer Institute (NCI) | <1 mi |
| A Study of 2141-V11 in Combination With Standard Treatments in People With Prostate Cancer | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL) | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Intracavitary Carrier-embedded Cs131 Brachytherapy for Recurrent Brain Metastases: a Randomized Phase II Study | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Pembrolizumab, Olaparib, and Temozolomide for People With Glioma | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Obecabtagene Autoleucel in People With B-cell Acute Lymphoblastic Leukemia | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Reduced-dose Radiation in People With Metastatic Tumors With a Genetic Change | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer | Phase 1 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Glioma Developmental and HyperActive Ras Tumor (DHART) Board | — | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of CRD3874-SI in People With Solid Tumors | Phase 1 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders | — | Memorial Sloan Kettering Cancer Center | <1 mi |
| Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| A Study of Neuropathy Caused by Enfortumab Vedotin in People With Urothelial Carcinoma | — | Memorial Sloan Kettering Cancer Center | <1 mi |
| Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma | Phase 1 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Impact of ICCAN on Cancer Treatment Completion and Quality of Life | — | Memorial Sloan Kettering Cancer Center | <1 mi |
| Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma | Early 1 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Kidney Cancer DNA Registry | — | Memorial Sloan Kettering Cancer Center | <1 mi |
| Collection of Information to Better Understand Young Onset Colorectal Cancer | — | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments | Phase 3 | Pfizer | <1 mi |
| A Study of Azacitidine and Venetoclax Versus a Stem Cell Transplant in People 65 Years and Older With Acute Myeloid Leukemia | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL) | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC | Phase 2 | Genentech, Inc. | <1 mi |
| A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer | N/A | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS) | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer | Phase 1 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Collecting Information About Treatment Results for Patients With Cushing's Syndrome | — | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Ivonescimab in People With Endometrial and Cervical Cancers | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties | N/A | Memorial Sloan Kettering Cancer Center | <1 mi |
| Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations | Phase 2 | Alliance for Clinical Trials in Oncology | <1 mi |
| Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas | Phase 2 | Dana-Farber Cancer Institute | <1 mi |
| A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL) | Phase 1 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Avutometinib (VS-6766) and Defactinib in People With Mesonephric Gynecologic Cancer | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Isoquercetin in People With Ovarian Cancer | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer | Phase 3 | Canadian Cancer Trials Group | <1 mi |
| A Study Comparing a Plant-Based Diet With Supplements and Placebo in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM) | N/A | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia (AML) | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS) | N/A | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Short-Course Radiation Therapy With Chemotherapy in People With Endometrial Cancer | Early 1 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Intra-operative Imaging in Women With Ovarian Cancer | Phase 3 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study on the Effects of Exercise on Side Effects From Treatment for Gastrointestinal Cancers | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Pembrolizumab in People With Ultra-Rare Sarcomas | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| An Intervention to Increase Genetic Testing in Families Who May Share a Gene Mutation Related to Cancer Risk and An Intervention to Help Patients and Their Primary Care Providers Stay Up-to-date About Uncertain Genetic Test Results | N/A | Memorial Sloan Kettering Cancer Center | <1 mi |
| Ulixertinib in People With Histiocytic Neoplasms | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Dietary Study for People With Multiple Myeloma | N/A | Memorial Sloan Kettering Cancer Center | <1 mi |
| Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer | N/A | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Enfortumab Vedotin in People With Adenoid Cystic Carcinoma | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Opportunistic Salpingectomy to Prevent Ovarian Cancer | N/A | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Avutometinib and Defactinib in People With Thyroid Cancer | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Meaning-Centered Psychotherapy for Caregivers to People With Cancer | N/A | Icahn School of Medicine at Mount Sinai | <1 mi |
| A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study Comparing Personalized Radiation Therapy With Standard Radiation Therapy in People With HPV-Positive Throat Cancer | Phase 3 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Deferoxamine (DFO) in People With Leptomeningeal Metastasis | Phase 1 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Sotorasib in People With Brain Tumors | Phase 1 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Decreasing Radiation Therapy and Chemotherapy in People With Head and Neck Cancer | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers | Phase 2 | NRG Oncology | <1 mi |
| A Study of Radiation Therapy After Surgery in People With Oral Tongue Squamous Cell Carcinoma | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1 | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment | Phase 1 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Assessment of Healing and Function After Reconstruction Surgery for Bone Sarcomas | — | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Ruxolitinib and Duvelisib in People With Lymphoma | Phase 1 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia | Phase 1 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Registry Study of People Who Are Having an Esophagectomy and Are at High Risk of Anastomotic Leak | — | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of 177Lu-PSMA-617 in People With Gliomas | Phase 1 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML) | Phase 1 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Discovering New Genetic Markers in Adults and Children Who May Be At Risk for Hereditary Forms of Cancer | — | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Multiparametric Ultrasound Imaging (mpUS) for People With Endometrial Cancer | N/A | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Surgical Techniques During Cystectomy | Phase 3 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Changes in Reproductive and Sexual Health in People With Early Onset Colorectal Cancer | — | Memorial Sloan Kettering Cancer Center | <1 mi |
| Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma | — | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Stereotactic Body Radiation Therapy (SBRT) Without Androgen Deprivation Therapy (ADT) in People With Unfavorable Intermediate-Risk Prostate Cancer | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30) | Phase 1 | Pfizer | <1 mi |
| Reflectance Confocal Microscopy of Oral Cancers in Vivo: a Preliminary Trial Comparing Intra-oral Imaging With Pathology | — | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2 | Phase 2 | Seagen, a wholly owned subsidiary of Pfizer | <1 mi |
| DESCANSO, a Mental Health Intervention for Depression, Insomnia, and Fatigue Symptoms in Latino People With Cancer | N/A | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of a Weight Loss Intervention in People With Endometrial Cancer | Early 1 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Study Assessing the Effects of Early Psychiatric Referral on Mental Health and Quality of Life in People With Sarcoma | N/A | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of an Anxiety Intervention for Latino/Latina/Hispanic Older Adults With Cancer and Their Caregivers | N/A | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of an Alternative Treatment Approach (Preoperative Radiotherapy, Then Mastectomy, Then Immediate Reconstruction Surgery) in People With T4 Breast Cancer | Phase 1 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study to Prevent and Improve Sexual Health Concerns for People With Breast Cancer | N/A | Memorial Sloan Kettering Cancer Center | <1 mi |
| Enhanced Pain Coping in Cancer (EPIC): A Study of Managing Treatment-Related Joint Pain in Breast Cancer Survivors | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Antibiotic Delivery to Prevent Infection After Breast Tissue Expander Placement | Phase 4 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Lymphedema Surveillance Study | — | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Observational Study of Bone Complications in People With Post-menopausal Breast Cancer Who Have Stopped Treatment With Denosumab and Aromatase Inhibitors | — | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer | Phase 1 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Serum Biomarkers to Characterize the Effects of Therapy on Ovarian Reserve in Premenopausal Women With Early-stage Breast Cancer or BRCA Mutations | — | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Surgery and Radiotherapy in People With Breast Cancer | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Registry for People With T-cell Lymphoma | — | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Pembrolizumab and Cryoablation in People With Breast Cancer | Phase 1 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors | Phase 2 | Seagen, a wholly owned subsidiary of Pfizer | <1 mi |
| A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of a One-Time Counseling Session to Help Reduce Depression, Anxiety, and Distress in People With Breast Cancer | N/A | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer | Phase 3 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Language Interpretation Solutions for People With Breast Cancer | N/A | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Changes in Thinking Related to Aging and Cancer in Breast Cancer Survivors (TRAC) | — | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study Comparing Cancer Imaging Approaches in People With Lobular Breast Cancer | — | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer | Phase 1 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Gabapentin And Breast Surgery Decision Architecture Randomization Trial (GABS-DART) Protocol | Phase 4 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Blood Pressure Control During Cancer Treatment | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer | Phase 3 | NRG Oncology | <1 mi |
| Factors Associated With Breast Cancer Risks and Outcomes | — | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Revaree Plus in People With Breast Cancer | Phase 4 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma | — | Memorial Sloan Kettering Cancer Center | <1 mi |
| Bupivacaine vs Placebo for Unilateral Mastectomy Surgical Site Post-operative Pain Control | Phase 3 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Talking to Employers and Medical Staff About Breast Cancer Treatment and Your Job | N/A | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer | Phase 1/2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of a Decision Tool for People Considering Breast Reconstruction Surgery | N/A | Memorial Sloan Kettering Cancer Center | <1 mi |
| Study of Aerobic Training for People Receiving Chemotherapy for Breast Cancer | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| MATCH-UP: MAking Telehealth-Delivery of Cancer Care at Home Effective and Safe-Upscaled: A Pragmatic Cluster Randomized Trial | N/A | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Registry for People With Lung Cancer | — | Memorial Sloan Kettering Cancer Center | <1 mi |
| Using E-Nose Technology to Measure Response to Treatment in People With Malignant Pleural Mesothelioma | N/A | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Intensity-Modulated Pleural Radiation Therapy (IMPRINT) in People With Thymic Cancer That Has Spread to the Lining of the Lungs and Chest | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Using Urine Samples to Identify Lung Cancer | — | Memorial Sloan Kettering Cancer Center | <1 mi |
| Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1 | Phase 3 | Summit Therapeutics | <1 mi |
| A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002) | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial) | Phase 2 | SWOG Cancer Research Network | <1 mi |
| A Study of Stereotactic Radiosurgery (SRS) and Standard Treatment in People With Lung Cancer That Has Spread to the Brain | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors | Phase 1 | Pfizer | <1 mi |
| Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer | Phase 1/2 | National Cancer Institute (NCI) | <1 mi |
| A Study of Tumor-Treating Fields (TTFields) in People With Lung Adenocarcinoma | Phase 1 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Using E-Nose Technology to Track Treatment Response in People With Non-Small Cell Lung Cancer | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Extracellular Vesicles and Particles (EVP) as Biomarkers of Recurrence in Non-Small Cell Lung Cancer | — | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of ZEN003694 in People With Squamous Cell Lung Cancer | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations. | Phase 1 | Pfizer | <1 mi |
| A Study of Sacituzumab Govitecan in People With Mesothelioma | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of CD8+ T Cell Imaging During Treatment in People With Non-Small Cell Lung Cancer | Phase 1 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Hospital-at-Home for People Receiving Tarlatamab | N/A | Memorial Sloan Kettering Cancer Center | <1 mi |
| Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer | Phase 1/2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Sotorasib in People With Non-Small Cell Lung Cancer | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue | N/A | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Valemetostat in Combination With Atezolizumab in People With Lung Cancer | Phase 1 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial | Phase 3 | NRG Oncology | <1 mi |
| A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Disease | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Lung Cancer Screening in People With Unexplained Weight Loss | — | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial | Phase 3 | ECOG-ACRIN Cancer Research Group | <1 mi |
| A Study of Single Fraction Stereotactic Body Radiation Therapy (SBRT) Guided by Magnetic Resonance Imaging (MRI) in People With Liver Metastasis From Colorectal Cancer | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Study of Radiotherapy and Pembrolizumab in People With Adrenocortical Carcinoma | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer | Phase 3 | Janssen Research & Development, LLC | <1 mi |
| Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) | Phase 2/3 | BicycleTx Limited | <1 mi |
| Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells | Phase 2/3 | Celgene | <1 mi |
| A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01) | Phase 2 | Daiichi Sankyo | <1 mi |
| A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma | Phase 3 | Janssen Research & Development, LLC | <1 mi |
| Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL | Phase 2 | Allogene Therapeutics | <1 mi |
| A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy | Phase 3 | Janssen Research & Development, LLC | <1 mi |
| A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Phase 3 | BeOne Medicines | <1 mi |
| Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2 | Phase 3 | AstraZeneca | <1 mi |
| A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | Phase 3 | Celgene | <1 mi |
| A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease | Phase 1 | Allogene Therapeutics | <1 mi |
| Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) | Phase 3 | Gilead Sciences | <1 mi |
| Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer | Phase 1/2 | Stemline Therapeutics, Inc. | <1 mi |
| A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer | Phase 3 | Hoffmann-La Roche | <1 mi |
| SLV-154 Treatment of Metastatic Solid Tumors | Phase 1 | Solve Therapeutics | <1 mi |
| A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer | Phase 1 | Stemline Therapeutics, Inc. | <1 mi |
| A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03) | Phase 1/2 | Daiichi Sankyo | <1 mi |
| ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation | — | Guardant Health, Inc. | <1 mi |
| Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors | Phase 1 | Exelixis | <1 mi |
| Nipocalimab in Moderate to Severe Sjogren's Disease | Phase 3 | Janssen Research & Development, LLC | <1 mi |
| LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve | Phase 1/2 | enGene, Inc. | <1 mi |
| Comparing Radiation Therapy to Usual Care for Patients With High-Risk Bone Asymptomatic Metastases, PREEMPT Trial | Phase 3 | NRG Oncology | <1 mi |
| Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma | Phase 3 | ECOG-ACRIN Cancer Research Group | <1 mi |
| Study to Assess the Impact of the Urine Test Cxbladder Triage Plus on the Number of Cystoscopies Performed on Patients With Invisible Blood in Their Urine. | N/A | Pacific Edge Limited | <1 mi |
| Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging | Phase 3 | ECOG-ACRIN Cancer Research Group | <1 mi |
| A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation | Phase 3 | AstraZeneca | <1 mi |
| Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients | — | PrECOG, LLC. | <1 mi |
| Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment | Phase 1 | National Cancer Institute (NCI) | <1 mi |
| Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma | Phase 1/2 | Regeneron Pharmaceuticals | <1 mi |
| A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01) | Phase 1/2 | Merck Sharp & Dohme LLC | <1 mi |
| A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations | Phase 3 | Children's Oncology Group | <1 mi |
| Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma | Phase 2 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | <1 mi |
| Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients | Phase 3 | Philogen S.p.A. | <1 mi |
| A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss | Phase 3 | Children's Oncology Group | <1 mi |
| Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors | Phase 1/2 | MBrace Therapeutics | <1 mi |
| Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies | — | Children's Oncology Group | <1 mi |
| Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations | Phase 1/2 | Turning Point Therapeutics, Inc. | <1 mi |
| A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma | Phase 2/3 | National Cancer Institute (NCI) | <1 mi |
| Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma | Phase 2 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | <1 mi |
| A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants | Phase 1 | Iovance Biotherapeutics, Inc. | <1 mi |
| A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer | Phase 3 | J-Pharma Co., Ltd. | <1 mi |
| A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer | Phase 3 | Janssen Research & Development, LLC | <1 mi |
| The Radiation Oncology-Biology Integration Network (ROBIN) Molecular Characterization Trial (MCT) of Standard Short Course Radiotherapy for Rectal Cancer | N/A | Weill Medical College of Cornell University | <1 mi |
| A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy | Phase 2 | Stemline Therapeutics, Inc. | <1 mi |
| CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition | Phase 2 | Mark Stein | <1 mi |
| A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL) | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study | Phase 2 | Hoffmann-La Roche | <1 mi |
| A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma | Phase 2 | Janssen Research & Development, LLC | <1 mi |
| Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors | Phase 1 | I-Mab Biopharma US Limited | <1 mi |
| Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) | Phase 1/2 | Juno Therapeutics, a Subsidiary of Celgene | <1 mi |
| Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body | — | Bayer | <1 mi |
| A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT | Phase 2 | Children's Oncology Group | <1 mi |
| A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma. | Phase 1 | Arvinas Inc. | <1 mi |
| A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) | — | Center for International Blood and Marrow Transplant Research | <1 mi |
| SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance) | Phase 3 | Nuvation Bio Inc. | <1 mi |
| A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL) | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer | Phase 2 | Criterium, Inc. | <1 mi |
| Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML | Phase 3 | Kura Oncology, Inc. | <1 mi |
| A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma | Phase 2 | Acrivon Therapeutics | <1 mi |
| A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies | Phase 1/2 | AstraZeneca | <1 mi |
| Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia | Phase 2 | Children's Oncology Group | <1 mi |
| Fabry Disease Registry & Pregnancy Sub-registry | — | Genzyme, a Sanofi Company | <1 mi |
| Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1) | Phase 1/2 | Sumitomo Pharma America, Inc. | <1 mi |
| A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer | Phase 2 | John Sfakianos | <1 mi |
| A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers | Phase 1/2 | Regeneron Pharmaceuticals | <1 mi |
| Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) | Phase 3 | Children's Oncology Group | <1 mi |
| Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL | Phase 2 | AstraZeneca | <1 mi |
| A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML | Phase 1 | Kura Oncology, Inc. | <1 mi |
| Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM) | Phase 3 | Immunocore Ltd | <1 mi |
| Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS) | Phase 1/2 | Rigel Pharmaceuticals | <1 mi |
| A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel | Phase 4 | Janssen Research & Development, LLC | <1 mi |
| Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma | Phase 1 | AbbVie | <1 mi |
| Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01) | Phase 1/2 | Merck Sharp & Dohme LLC | <1 mi |
| A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT | Phase 2 | Children's Oncology Group | <1 mi |
| uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto | — | UroGen Pharma Ltd. | <1 mi |
| Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients | Phase 2 | Vyriad, Inc. | <1 mi |
| A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment | Phase 1/2 | Regeneron Pharmaceuticals | <1 mi |
| A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer | Phase 1 | Astellas Pharma Global Development, Inc. | <1 mi |
| Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma | Phase 3 | Children's Oncology Group | <1 mi |
| Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial) | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG) | Phase 1/2 | National Cancer Institute (NCI) | <1 mi |
| A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma | Phase 2 | Children's Oncology Group | <1 mi |
| Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND) | N/A | Abbott Medical Devices | <1 mi |
| A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam) | Phase 2 | Alzheimer's Disease Cooperative Study (ADCS) | <1 mi |
| Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial | N/A | Edwards Lifesciences | <1 mi |
| A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events | N/A | Cleerly, Inc. | <1 mi |
| The ENCIRCLE Trial | N/A | Edwards Lifesciences | <1 mi |
| Abbott Structural Heart Device Registry | — | Abbott Medical Devices | <1 mi |
| Comparative Effectiveness of Prophylactic ICD Versus Non-ICD Therapy | N/A | University of Rochester | <1 mi |
| Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant | Phase 3 | Eidos Therapeutics, a BridgeBio company | <1 mi |
| Clinical Evaluation of the AccuCinch® Ventricular Restoration System in Patients Who Present With Symptomatic Heart Failure With Reduced Ejection Fraction (HFrEF): The CORCINCH-HF Study | N/A | Ancora Heart, Inc. | <1 mi |
| Abatacept in Immune Checkpoint Inhibitor Myocarditis | Phase 3 | Massachusetts General Hospital | <1 mi |
| ALLIANCE AVIV: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve in Failing Aortic Bioprosthetic Valves | N/A | Edwards Lifesciences | <1 mi |
| Individualizing Treatment for Asthma in Primary Care (Full Study) | Phase 4 | DARTNet Institute | <1 mi |
| Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry | — | Duke University | <1 mi |
| Parkinson's Foundation PD GENEration Genetic Registry | — | Parkinson's Foundation | <1 mi |
| Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer | Phase 1 | National Cancer Institute (NCI) | <1 mi |
| Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis | Phase 3 | Sanofi | <1 mi |
| First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer | Phase 1 | Relay Therapeutics, Inc. | <1 mi |
| Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer | Phase 2 | Oana Danciu | <1 mi |
| Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer | Phase 3 | AstraZeneca | <1 mi |
| Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability | Phase 2 | Rutgers, The State University of New Jersey | <1 mi |
| An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) | Phase 3 | AstraZeneca | <1 mi |
| A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence | Phase 3 | Stemline Therapeutics, Inc. | <1 mi |
| Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation | Phase 3 | Sermonix Pharmaceuticals Inc. | <1 mi |
| I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer | Phase 2 | QuantumLeap Healthcare Collaborative | <1 mi |
| Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer | Phase 3 | Relay Therapeutics, Inc. | <1 mi |
| Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease | Phase 3 | Pfizer | <1 mi |
| A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors | Phase 1 | Exelixis | <1 mi |
| A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | Phase 3 | Jazz Pharmaceuticals | <1 mi |
| Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC) | Phase 3 | Shanghai Junshi Bioscience Co., Ltd. | <1 mi |
| A Phase 1/1b Study of IAM1363 in HER2 Cancers | Phase 1 | Iambic Therapeutics, Inc | <1 mi |
| TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers | Phase 1 | Tizona Therapeutics, Inc | <1 mi |
| A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | Janssen Research & Development, LLC | <1 mi |
| Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors | Phase 1 | SystImmune Inc. | <1 mi |
| A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation | Phase 1 | AstraZeneca | <1 mi |
| Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma | Phase 1 | Xencor, Inc. | <1 mi |
| Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion | Phase 1 | Bristol-Myers Squibb | <1 mi |
| Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma | Phase 3 | Children's Oncology Group | <1 mi |
| Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment | Phase 3 | AstraZeneca | <1 mi |
| A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements | Phase 1/2 | Turning Point Therapeutics, Inc. | <1 mi |
| A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD) | — | Target PharmaSolutions, Inc. | <1 mi |
| SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry | — | Massive Bio, Inc. | <1 mi |
| A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis | Phase 2 | Genentech, Inc. | <1 mi |
| Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma | Phase 3 | AstraZeneca | <1 mi |
| Registry Study for Radiation Therapy Outcomes | — | Proton Collaborative Group | <1 mi |
| Proton and Photon Consortium Registry (PPCR): A Multi Center Registry of Pediatric Patients Treated With Radiation Therapy | — | Massachusetts General Hospital | <1 mi |
| EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease | Phase 3 | Boehringer Ingelheim | <1 mi |
| Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function | Phase 3 | AstraZeneca | <1 mi |
| Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity | Phase 3 | Amgen | <1 mi |
| Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+) | Phase 1 | Oryzon Genomics S.A. | <1 mi |
| Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma | N/A | Melanoma and Skin Cancer Trials Limited | <1 mi |
| The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation | Phase 3 | Johns Hopkins University | <1 mi |
| Assessment of CCM in HF With Higher Ejection Fraction | N/A | Impulse Dynamics | <1 mi |
| Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects | — | Alliance for Clinical Trials in Oncology | <1 mi |
| Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention | Phase 4 | Duke University | <1 mi |
| Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer. | Phase 3 | BriaCell Therapeutics Corporation | <1 mi |
| A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 ) | Phase 3 | Inventiva Pharma | <1 mi |
| JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC | Phase 3 | Johnson & Johnson Enterprise Innovation Inc. | <1 mi |
| Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive Disorder | Phase 3 | Neumora Therapeutics, Inc. | <1 mi |
| Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder | Phase 3 | Vanda Pharmaceuticals | <1 mi |
| A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms | Phase 4 | Axsome Therapeutics, Inc. | <1 mi |
| Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY) | Phase 2 | Autobahn Therapeutics, Inc. | <1 mi |
| A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1) | Phase 3 | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | <1 mi |
| Reduce Loneliness in Care Partners of Persons With AD/ADRD | N/A | Northwell Health | <1 mi |
| Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS | Phase 3 | DalCor Pharmaceuticals | <1 mi |
| Anticoagulation in ICH Survivors for Stroke Prevention and Recovery | Phase 3 | Yale University | <1 mi |
| Does Batten Grafting Improve Nasal Outcomes in Septoplasty and Turbinate Reduction? | N/A | Northwell Health | <1 mi |
| Product Surveillance Registry | — | Medtronic | <1 mi |
| A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study) | Phase 2 | Seaport Therapeutics | <1 mi |
| Evaluating the Implementation of a Comprehensive Multilevel Virtual Oncology Program Among Veterans Diagnosed With Lung, Colorectal, Prostate, and Breast Cancers in the US Department of Veterans Affairs | — | NYU Langone Health | <1 mi |
| S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity | Phase 3 | SWOG Cancer Research Network | <1 mi |
| A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation | Phase 3 | Novo Nordisk A/S | <1 mi |
| A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight | Phase 3 | Eli Lilly and Company | <1 mi |
| LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis | Phase 3 | Boehringer Ingelheim | <1 mi |
| NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) | Phase 3 | Neurocrine Biosciences | <1 mi |
| A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder | Phase 2 | Syndeio Biosciences, Inc | <1 mi |
| P3b Short-term Study of CTN in Patients With ADHD and Comorbid Anxiety | Phase 3 | Otsuka Pharmaceutical Development & Commercialization, Inc. | <1 mi |
| Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma | Phase 3 | Regeneron Pharmaceuticals | <1 mi |
| Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3) | Phase 3 | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | <1 mi |
| Validating CGM for GDM | N/A | Icahn School of Medicine at Mount Sinai | <1 mi |
| PReclude Infection EVEnts With No Prophylaxis Transperineal Biopsy 2 | N/A | Weill Medical College of Cornell University | <1 mi |
| A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer | Phase 1 | Janssen Research & Development, LLC | <1 mi |
| A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer | N/A | GOG Foundation | <1 mi |
| mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma | Phase 3 | Alliance for Clinical Trials in Oncology | <1 mi |
| International Registry for Men With Advanced Prostate Cancer (IRONMAN) | — | Prostate Cancer Clinical Trials Consortium | <1 mi |
| Trial of Combined Obstetric Carrier Screening and Hereditary Cancer Screening | N/A | Weill Medical College of Cornell University | <1 mi |
| A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC) | Phase 3 | Janssen Research & Development, LLC | <1 mi |
| A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects | Phase 1 | C4 Therapeutics, Inc. | <1 mi |
| Clinical Outcomes in Prostate Cancer Patients Undergoing HIFU Ablation | — | NYU Langone Health | <1 mi |
| Chatbot to Maximize Hereditary Cancer Genetic Risk Assessment | N/A | Weill Medical College of Cornell University | <1 mi |
| A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma | Phase 3 | Bristol-Myers Squibb | <1 mi |
| Rare and Atypical Diabetes Network | — | University of South Florida | <1 mi |
| DISCOVERY of Risk Factors for Type 2 Diabetes in Youth | — | George Washington University | <1 mi |
| Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms | Phase 3 | Janssen Research & Development, LLC | <1 mi |
| A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder | Phase 2 | Sirtsei Pharmaceuticals, Inc. | <1 mi |
| Lay-Delivered Behavioral Activation in Senior Centers | N/A | University of Washington | <1 mi |
| Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia | Phase 2/3 | Exciva GmbH | <1 mi |
| STICH3C Cardiac Magnetic Resonance Observational Study | — | Weill Medical College of Cornell University | <1 mi |
| MagicTouch™Sirolimus-Coated Balloon for Treatment of Coronary Artery Lesions in Small Vessels | N/A | Concept Medical Inc. | <1 mi |
| Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) | Phase 2 | Bristol-Myers Squibb | <1 mi |
| Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors | — | Weill Medical College of Cornell University | <1 mi |
| Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women | N/A | Weill Medical College of Cornell University | <1 mi |
| A Study of Dotinurad Versus Allopurinol in Participants With Gout | Phase 3 | Crystalys Therapeutics | <1 mi |
| An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis | Phase 2 | Eli Lilly and Company | <1 mi |
| A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus | Phase 3 | UCB Biopharma SRL | <1 mi |
| A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus | Phase 2/3 | Biogen | <1 mi |
| A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus | Phase 3 | AstraZeneca | <1 mi |
| Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus | Phase 3 | AbbVie | <1 mi |
| ATEMPT 2.0: Adjuvant T-DM1 vs TH | Phase 2 | Dana-Farber Cancer Institute | <1 mi |
| Personalized Second Chance Breast Conservation (PSCBC): A Prospective Phase II Clinical Study | N/A | Weill Medical College of Cornell University | <1 mi |
| A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer | Phase 2 | Dana-Farber Cancer Institute | <1 mi |
| Developing New Educational Materials About Genetic Testing for a Diverse Group of Cancer Patients | N/A | Memorial Sloan Kettering Cancer Center | <1 mi |
| Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292) | Phase 3 | AstraZeneca | <1 mi |
| Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer | Phase 3 | AstraZeneca | <1 mi |
| Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation | Phase 2 | Mirati Therapeutics Inc. | <1 mi |
| A Study of Sigvotatug Vedotin in Advanced Solid Tumors | Phase 1 | Seagen, a wholly owned subsidiary of Pfizer | <1 mi |
| Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor | Phase 3 | OSE Immunotherapeutics | <1 mi |
| A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer | Phase 3 | Eli Lilly and Company | <1 mi |
| A Study of Bexarotene Combined With Radiotherapy in People With Mycosis Fungoides | Phase 1 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of BMS986365 in Combination With Degarelix in People With Prostate Cancer | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease | Phase 3 | Hoffmann-La Roche | <1 mi |
| Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies | Phase 3 | Hoffmann-La Roche | <1 mi |
| A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202) | Phase 3 | Bristol-Myers Squibb | <1 mi |
| Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML) | Phase 3 | PedAL BCU, LLC | <1 mi |
| Quality of Pediatric Resuscitation in a Multicenter Collaborative | — | Children's Hospital of Philadelphia | <1 mi |
| Phase IIIb Study of Ribociclib + ET in Early Breast Cancer | Phase 3 | Novartis Pharmaceuticals | <1 mi |
| An Acupuncture Study for Cancer Survivors With Joint Pain | N/A | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of a Distress Screening and Referral Program in People With Recently Diagnosed Cancer | N/A | Memorial Sloan Kettering Cancer Center | <1 mi |
| Novel Imaging Technique to Assess Gynecologic Cancer | Phase 1 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease | Phase 2 | Janssen Pharmaceutica N.V., Belgium | <1 mi |
| Quality of Life (QoL) Assessment in Cancer Patients and Survivors With Dermatologic Conditions Using Dermatologic QoL Instruments | — | Memorial Sloan Kettering Cancer Center | <1 mi |
| The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials | Phase 4 | Pfizer | <1 mi |
| Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma | Phase 3 | AstraZeneca | <1 mi |
| ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer | Phase 1 | Janssen Research & Development, LLC | <1 mi |
| IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma | Phase 2/3 | IDEAYA Biosciences | <1 mi |
| A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | Phase 3 | Eli Lilly and Company | <1 mi |
| Role of Insulin Action in Psoriasis Pathogenesis | — | Columbia University | <1 mi |
| Investigating the Impact of Duration and Amount of Light on the Circadian System Response - Aim 3 | N/A | Icahn School of Medicine at Mount Sinai | <1 mi |
| SRG-514 Administered Intraoperatively to Patients Undergoing Breast-conserving Cancer Surgery | Phase 1 | SURGE Therapeutics | <1 mi |
| Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer | Phase 3 | Genmab | <1 mi |
| Focal US-guided Cryo-ablation Using DynaCAD / UroNAV Preplanning / Guidance of Intermediate Risk Prostate Cancer | N/A | Northwell Health | <1 mi |
| A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2) | Phase 3 | Erasca, Inc. | <1 mi |
| Enteral Anastomosis for the Treatment of Gastric Outlet Obstruction: A Randomized Controlled Study Comparing Endoscopic Versus Surgical Gastrojejunostomy | N/A | Northwell Health | <1 mi |
| A Study to Test KISIMA-02 Vaccine-based Immunotherapy and Ezabenlimab in People With Pancreatic Cancer | Phase 1 | Boehringer Ingelheim | <1 mi |
| Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors | Phase 1 | National Cancer Institute (NCI) | <1 mi |
| First in Human Study of IMGN151 in Recurrent Gynaecological Cancers | Phase 1 | AbbVie | <1 mi |
| A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation | Phase 2 | VA Office of Research and Development | <1 mi |
| Study of Narazaciclib (ON 123300) Plus Letrozole in Endometrial Cancer and Other Gynecologic Malignancies | Phase 1/2 | Traws Pharma, Inc. | <1 mi |
| A Study of Oral Minoxidil to Treat Hair Loss in Children, Teens, and Young Adults Who Are Cancer Survivors | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based Obinutuzumab | Phase 2 | Weill Medical College of Cornell University | <1 mi |
| RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis | Phase 1/2 | Cabaletta Bio | <1 mi |
| MR/TRUS Fusion Guided Prostate Biopsy - An Improved Way to Detect and Quantify Prostate Cancer | N/A | Ardeshir Rastinehad | <1 mi |
| Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 | Phase 3 | Seagen, a wholly owned subsidiary of Pfizer | <1 mi |
| A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma | Phase 1/2 | Bristol-Myers Squibb | <1 mi |
| A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma | Phase 1/2 | Hoffmann-La Roche | <1 mi |
| A Clinical Investigation Evaluating Wound Closure with OptiPulse™ Versus SOC in the Treatment of Non-Healing DFU's | N/A | Compedica Inc | <1 mi |
| A Phase 3 Trial of MM120 for Major Depressive Disorder (Emerge) | Phase 3 | Definium Therapeutics US, Inc. | <1 mi |
| Clinical Data Collection Study Using CPM System | N/A | Analog Device, Inc. | <1 mi |
| The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) | Phase 3 | Eli Lilly and Company | <1 mi |
| Level of Physical Activity and Fear Learning | N/A | NYU Langone Health | <1 mi |
| Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis | Phase 3 | AstraZeneca | <1 mi |
| A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies | Phase 1/2 | Ascendis Pharma Oncology Division A/S | <1 mi |
| Quantitative Susceptibility Mapping (QSM) to Guide Iron Chelating Therapy | — | Weill Medical College of Cornell University | <1 mi |
| A Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection | Phase 2/3 | Bluejay Therapeutics, Inc. | <1 mi |
| A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor | Phase 1/2 | Eisai Inc. | <1 mi |
| Cryotherapy & Oxaliplatin | N/A | NYU Langone Health | <1 mi |
| A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2 | Phase 1 | Dana-Farber Cancer Institute | <1 mi |
| Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors | Phase 1/2 | Immunocore Ltd | <1 mi |
| Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients | Phase 2 | City of Hope Medical Center | <1 mi |
| A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant | Phase 1 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS | Phase 1 | Auron Therapeutics, Inc. | <1 mi |
| A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia | Phase 1/2 | Astellas Pharma Global Development, Inc. | <1 mi |
| Autonomic Modulation in Takotsubo Syndrome | N/A | NYU Langone Health | <1 mi |
| Treatment of Breast Fibroadenoma Targeted Tissue With HIFU | N/A | Theraclion | <1 mi |
| U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer | Phase 1 | Daiichi Sankyo | <1 mi |
| Study of Oral MRT-2359 in Selected Cancer Patients | Phase 1/2 | Monte Rosa Therapeutics, Inc | <1 mi |
| miroliverELAP® for the Treatment of Acute Liver Failure: A Phase 1 Trial | Phase 1 | Miromatrix Medical Inc. | <1 mi |
| Radioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC) | N/A | ABK Biomedical | <1 mi |
| US Study of ECT-001-CB in Pediatric and Young Adult Patients With High-Risk Myeloid Malignancies | Phase 1/2 | ExCellThera inc. | <1 mi |
| A Study of Tooth Erosion in People With Esophagogastric Cancer | N/A | Memorial Sloan Kettering Cancer Center | <1 mi |
| An Investigational Study of BG-89894 Tablets in Participants With Advanced Solid Tumors | Phase 1 | BeOne Medicines | <1 mi |
| A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006) | Phase 2 | Merck Sharp & Dohme LLC | <1 mi |
| Phase 1, Open-label, Dose-escalation Trial with CD38-SADA:177 Lu-DOTA Drug Complex in Subjects with Relapsed or Refractory Non-Hodgkin Lymphoma | Phase 1 | Y-mAbs Therapeutics | <1 mi |
| SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations | Phase 3 | Palvella Therapeutics, Inc. | <1 mi |
| Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma | Phase 1 | Institut de Recherches Internationales Servier | <1 mi |
| Defining Response Criteria for PET Scans for People With Neuroendocrine Tumors | — | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study to Evaluate Pharmacokinetics of LY3209590 in Pediatric Participants With Type 2 Diabetes Mellitus | Phase 1 | Eli Lilly and Company | <1 mi |
| Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3) | — | University of Southern California | <1 mi |
| A Study to Evaluate the Efficacy and Safety of GDC-8264 in Preventing Cardiac Surgery-Associated Acute Kidney Injury (AKI) and Major Adverse Kidney Events (MAKE) | Phase 2 | Genentech, Inc. | <1 mi |
| Heart Attack Research Program- Imaging Study | — | NYU Langone Health | <1 mi |
| RESPONDER-HF Trial | N/A | Corvia Medical | <1 mi |
| Autus Valve Pivotal Study | N/A | Autus Valve Technologies, Inc. | <1 mi |
| ASCEND CSP IDE Study | N/A | Abbott Medical Devices | <1 mi |
| BIOTRONIK Conduction System Pacing With the Solia Lead - Solia CSP S | N/A | Biotronik, Inc. | <1 mi |
| NIOSH R21 WTC Asthma | — | Icahn School of Medicine at Mount Sinai | <1 mi |
| A Long-term Extension Study of Ustekinumab in Pediatric Participants | Phase 3 | Janssen Research & Development, LLC | <1 mi |
| Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL) | Phase 1/2 | Prevail Therapeutics | <1 mi |
| Exploring the Effects of Spinal Cord Stimulation in Parkinson's Disease. | N/A | Nora Vanegas | <1 mi |
| Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus | Phase 2 | Sanofi | <1 mi |
| Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs. | Phase 1/2 | RayzeBio, Inc. | <1 mi |
| DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer | Phase 1 | Legend Biotech USA Inc | <1 mi |
| Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene) | Phase 1 | Boehringer Ingelheim | <1 mi |
| Study of DF1001 in Patients with Advanced Solid Tumors | Phase 1/2 | Dragonfly Therapeutics | <1 mi |
| A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors | Phase 1 | Eli Lilly and Company | <1 mi |
| Daratumumab in STK11 Mutated NSCLC | Phase 2 | NYU Langone Health | <1 mi |
| Study of DF6215 in Patients with Advanced Solid Tumors | Phase 1 | Dragonfly Therapeutics | <1 mi |
| A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML) | Phase 1 | Bio-Path Holdings, Inc. | <1 mi |
| An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC. | Phase 3 | Novartis Pharmaceuticals | <1 mi |
| Precision-Based Genomics in Prostate Cancer | — | National Cancer Institute (NCI) | <1 mi |
| Intent of Surgery for IPMN | — | NYU Langone Health | <1 mi |
| A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies | Phase 1/2 | BeOne Medicines | <1 mi |
| Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical) | Phase 3 | AstraZeneca | <1 mi |
| Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA | Phase 2 | Northwell Health | <1 mi |
| Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer | Phase 3 | Children's Oncology Group | <1 mi |
| Characterization of Hyperpolarized Pyruvate MRI Reproducibility | N/A | Memorial Sloan Kettering Cancer Center | <1 mi |
| Registry to Collect Health Information About Desmoplastic Small Round Cell Tumor | — | Memorial Sloan Kettering Cancer Center | <1 mi |
| Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System | Phase 1/2 | SpectraCure AB | <1 mi |
| R-MVST Cells for Treatment of Viral Infections | Phase 1 | Columbia University | <1 mi |
| Mobile Health Application (PACT) to Improve Engagement in Advance Care Planning | N/A | Fred Hutchinson Cancer Center | <1 mi |
| A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM) | Phase 1/2 | AbbVie | <1 mi |
| A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma | Phase 3 | Regeneron Pharmaceuticals | <1 mi |
| A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate Cancer | Phase 2 | Debiopharm International SA | <1 mi |
| A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome | Phase 1 | BlossomHill Therapeutics | <1 mi |
| A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate Cancer | Phase 1 | Daiichi Sankyo | <1 mi |
| CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma | Phase 1/2 | Children's Oncology Group | <1 mi |
| Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| InterNatIonal CHildhood Leukemia Microbiome/MEtabolome Cohort | — | Columbia University | <1 mi |
| A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials | Phase 3 | Celgene | <1 mi |
| A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | Phase 1 | Incyte Corporation | <1 mi |
| An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | Phase 2 | Novartis Pharmaceuticals | <1 mi |
| Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS) | Phase 3 | Advenchen Laboratories, LLC | <1 mi |
| Advanced Diffusion Imaging in Renal Cancer Patients | N/A | NYU Langone Health | <1 mi |
| Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma | Phase 1/2 | Remix Therapeutics | <1 mi |
| Gemcitabine, Cisplatin, Nab-paclitaxel (GAP) and Cemiplimab for Locally Advanced Biliary Tract Cancer (BTC) | Phase 2 | Columbia University | <1 mi |
| A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| Walnuts and Colon Health | N/A | UConn Health | <1 mi |
| FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Phase 2 | Fusion Pharmaceuticals Inc. | <1 mi |
| Pancreas Registry and High Risk Registry | — | Icahn School of Medicine at Mount Sinai | <1 mi |
| A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy | Phase 2 | OncoVerity, Inc. | <1 mi |
| RCT of Olanzapine for Control of CIV in Children Receiving Highly Emetogenic Chemotherapy | Phase 2 | The Hospital for Sick Children | <1 mi |
| A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors | Phase 1 | Arcus Biosciences, Inc. | <1 mi |
| Early Feeding After Oral Cavity Reconstruction | N/A | Icahn School of Medicine at Mount Sinai | <1 mi |
| A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer | Phase 1 | Janssen Research & Development, LLC | <1 mi |
| Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma | Phase 1/2 | Jazz Pharmaceuticals | <1 mi |
| Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer | Phase 3 | GlaxoSmithKline | <1 mi |
| Mechanisms of Resistance to PSMA Radioligand Therapy | — | University of California, San Francisco | <1 mi |
| A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma | Phase 2 | Genmab | <1 mi |
| Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread | Phase 2 | Gilead Sciences | <1 mi |
| Study of INCA036978 in Participants With Myeloproliferative Neoplasms | Phase 1 | Incyte Corporation | <1 mi |
| A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms | Phase 1 | Incyte Corporation | <1 mi |
| Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma | Phase 1/2 | Innate Pharma | <1 mi |
| A Study of Time-Restricted Eating in Childhood Cancer Survivors | N/A | Memorial Sloan Kettering Cancer Center | <1 mi |
| Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation | Phase 3 | European Myeloma Network B.V. | <1 mi |
| ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer | Phase 2 | NYU Langone Health | <1 mi |
| A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer | Phase 1 | AstraZeneca | <1 mi |
| Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01) | Phase 3 | Daiichi Sankyo | <1 mi |
| Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy | Phase 1 | National Cancer Institute (NCI) | <1 mi |
| Study of REM-422 in Patients With AML or Higher Risk MDS | Phase 1 | Remix Therapeutics | <1 mi |
| Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo) | Phase 3 | PharmaMar | <1 mi |
| ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study | Phase 3 | Steba Biotech S.A. | <1 mi |
| A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma | Phase 2 | Janssen Research & Development, LLC | <1 mi |
| A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed | Phase 1/2 | GlaxoSmithKline | <1 mi |
| Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission | Phase 2 | Daiichi Sankyo | <1 mi |
| Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma | Phase 1 | Ono Pharmaceutical Co. Ltd | <1 mi |
| Tumor Microenvironment Analysis of Prostate Cancer Metastasis | — | Columbia University | <1 mi |
| Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase | Phase 2 | Augusta University | <1 mi |
| Registry to Collect Data on Patients Undergoing Segmental Mandibular Defect Reconstruction Following Oral Squamous Cell Carcinoma Resection and Drugs-induced Osteonecrosis | — | AO Innovation Translation Center | <1 mi |
| 68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors. | Phase 4 | Weill Medical College of Cornell University | <1 mi |
| Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy | Phase 2/3 | Bristol-Myers Squibb | <1 mi |
| Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy | Phase 2 | Beth Israel Deaconess Medical Center | <1 mi |
| Carboplatin or Olaparib for BRcA Deficient Prostate Cancer | Phase 2 | VA Office of Research and Development | <1 mi |
| Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021) | Phase 1 | University of California, San Francisco | <1 mi |
| Evaluation of Stool Based Markers for the Early Detection of Colorectal Cancers and Adenomas | — | University of Michigan Rogel Cancer Center | <1 mi |
| Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer | Phase 3 | Massachusetts General Hospital | <1 mi |
| Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies | Phase 1/2 | Replimune Inc. | <1 mi |
| A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer | Phase 3 | Janssen Research & Development, LLC | <1 mi |
| A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma | Phase 3 | Janssen Research & Development, LLC | <1 mi |
| A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma | Phase 1/2 | Debiopharm International SA | <1 mi |
| Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial | Phase 2/3 | National Cancer Institute (NCI) | <1 mi |
| Amping up With PemJAK | Phase 2 | Seda S. Tolu | <1 mi |
| A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011) | Phase 2 | Merck Sharp & Dohme LLC | <1 mi |
| Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 2 | Karyopharm Therapeutics Inc | <1 mi |
| A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma | Phase 2 | AstraZeneca | <1 mi |
| Effects of Belzutifan on 89Zr-DFO-girentuximab PET Uptake in Patients With Renal Cell Carcinoma (RCC) | Phase 1 | NYU Langone Health | <1 mi |
| A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) | Phase 3 | Janssen Research & Development, LLC | <1 mi |
| FUS Etoposide for DMG | Phase 1 | Columbia University | <1 mi |
| (Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis | Phase 2 | Cogent Biosciences, Inc. | <1 mi |
| A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors. | Phase 1 | Whitehawk Therapeutics, Inc. | <1 mi |
| Neuroblastoma Maintenance Therapy Trial | Phase 2 | Giselle Sholler | <1 mi |
| A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204) | Phase 2/3 | Bristol-Myers Squibb | <1 mi |
| Lesion Dosimetry With Iodine-124 in Metastatic Thyroid Carcinoma | Phase 1 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Neurocutaneous Melanocytosis Registry | — | Memorial Sloan Kettering Cancer Center | <1 mi |
| ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors | Phase 1/2 | Immatics US, Inc. | <1 mi |
| Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse | Phase 2 | Larysa Sanchez | <1 mi |
| Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors | Phase 1 | Xencor, Inc. | <1 mi |
| RFA for Superficial Lipomas | N/A | Columbia University | <1 mi |
| Study of SGR-3515 In Participants With Advanced Solid Tumors. | Phase 1 | Schrödinger, Inc. | <1 mi |
| A Clinical Study to Investigate the Efficacy of Intratumoral Tigilanol Tiglate in Soft Tissue Sarcoma | Phase 2 | QBiotics Group Limited | <1 mi |
| Remote Digital Physiologic Data Collection in Cancer: An MSK Registry Protocol | — | Memorial Sloan Kettering Cancer Center | <1 mi |
| Simple Bone Cysts in Kids | Phase 3 | The Hospital for Sick Children | <1 mi |
| Taxi ROADmAP (Realizing Optimization Around Diet And Physical Activity) | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics | Phase 1 | medac GmbH | <1 mi |
| CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) | Phase 1 | Cullinan Therapeutics Inc. | <1 mi |
| A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors | Phase 1 | OnCusp Therapeutics, Inc. | <1 mi |
| Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors | Phase 1/2 | Revolution Medicines, Inc. | <1 mi |
| A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia | Phase 3 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Cabozantinib for Patients With Recurrent or Progressive Meningioma | Phase 2 | Baptist Health South Florida | <1 mi |
| Photopheresis in Early-stage Mycosis Fungoides | Phase 2 | Columbia University | <1 mi |
| Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC | Phase 2 | CG Oncology, Inc. | <1 mi |
| Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors | Phase 1/2 | Impact Therapeutics, Inc. | <1 mi |
| A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2) | Phase 3 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | <1 mi |
| A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1) | Phase 1/2 | Janssen Research & Development, LLC | <1 mi |
| Two Fraction Prostate SBRT With DIL SIB | Phase 1 | NYU Langone Health | <1 mi |
| A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) | Phase 1 | Bristol-Myers Squibb | <1 mi |
| International Rare Histiocytic Disorders Registry (IRHDR) | — | The Hospital for Sick Children | <1 mi |
| Tislelizumab in People With Colorectal Cancer | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Tazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma | Phase 2 | Weill Medical College of Cornell University | <1 mi |
| Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma | Phase 1/2 | Heidelberg Pharma AG | <1 mi |
| Anti-GD2 ADC M3554 in Advanced Solid Tumors | Phase 1 | EMD Serono Research & Development Institute, Inc. | <1 mi |
| Testing Gene PilotLX With Latinx Cancer Patients | N/A | Fox Chase Cancer Center | <1 mi |
| Prospective Evaluation of the Pulse Biosciences nPulse™ Vybrance™ Percutaneous Electrode System | N/A | Pulse Biosciences, Inc. | <1 mi |
| A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma | Phase 4 | Eli Lilly and Company | <1 mi |
| Food and Microbiome Longitudinal Investigation (FAMiLI) | — | NYU Langone Health | <1 mi |
| A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer. | Phase 2 | Weill Medical College of Cornell University | <1 mi |
| DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | Phase 1 | Dizal Pharmaceuticals | <1 mi |
| A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs) | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Neoadjuvant Darovasertib in Primary Uveal Melanoma | Phase 3 | IDEAYA Biosciences | <1 mi |
| The Ambient Light Multiple Myeloma Study | N/A | Icahn School of Medicine at Mount Sinai | <1 mi |
| A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer | Phase 1 | Astellas Pharma Global Development, Inc. | <1 mi |
| A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma | Phase 3 | Kite, A Gilead Company | <1 mi |
| Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial | Phase 2 | City of Hope Medical Center | <1 mi |
| A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG) | Phase 3 | Vor Biopharma | <1 mi |
| A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma | Phase 1/2 | Hoffmann-La Roche | <1 mi |
| Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow | Phase 2 | Y-mAbs Therapeutics | <1 mi |
| A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression | Phase 2 | Incyte Corporation | <1 mi |
| Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET | Phase 3 | Novartis Pharmaceuticals | <1 mi |
| ART-Pro: Clinical Trial Evaluating Biparametric MRI and Advanced, Quantitative Diffusion MRI for Detection of Prostate Cancer | — | University of California, San Diego | <1 mi |
| A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) | Phase 1/2 | Merck Sharp & Dohme LLC | <1 mi |
| A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20) | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| Personalized Models for Cancer Research | — | New York Stem Cell Foundation Research Institute | <1 mi |
| Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment | — | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer | Phase 1 | Pfizer | <1 mi |
| Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD) | Phase 2 | Jennifer Amengual | <1 mi |
| BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen | Phase 3 | Servier Bio-Innovation LLC | <1 mi |
| HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy | Phase 2 | Children's Hospital Medical Center, Cincinnati | <1 mi |
| Actinium Therapy for Late-stage Aggressive Sarcomas | Phase 1 | Ratio Therapeutics, Inc. | <1 mi |
| AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 | Phase 3 | AstraZeneca | <1 mi |
| Teclistamab-Daratumumab in AL Amyloidosis | Phase 2 | Suzanne Lentzsch, MD | <1 mi |
| Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma | Phase 1 | Marker Therapeutics, Inc. | <1 mi |
| A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer | Phase 2 | BioNTech SE | <1 mi |
| A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis | Phase 1 | Janssen Research & Development, LLC | <1 mi |
| A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer | Phase 1/2 | Engeneic Pty Limited | <1 mi |
| A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors | Phase 1/2 | Astellas Pharma Global Development, Inc. | <1 mi |
| Combination Therapy for the Treatment of Diffuse Midline Gliomas | Phase 2 | University of California, San Francisco | <1 mi |
| CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma | Phase 1 | Caribou Biosciences, Inc. | <1 mi |
| Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia | N/A | University of Colorado, Denver | <1 mi |
| Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer | Phase 3 | Daiichi Sankyo | <1 mi |
| A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma | Phase 1 | AbbVie | <1 mi |
| Environmental Factors and Thyroid Cancer | — | Icahn School of Medicine at Mount Sinai | <1 mi |
| Screening for AL Amyloidosis in Smoldering Multiple Myeloma | — | Tufts Medical Center | <1 mi |
| A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer | Phase 1 | Janssen Research & Development, LLC | <1 mi |
| N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors | Phase 1/2 | Sanofi | <1 mi |
| Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid Tumors | N/A | Memorial Sloan Kettering Cancer Center | <1 mi |
| Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma | Phase 1/2 | Children's Oncology Group | <1 mi |
| P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma | Phase 1 | Poseida Therapeutics, Inc. | <1 mi |
| Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer | Phase 1 | Amgen | <1 mi |
| A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) | Phase 2 | Novartis Pharmaceuticals | <1 mi |
| A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors | Phase 1 | BeOne Medicines | <1 mi |
| Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120) | Phase 2 | Icahn School of Medicine at Mount Sinai | <1 mi |
| Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer | Phase 2 | Faeth Therapeutics | <1 mi |
| Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression | Phase 1/2 | AstraZeneca | <1 mi |
| A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide | Phase 3 | Janssen Research & Development, LLC | <1 mi |
| A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies | Phase 1 | Incyte Corporation | <1 mi |
| DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer | Phase 3 | AstraZeneca | <1 mi |
| Psychotherapy Intervention for Latinos With Adv Cancer | N/A | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of D3L-001 as Monotherapy in Subjects With HER2-Positive Advanced Solid Tumors | Phase 1 | D3 Bio (Wuxi) Co., Ltd | <1 mi |
| Prospective Database of Clinical Outcomes Following Cryotherapy for Ablation of Clinically Localized Prostate Cancer | — | NYU Langone Health | <1 mi |
| Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL | Phase 3 | Soligenix | <1 mi |
| A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors | Phase 1 | Avistone Biotechnology Co., Ltd. | <1 mi |
| Study of Canakinumab in Patients With Myelofibrosis | Phase 2 | John Mascarenhas | <1 mi |
| A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors | Phase 1 | NextCure, Inc. | <1 mi |
| Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis | Phase 3 | Immunovant Sciences GmbH | <1 mi |
| CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER) | Phase 1 | Caribou Biosciences, Inc. | <1 mi |
| A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors | Phase 1/2 | DualityBio Inc. | <1 mi |
| A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer | Phase 3 | Astellas Pharma Global Development, Inc. | <1 mi |
| Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer | Phase 2 | Aadi Bioscience, Inc. | <1 mi |
| Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies | Phase 1 | Therapeutic Advances in Childhood Leukemia Consortium | <1 mi |
| Detection of Oral and Throat Cancers Using OralViome Cancer Testing System | — | Viome | <1 mi |
| Trial of Ixazomib for Kaposi Sarcoma | Phase 2 | AIDS Malignancy Consortium | <1 mi |
| A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer | Phase 3 | Celgene | <1 mi |
| Prospective Study to Assess a Diagnostic Aid for Cancer | — | Harbinger Health | <1 mi |
| An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors | Phase 1 | BeOne Medicines | <1 mi |
| A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib | Phase 1/2 | M.D. Anderson Cancer Center | <1 mi |
| A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma | Phase 1/2 | BeOne Medicines | <1 mi |
| BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma | Phase 2 | Christine Ryan | <1 mi |
| Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302) | Phase 3 | NX Development Corp | <1 mi |
| Evaluation of Grief Therapy Approaches for Bereaved Parents | N/A | University of Miami | <1 mi |
| Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer | Phase 3 | AbbVie | <1 mi |
| Visual Communication: Digital Tool to Improve the Understanding of Treatment Options for Patients With Cancer and Increase Satisfaction of the Overall Experience for Patients, Caregivers, and Providers | N/A | NYU Langone Health | <1 mi |
| FITting Non-invasive Tests in Lynch Syndrome Surveillance | — | University of Chicago | <1 mi |
| Trial Evaluating the Safety and Efficacy Of MR-Linac-Guided Radiotherapy as Salvage Treatment After External Beam Radiotherapy Recurrence (TUMORNATOR II) | N/A | NYU Langone Health | <1 mi |
| A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients | Phase 3 | AstraZeneca | <1 mi |
| A Study of GC012F (AZD0120), a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma | Phase 1/2 | AstraZeneca | <1 mi |
| Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplant Receiving FQ Prophylaxis & Harboring FQR Ecoli Pre-Transplant | Phase 1/2 | SNIPR Biome Aps. | <1 mi |
| Circulating Human Papilloma Virus (HPV) DNA for the Screening and Surveillance of Gynecologic Cancers | N/A | Northwell Health | <1 mi |
| Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas | Phase 1 | Inhibrx Biosciences, Inc | <1 mi |
| A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors | Phase 1 | Erasca, Inc. | <1 mi |
| Study of IBI3020 Treatment in Participants With Late-Stage Solid Tumors | Phase 1 | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | <1 mi |
| A Study of ZL-1310 in Participants With Selected Solid Tumors | Phase 1/2 | Zai Lab (Shanghai) Co., Ltd. | <1 mi |
| A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study | Phase 2 | Astellas Pharma Global Development, Inc. | <1 mi |
| Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors | Phase 1/2 | Daiichi Sankyo | <1 mi |
| Identify Barriers to Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed and Relapsed Acute Leukemia | — | Memorial Sloan Kettering Cancer Center | <1 mi |
| Diphencyprone Plus Immune Checkpoint Inhibition in the Treatment of Cutaneous Metastases | Phase 1 | Nicholas Gulati | <1 mi |
| Screening Women With Prior HPV for Anal Neoplasia | N/A | Icahn School of Medicine at Mount Sinai | <1 mi |
| A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy | Phase 1 | Children's Oncology Group | <1 mi |
| Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01) | Phase 1/2 | Cellectis S.A. | <1 mi |
| A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma | — | Aura Biosciences | <1 mi |
| Upright MRI for Prostate Cancer Screening | — | Icahn School of Medicine at Mount Sinai | <1 mi |
| Metastatic Leiomyosarcoma Biomarker Protocol | — | University of Michigan Rogel Cancer Center | <1 mi |
| Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer | Phase 1/2 | AstraZeneca | <1 mi |
| The Sinai Robotic Surgery Trial in HPV-related Oropharyngeal Squamous Cell Carcinoma (SIRS 2.0 Trial) | Phase 2 | Icahn School of Medicine at Mount Sinai | <1 mi |
| A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas | Phase 1/2 | Bristol-Myers Squibb | <1 mi |
| A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors | Phase 1 | Nested Therapeutics, Inc | <1 mi |
| A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | Phase 3 | AbbVie | <1 mi |
| Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer | Phase 1/2 | National Cancer Institute (NCI) | <1 mi |
| A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma | Phase 1 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL) | Phase 1 | Imugene Limited | <1 mi |
| Sacral Neuromodulation for Male Overactive Bladder (MOAB) | N/A | Axonics, Inc. | <1 mi |
| A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer | Phase 1 | AstraZeneca | <1 mi |
| Sequential Therapy in Multiple Myeloma Guided by MRD Assessments | Phase 2 | University of Alabama at Birmingham | <1 mi |
| A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer | Phase 2 | Eli Lilly and Company | <1 mi |
| A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma | Phase 1 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | <1 mi |
| Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma | Phase 2 | Alpheus Medical, Inc. | <1 mi |
| A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies. | Phase 1/2 | AstraZeneca | <1 mi |
| Comparing Cooling and/or Compression Approaches of Limbs for Prevention of Chemotherapy-Induced Peripheral Neuropathy | Phase 3 | SWOG Cancer Research Network | <1 mi |
| Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors | Phase 1 | National Cancer Institute (NCI) | <1 mi |
| A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST) | Phase 1/2 | Deciphera Pharmaceuticals, LLC | <1 mi |
| Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | Phase 2 | City of Hope Medical Center | <1 mi |
| Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations | Phase 2 | Rana McKay, MD | <1 mi |
| Determining Whether Multiple Anesthesia Exposures Affect Cognitive Function for Retinoblastoma Patients | — | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment | — | Daiichi Sankyo | <1 mi |
| Primary Tumor Research and Outcomes Network | — | AO Innovation Translation Center | <1 mi |
| Asciminib Roll-over Study | Phase 4 | Novartis Pharmaceuticals | <1 mi |
| Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors | Phase 1 | Debiopharm International SA | <1 mi |
| A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies | Phase 1 | Nurix Therapeutics, Inc. | <1 mi |
| A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors | Phase 1/2 | Hoffmann-La Roche | <1 mi |
| Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors | Phase 1 | Oxford BioTherapeutics Ltd | <1 mi |
| Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers | Phase 1 | National Cancer Institute (NCI) | <1 mi |
| Precision Medicine Study | — | Icahn School of Medicine at Mount Sinai | <1 mi |
| TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer | Phase 2 | American Society of Clinical Oncology | <1 mi |
| Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma | Phase 1 | Neomorph, Inc | <1 mi |
| A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer | Phase 1/2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06) | Phase 1/2 | Merck Sharp & Dohme LLC | <1 mi |
| A Phase 1/2 Study of STP938 for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas | Phase 1/2 | Step Pharma, SAS | <1 mi |
| Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML | Phase 3 | Daiichi Sankyo | <1 mi |
| A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors | Phase 1/2 | Krystal Biotech, Inc. | <1 mi |
| A Study of HLD-0915 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) | Phase 1/2 | Halda Therapeutics OpCo, Inc. | <1 mi |
| Zanubrutinib, Obinutuzumab, and Sonrotoclax in Previously Untreated Patients With CLL or SLL | Phase 2 | Massachusetts General Hospital | <1 mi |
| ACTengine® IMA203 Combined With mRNA-4203 | Phase 1 | Immatics US, Inc. | <1 mi |
| A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors | Phase 1 | Genentech, Inc. | <1 mi |
| RFA of Benign Thyroid Nodules: Clinical Outcomes and Quality of Life Study | — | Columbia University | <1 mi |
| A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma | Phase 2/3 | Global Coalition for Adaptive Research | <1 mi |
| Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps | N/A | NRG Oncology | <1 mi |
| Tissue Collection for Drug Screening and Bioanalysis | — | Weill Medical College of Cornell University | <1 mi |
| A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30) | Phase 2/3 | Bristol-Myers Squibb | <1 mi |
| Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma | Phase 2 | Jazz Pharmaceuticals | <1 mi |
| Feasibility of Intraoperative Tracing of Meningioma Using [Cu64]DOTATATE | Phase 4 | Weill Medical College of Cornell University | <1 mi |
| Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study | N/A | M.D. Anderson Cancer Center | <1 mi |
| Confocal Laser Endomicroscopy as an Imaging Biomarker for the Diagnosis of Pancreatic Cystic Lesions | — | Ohio State University Comprehensive Cancer Center | <1 mi |
| Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC) | Phase 3 | Polaris Group | <1 mi |
| Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma | Phase 1 | National Cancer Institute (NCI) | <1 mi |
| Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis | Phase 1/2 | Rajshekhar Chakraborty, MD | <1 mi |
| A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms | Phase 1 | Janssen Research & Development, LLC | <1 mi |
| PANCREATIC DISEASE COHORT A Registry and Biospecimen Bank to Better Understand Pancreatic Disease | — | Columbia University | <1 mi |
| Evaluation of Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography in Active Surveillance for Prostate CancEr | N/A | Weill Medical College of Cornell University | <1 mi |
| Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer | Phase 3 | GOG Foundation | <1 mi |
| Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer | Phase 3 | Ferring Pharmaceuticals | <1 mi |
| A Study of PYX-201 in Advanced Solid Tumors | Phase 1 | Pyxis Oncology, Inc | <1 mi |
| A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma | Phase 1 | Treeline Biosciences, Inc. | <1 mi |
| A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors | Phase 1 | MediLink Therapeutics (Suzhou) Co., Ltd. | <1 mi |
| A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22) | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| Efficacy and Safety of the CG-100 Intraluminal Bypass Device | N/A | Colospan Ltd. | <1 mi |
| First in Human Study of TORL-1-23 in Participants With Advanced Cancer | Phase 1 | TORL Biotherapeutics, LLC | <1 mi |
| Limited-duration Teclistamab | Phase 2 | Abramson Cancer Center at Penn Medicine | <1 mi |
| A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations | Phase 2 | Sameek Roychowdhury | <1 mi |
| A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) | Phase 1 | Kura Oncology, Inc. | <1 mi |
| A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma | Phase 3 | GlaxoSmithKline | <1 mi |
| Study of How People Make Decisions About Prostate Cancer Risk | — | Memorial Sloan Kettering Cancer Center | <1 mi |
| Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma | Phase 3 | Genmab | <1 mi |
| Study of SGR-1505 in Mature B-Cell Neoplasms | Phase 1 | Schrödinger, Inc. | <1 mi |
| EUS RFA for Treatment of Pancreatic Ductal Adenocarcinoma (PDAC) | Phase 1 | NYU Langone Health | <1 mi |
| A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2) | Phase 1 | AstraZeneca | <1 mi |
| A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | Phase 1 | Edgewood Oncology Inc. | <1 mi |
| A New Psychotherapy Intervention for Older Cancer Patients | N/A | Memorial Sloan Kettering Cancer Center | <1 mi |
| European Prospective Investigation Into Childhood Cancer | — | Columbia University | <1 mi |
| Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors | Phase 1/2 | Georgiamune Inc | <1 mi |
| Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes | Phase 1 | Remedy Plan, Inc. | <1 mi |
| Psychotherapy Intervention for Latinos With Advanced Cancer | N/A | Memorial Sloan Kettering Cancer Center | <1 mi |
| Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM | Phase 1/2 | Northwell Health | <1 mi |
| Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06) | Phase 1/2 | Merck Sharp & Dohme LLC | <1 mi |
| Study of AZD0754 in Participants With Metastatic Prostate Cancer | Phase 1/2 | AstraZeneca | <1 mi |
| P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies | Phase 1 | Poseida Therapeutics, Inc. | <1 mi |
| CD4CAR for CD4+ Leukemia and Lymphoma | Phase 1 | Huda Salman | <1 mi |
| Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy | Phase 1/2 | National Cancer Institute (NCI) | <1 mi |
| Hybrid Effectiveness-Implementation Trial to Integrate Precision Skin Cancer Risk Feedback in FQHCs | N/A | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| MMRC Horizon One Adaptive Platform Trial Evaluating Therapies in RRMM | Phase 2 | Multiple Myeloma Research Consortium | <1 mi |
| A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1) | Phase 1/2 | Nuvalent Inc. | <1 mi |
| BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20) | Phase 1/2 | BioInvent International AB | <1 mi |
| A Study of Daratumumab | Phase 3 | Janssen Research & Development, LLC | <1 mi |
| A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4) | Phase 3 | AstraZeneca | <1 mi |
| FOG-001 in Locally Advanced or Metastatic Solid Tumors | Phase 1/2 | Parabilis Medicines, Inc. | <1 mi |
| A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma | Phase 1 | Flare Therapeutics Inc. | <1 mi |
| Chinese American Cancer Survivors Writing Study | N/A | New York University | <1 mi |
| A Study of YL201 in Patients With Advanced Solid Tumors | Phase 1/2 | MediLink Therapeutics (Suzhou) Co., Ltd. | <1 mi |
| A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL) | Phase 1/2 | Terns, Inc. | <1 mi |
| A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan | Phase 2 | AbbVie | <1 mi |
| Pancreatic Cancer Early Detection Consortium | — | Arbor Research Collaborative for Health | <1 mi |
| Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers | — | AIDS Malignancy Consortium | <1 mi |
| Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors | Phase 1 | SystImmune Inc. | <1 mi |
| Navigating Financial and Health-Related Social Needs in Adolescent and Young Adult Cancer Survivors (AYA-NAV) | N/A | Columbia University | <1 mi |
| AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma | Phase 1/2 | AstraZeneca | <1 mi |
| Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance | Phase 2 | Icahn School of Medicine at Mount Sinai | <1 mi |
| Clinical Trial of Approaches to Prostate Cancer Surgery | N/A | Weill Medical College of Cornell University | <1 mi |
| Pacritinib in CMML | Phase 1/2 | Douglas Tremblay | <1 mi |
| Chlorhexidine Antiseptic Irrigation of the Bowel Segment During Radical Cystectomy and Urinary Diversion | N/A | Icahn School of Medicine at Mount Sinai | <1 mi |
| Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection | Phase 1/2 | Blue Earth Therapeutics Ltd | <1 mi |
| Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination with Pembrolizumab, in Unresectable Melanoma Patients | Phase 2 | Philogen S.p.A. | <1 mi |
| Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment | Phase 2 | SWOG Cancer Research Network | <1 mi |
| Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours | Phase 3 | University of Sydney | <1 mi |
| Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma | N/A | Northwell Health | <1 mi |
| Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma | Phase 3 | Corvus Pharmaceuticals, Inc. | <1 mi |
| Pleuroscopy First Versus Thoracentesis First in Patients With Suspected Malignant Pleural Effusions | N/A | Icahn School of Medicine at Mount Sinai | <1 mi |
| Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma | Phase 2 | Gulam Manji | <1 mi |
| Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRC | Phase 1/2 | Dan Feng | <1 mi |
| Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma | Phase 3 | Alliance for Clinical Trials in Oncology | <1 mi |
| Avutometinib and Defactinib in Diffuse Gastric Cancer | Phase 2 | Ryan H. Moy, MD, PhD | <1 mi |
| A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer | Phase 1/2 | Alliance Foundation Trials, LLC. | <1 mi |
| A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib | Phase 4 | Eli Lilly and Company | <1 mi |
| A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate | Phase 2 | Prostate Cancer Clinical Trials Consortium | <1 mi |
| Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma | N/A | University of Southern California | <1 mi |
| A Study of CTD402 in T-ALL/LBL Patients | Phase 1/2 | BIOHENG THERAPEUTICS US LLC | <1 mi |
| A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer | Phase 3 | Astellas Pharma Global Development, Inc. | <1 mi |
| A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815 | Phase 1 | Jazz Pharmaceuticals | <1 mi |
| Evaluation of Tumor Control Based on Serial Multiparametric MRI and Post-Treatment Biopsies For Patients Treated With Dose Intensification to the Dominant Intra-Prostatic Lesion (DIL) Using Ultra-Hypofractionated, MR-Guided Radiotherapy | N/A | NYU Langone Health | <1 mi |
| Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | Phase 1 | Bristol-Myers Squibb | <1 mi |
| A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A) | Phase 1/2 | Merck Sharp & Dohme LLC | <1 mi |
| FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors | Phase 1 | Fate Therapeutics | <1 mi |
| A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001) | Phase 1 | Merck Sharp & Dohme LLC | <1 mi |
| New MRI Biomarkers in Head and Neck Cancers | — | Memorial Sloan Kettering Cancer Center | <1 mi |
| Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study | Phase 2 | Uma Borate | <1 mi |
| Selinexor and Backbone Treatments of Multiple Myeloma Patients | Phase 1/2 | Karyopharm Therapeutics Inc | <1 mi |
| A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments | Phase 1 | Regeneron Pharmaceuticals | <1 mi |
| Longitudinal Oral Microbiome Sampling for BE | — | Columbia University | <1 mi |
| A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence | Phase 2 | Philogen S.p.A. | <1 mi |
| Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML | Phase 1/2 | Sellas Life Sciences Group | <1 mi |
| A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer | Phase 4 | Coherus Oncology, Inc. | <1 mi |
| A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors | Phase 1 | Context Therapeutics Inc. | <1 mi |
| A Study of 177Lu-FAP-2286 in Advanced Solid Tumors | Phase 1/2 | Novartis Pharmaceuticals | <1 mi |
| A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant | Phase 2/3 | AbbVie | <1 mi |
| MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) Trial | Phase 2 | Icahn School of Medicine at Mount Sinai | <1 mi |
| Multi-Institutional Registry for Malignant Peripheral Nerve Sheath Tumors | — | Washington University School of Medicine | <1 mi |
| Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma | Phase 1 | Jiangsu Simcere Pharmaceutical Co., Ltd. | <1 mi |
| A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract | Phase 3 | Eli Lilly and Company | <1 mi |
| A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001) | Phase 1 | K36 Therapeutics, Inc. | <1 mi |
| TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II | Phase 1/2 | Tanja Andrea Gruber | <1 mi |
| PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness | — | Prostate Cancer Clinical Trials Consortium | <1 mi |
| A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer | Phase 1/2 | ImmunityBio, Inc. | <1 mi |
| A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors | Phase 1 | Johnson & Johnson Enterprise Innovation Inc. | <1 mi |
| A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer | Phase 3 | Incyte Corporation | <1 mi |
| A Study to Collect Information About the Use of Redifferentiating Medications as a Standard Treatment for Thyroid Cancer | — | Memorial Sloan Kettering Cancer Center | <1 mi |
| Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer | Phase 2 | Icahn School of Medicine at Mount Sinai | <1 mi |
| Stimulation With Bethanechol in Combination With Gemcitabine and Nab-paclitaxel in Pancreatic Adenocarcinoma | Phase 2 | Susan E. Bates | <1 mi |
| Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer | Phase 2 | Icahn School of Medicine at Mount Sinai | <1 mi |
| A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL) | Phase 1 | AbbVie | <1 mi |
| Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults | Phase 2 | Sabine Mueller, MD, PhD | <1 mi |
| Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes | Phase 1 | National Cancer Institute (NCI) | <1 mi |
| PRISM Study: Prostate Recurrence Detection Using Imaging With PSMA PET/MRI Post-high Intensity Focused Ultrasound | — | NYU Langone Health | <1 mi |
| Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma | Phase 2 | Yale University | <1 mi |
| A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma | Phase 1 | HiberCell, Inc. | <1 mi |
| The Use of Nanoparticles to Guide the Surgical Treatment of Prostate Cancer | Phase 1 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL) | Phase 3 | BeOne Medicines | <1 mi |
| Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer | Phase 3 | Jazz Pharmaceuticals | <1 mi |
| A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies | Phase 1 | Nurix Therapeutics, Inc. | <1 mi |
| Special Care Patterns for Elderly HNSCC Patients Undergoing Radiotherapy | — | University Hospital Freiburg | <1 mi |
| Outcomes of Low-Risk Endometrial Cancer With Isolated Tumor Cells in the Sentinel Lymph Nodes: A Prospective, Multicenter, Single-Arm Observational Study | — | Mayo Clinic | <1 mi |
| A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC) | — | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of the Use of Fat Flap Reconstruction to Reduce Neck Injury After Cancer Treatment | N/A | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL | Phase 1/2 | Amgen | <1 mi |
| Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC) | Phase 1 | Rgenta Therapeutics Inc | <1 mi |
| An Extension Study for Patients Previously Enrolled in Studies With Pelabresib | Phase 3 | Novartis Pharmaceuticals | <1 mi |
| 177Lu-DOTA-EB-TATE in Adult Patients With Advanced, Well- Differentiated Neuroendocrine Tumors | Phase 1 | Molecular Targeting Technologies, Inc. | <1 mi |
| FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC | Phase 2/3 | Bicara Therapeutics | <1 mi |
| A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations | Phase 2 | Fore Biotherapeutics | <1 mi |
| A Study of XB628 in Participants With Recurrent Advanced or Metastatic Solid Tumors | Phase 1 | Exelixis | <1 mi |
| Photodynamic Therapy of Primary Localized Prostate Cancer With the SpectraCure P18 System | Phase 1/2 | SpectraCure AB | <1 mi |
| Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors | Phase 1 | Riboscience, LLC. | <1 mi |
| Pan Tumor Rollover Study | Phase 2 | Bristol-Myers Squibb | <1 mi |
| SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma | Phase 3 | Immatics US, Inc. | <1 mi |
| Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL | Phase 1 | Meryx, Inc. | <1 mi |
| Surgery and Heated Intraperitoneal Chemotherapy for Adrenocortical Carcinoma | Phase 2 | Columbia University | <1 mi |
| (HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis | Phase 2/3 | Blueprint Medicines Corporation | <1 mi |
| Auditory Brainstem Implant (ABI) in Children With No Cochleae or Auditory Nerves | N/A | NYU Langone Health | <1 mi |
| A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC) | — | Tempus AI | <1 mi |
| Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute) | Phase 3 | Amgen | <1 mi |
| Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma | Phase 1 | National Cancer Institute (NCI) | <1 mi |
| Concurrent Azeliragon With Craniospinal Irradiation | Phase 1 | NYU Langone Health | <1 mi |
| Tissue Repository: CTCL Collection Protocol | — | Columbia University | <1 mi |
| Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors | Phase 1/2 | OncoC4, Inc. | <1 mi |
| A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma | Phase 1/2 | Hoffmann-La Roche | <1 mi |
| A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors | Phase 1/2 | Biohaven Therapeutics Ltd. | <1 mi |
| Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets | Phase 1 | AbbVie | <1 mi |
| A Study of MGC028 in Participants With Advanced Solid Tumors | Phase 1 | MacroGenics | <1 mi |
| Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer. | Phase 3 | SOFIE | <1 mi |
| A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011) | Phase 2 | Merck Sharp & Dohme LLC | <1 mi |
| A Study of ZN-c3 in Patients With Ovarian Cancer | Phase 1 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | <1 mi |
| Feasibility of Timesaving When Using Histolog Confocal Laser Endomicroscopy for Margin Assessment in Prostatectomy Specimen | N/A | Icahn School of Medicine at Mount Sinai | <1 mi |
| Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC | Phase 2 | Karie Runcie | <1 mi |
| An Acupuncture Study for People At High Risk for Sepsis | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis | Phase 3 | Cartesian Therapeutics | <1 mi |
| Correlation Vitamin D Level to Endocrine Autoimmune Toxicity Due to Immune Checkpoint Inhibitors | — | Icahn School of Medicine at Mount Sinai | <1 mi |
| Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia | Phase 1/2 | Novartis Pharmaceuticals | <1 mi |
| Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers | Phase 1/2 | Regeneron Pharmaceuticals | <1 mi |
| A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation | Phase 1 | TScan Therapeutics, Inc. | <1 mi |
| Lurbinectedin in FET-Fused Tumors | Phase 1/2 | Children's Hospital of Philadelphia | <1 mi |
| CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer | Phase 1 | National Cancer Institute (NCI) | <1 mi |
| A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation | Phase 2 | Center for International Blood and Marrow Transplant Research | <1 mi |
| Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Hematological Malignancies After T Cell Depleted Allo-HSCT | Phase 1/2 | Smart Immune SAS | <1 mi |
| A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02) | Phase 3 | AstraZeneca | <1 mi |
| Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer or Skin Cancer | Phase 1 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies | Phase 1/2 | BeOne Medicines | <1 mi |
| A Bilingual Virtually-based Intervention (PEDALL) for the Prevention of Weight Gain in Childhood ALL Patients Considering Key Genetic and Sociodemographic Risk Factors | N/A | Columbia University | <1 mi |
| AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC) | Phase 1/2 | Arsenal Biosciences, Inc. | <1 mi |
| Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm | Phase 1 | Marina Kremyanskaya | <1 mi |
| Registry for Esophageal and Gastroesophageal Junction Cancer | — | Memorial Sloan Kettering Cancer Center | <1 mi |
| Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer | Phase 1/2 | Icahn School of Medicine at Mount Sinai | <1 mi |
| Childhood Cancer Survivor Study | — | St. Jude Children's Research Hospital | <1 mi |
| Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer | Phase 2 | Tyra Biosciences, Inc | <1 mi |
| Adoptive Cell Therapy Long-term Follow-up (LTFU) Study | Phase 1 | USWM CT, LLC | <1 mi |
| Surgical Pembro +/- Olaparib w TMZ for rGBM | Phase 2 | L. Nicolas Gonzalez Castro, MD, PhD | <1 mi |
| CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL) | Phase 1/2 | Curis, Inc. | <1 mi |
| Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM | Phase 3 | Northwell Health | <1 mi |
| MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs) | — | MPN Research Foundation | <1 mi |
| A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab | Phase 1/2 | Regeneron Pharmaceuticals | <1 mi |
| A Study to Evaluate Preventive Treatments for Talquetamab-related Oral Toxicity | Phase 2 | Janssen Research & Development, LLC | <1 mi |
| A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation | Phase 1/2 | Syndax Pharmaceuticals | <1 mi |
| A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma | Phase 3 | AVEO Pharmaceuticals, Inc. | <1 mi |
| Feasibility Trial of Combination of Obstetrical Carrier Screening and Hereditary Cancer Screening | N/A | Columbia University | <1 mi |
| Neurofibromatosis (NF) Registry Portal | — | The Children's Tumor Foundation | <1 mi |
| Stereotactic MRI-guided Focused Ultrasound Mesencephalotomy | N/A | University of Virginia | <1 mi |
| Ablative Therapy in the Management of Prostate Cancer | — | Weill Medical College of Cornell University | <1 mi |
| Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera | Phase 3 | Italfarmaco | <1 mi |
| Association Between Exercise, Patient-Reported Outcomes, and Clinical Events in Adult Cancer Survivors | — | Memorial Sloan Kettering Cancer Center | <1 mi |
| R-MVST Cells for Treatment of Viral Infections in Children and Young Adults | Phase 1 | Columbia University | <1 mi |
| Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function | Phase 2 | Novartis Pharmaceuticals | <1 mi |
| A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC) | Phase 3 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Emapalumab for Pediatric Aplastic Anemia | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML | Phase 1 | Stelexis BioSciences | <1 mi |
| Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02) | Phase 1/2 | Merck Sharp & Dohme LLC | <1 mi |
| QTX3034 in Patients With KRAS G12D Mutation | Phase 1 | Quanta Therapeutics | <1 mi |
| Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma and Ependymoma | N/A | University of California, San Francisco | <1 mi |
| Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia | Phase 1 | St. Jude Children's Research Hospital | <1 mi |
| ORIC-114 in Combination with Subcutaneous Amivantamab in Patients with EGFR Exon20 Insertion Mutant NSCLC | Phase 1 | ORIC Pharmaceuticals | <1 mi |
| Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer | Phase 3 | SWOG Cancer Research Network | <1 mi |
| Longitudinal Screening for Financial Hardship to Improve Outcomes in Patients With Advanced Cancer | N/A | Alliance Foundation Trials, LLC. | <1 mi |
| Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation | Phase 2 | Weill Medical College of Cornell University | <1 mi |
| The SUGAR Study; SBRT and Relugolix) for Prostate Cancer | Phase 2 | Yale University | <1 mi |
| The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global) | Phase 3 | Telix Pharmaceuticals (Innovations) Pty Limited | <1 mi |
| EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma | Phase 3 | NovoCure GmbH | <1 mi |
| DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2) | Phase 3 | Day One Biopharmaceuticals, Inc. | <1 mi |
| Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations | Phase 2 | Boehringer Ingelheim | <1 mi |
| 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE) | Phase 1/2 | Clarity Pharmaceuticals Ltd | <1 mi |
| A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003) | Phase 1/2 | Merck Sharp & Dohme LLC | <1 mi |
| IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers | Phase 1/2 | Indapta Therapeutics, INC. | <1 mi |
| A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias | Phase 1 | Syndax Pharmaceuticals | <1 mi |
| A Study of Avutometinib for People With Solid Tumor Cancers | Phase 1 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Decentralized Clinical Trial of Effectiveness of EnergyPoints App in Cancer Survivors | N/A | 5 Point App, Inc. | <1 mi |
| In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET | Early 1 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Adaptive Radiation in Anal Cancer | N/A | Columbia University | <1 mi |
| Treatment of Inflammatory Myelitis and Optic Neuritis With Early vs Rescue Plasma Exchange (TIMELY-PLEX) | Phase 3 | Mayo Clinic | <1 mi |
| MB-105 in Patients With CD5 Positive T-cell Lymphoma | Phase 2 | March Biosciences Inc | <1 mi |
| A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma | Phase 1/2 | Bristol-Myers Squibb | <1 mi |
| Observing People With Desmoid-Type Fibromatosis | — | Memorial Sloan Kettering Cancer Center | <1 mi |
| FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3 | Phase 1 | Eli Lilly and Company | <1 mi |
| Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) | Phase 2 | AstraZeneca | <1 mi |
| A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma | Phase 1 | K36 Therapeutics, Inc. | <1 mi |
| Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours | Phase 1/2 | AstraZeneca | <1 mi |
| A Study of EP0031 in Patients With Advanced RET-altered Malignancies | Phase 1/2 | Ellipses Pharma | <1 mi |
| The Efficacy of Conventional Screening Versus mHealth Screening in Early Detection of Oral Potentially Malignant Disorders and Oral Cancer Amongst the Rural Population of Varanasi: A Prospective and Blinded Study | — | Memorial Sloan Kettering Cancer Center | <1 mi |
| First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma | Phase 1/2 | Adcendo ApS | <1 mi |
| A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel | Phase 2 | Janssen Research & Development, LLC | <1 mi |
| A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma | Phase 3 | Ivy Brain Tumor Center | <1 mi |
| Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial | Phase 3 | M.D. Anderson Cancer Center | <1 mi |
| Psilocybin Therapy in Advanced Cancer | Phase 2/3 | NYU Langone Health | <1 mi |
| Colonoscopy vs Stool Testing for Older Adults With Colon Polyps | N/A | Dartmouth-Hitchcock Medical Center | <1 mi |
| Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder | Phase 1/2 | Noah Hahn, M.D. | <1 mi |
| A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma | Phase 2/3 | Replimune Inc. | <1 mi |
| Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma | Phase 1/2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC | Phase 3 | RenovoRx | <1 mi |
| A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy | Phase 3 | GlaxoSmithKline | <1 mi |
| Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions | Phase 1/2 | IDEAYA Biosciences | <1 mi |
| Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs | Phase 1 | Cellenkos, Inc. | <1 mi |
| Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer | Phase 3 | NRG Oncology | <1 mi |
| A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 | Phase 2/3 | BioNTech SE | <1 mi |
| A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors | Phase 1/2 | Regeneron Pharmaceuticals | <1 mi |
| A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors | Phase 2 | Day One Biopharmaceuticals, Inc. | <1 mi |
| TLN-372 in Advanced KRAS Mutant Solid Tumors | Phase 1 | Treeline Biosciences, Inc. | <1 mi |
| A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010) | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| Evaluating the Long-term Safety and Tolerability of Imatinib in Patients With Lymphangioleiomyomatosis (LAM) | Phase 1 | Columbia University | <1 mi |
| A Study of Noninvasive Methods to Evaluate Skin and Mucosal Conditions | — | Memorial Sloan Kettering Cancer Center | <1 mi |
| Concurrent XRD-0394 With Radiation Therapy for High Grade Gliomas | Early 1 | NYU Langone Health | <1 mi |
| Comprehensive Assessment of Cancer Theranostic Response | N/A | AIQ Solutions | <1 mi |
| IVIG for Infection Prevention After CAR-T-Cell Therapy | Phase 2 | Fred Hutchinson Cancer Center | <1 mi |
| Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia | Phase 1/2 | Disc Medicine, Inc | <1 mi |
| A Multi Center Study of Sexual Toxicities After Radiotherapy | — | Icahn School of Medicine at Mount Sinai | <1 mi |
| Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy | Phase 3 | Clarity Pharmaceuticals Ltd | <1 mi |
| A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes | Phase 1 | GluBio Therapeutics Inc. | <1 mi |
| PediRISE Feasibility | N/A | Dana-Farber Cancer Institute | <1 mi |
| A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis. | Phase 1/2 | Alexion Pharmaceuticals, Inc. | <1 mi |
| A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC) | Phase 1 | Hoffmann-La Roche | <1 mi |
| Gadopiclenol in Contrast Enhanced MRI of the Prostate | Phase 4 | Columbia University | <1 mi |
| A Study of Changes to Prostate Procedures | Phase 3 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation | Phase 2 | Medical College of Wisconsin | <1 mi |
| A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer | Phase 1 | Bristol-Myers Squibb | <1 mi |
| SARC046: A Phase II Trial of Nab-Sirolimus in Patients With Progressing or Symptomatic Epithelioid Hemangioendothelioma | Phase 2 | Sarcoma Alliance for Research through Collaboration | <1 mi |
| Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer | Phase 2/3 | VA Office of Research and Development | <1 mi |
| A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer | Phase 1/2 | Compugen Ltd | <1 mi |
| A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer | Phase 3 | Verastem, Inc. | <1 mi |
| Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER | Phase 2 | Canadian Cancer Trials Group | <1 mi |
| Adaptive Radiotherapy and MRIs Based on Patients With Newly Diagnosed High-Grade Glioma | N/A | Columbia University | <1 mi |
| Intratumoral and Systemic Hiltonol® (Poly-ICLC) in Prostate Cancer Patients on Active Surveillance | Phase 2 | Ashutosh Kumar Tewari | <1 mi |
| A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms | Phase 1 | Incyte Corporation | <1 mi |
| A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies | Phase 1/2 | Daiichi Sankyo | <1 mi |
| A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1) | Phase 1/2 | Ranok Therapeutics (Hangzhou) Co., Ltd. | <1 mi |
| High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer | Phase 3 | Alliance for Clinical Trials in Oncology | <1 mi |
| Pembrolizumab, Ibrutinib and Rituximab in PCNSL | Phase 1/2 | Dana-Farber Cancer Institute | <1 mi |
| Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies | Phase 4 | Rigel Pharmaceuticals | <1 mi |
| A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia | Phase 1 | Hoffmann-La Roche | <1 mi |
| Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer | Phase 2 | Catherine Spina | <1 mi |
| Investigations of Reproductive Cancers in Women | — | PinkDx, Inc. | <1 mi |
| A Study of Codrituzumab in Children and Young Adults With Solid Tumors and Have Not Responded to Treatment or Have Come Back After Treatment | Phase 1 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Decision Aid (DA) for Renal Patients | N/A | NYU Langone Health | <1 mi |
| Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC) | Phase 2 | Convergent Therapeutics | <1 mi |
| Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | Phase 2 | AstraZeneca | <1 mi |
| To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid Tumors | Phase 1 | Day One Biopharmaceuticals, Inc. | <1 mi |
| Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC) | Phase 3 | The Netherlands Cancer Institute | <1 mi |
| A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer | Phase 2 | Syncromune, Inc. | <1 mi |
| A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma | Early 1 | AIDS Malignancy Consortium | <1 mi |
| Implementing the NYU Electronic Patient Visit Assessment (ePVA) for Head and Neck Cancer In Rural and Urban Populations | N/A | The University of Texas Health Science Center, Houston | <1 mi |
| Changes Associated With H. Pylori and Gastric Carcinogenesis | — | Weill Medical College of Cornell University | <1 mi |
| Cryopreservation of Ovarian Tissue | N/A | Weill Medical College of Cornell University | <1 mi |
| Study of CAR-T Therapy in Older Patients | — | Memorial Sloan Kettering Cancer Center | <1 mi |
| Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment | Phase 3 | SWOG Cancer Research Network | <1 mi |
| Adaptive Treatment De-escalation in Favorable Risk HPV-Positive Oropharyngeal Carcinoma | Phase 2 | NYU Langone Health | <1 mi |
| Omental Tissue Autograft in Human Recurrent Glioblastoma Multiforme (rGBM) | N/A | Northwell Health | <1 mi |
| Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles) | — | GT Medical Technologies, Inc. | <1 mi |
| A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1 | Phase 2 | Healx Limited | <1 mi |
| Treating Basal and Squamous Cell Carcinomas With Fractional Laser and Tirbanibulin Ointment | Phase 1/2 | Bruce Robinson, MD | <1 mi |
| Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma | Phase 2 | Academic and Community Cancer Research United | <1 mi |
| A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study) | Phase 2/3 | Taiho Oncology, Inc. | <1 mi |
| Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer | Phase 2 | Weill Medical College of Cornell University | <1 mi |
| INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) | Phase 2 | Patrick Wen, MD | <1 mi |
| Molecular Characterization of Neuroblastic Tumor: Correlation With Clinical Outcome | — | Memorial Sloan Kettering Cancer Center | <1 mi |
| Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma | Phase 1 | SciTech Development, Inc. | <1 mi |
| SPEARHEAD-3 Pediatric Study | Phase 1/2 | USWM CT, LLC | <1 mi |
| WATER IV Prostate Cancer | N/A | PROCEPT BioRobotics | <1 mi |
| A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors | Phase 1 | Daiichi Sankyo | <1 mi |
| Cord Blood Transplant in Adults With Blood Cancers | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | Phase 2/3 | Daiichi Sankyo | <1 mi |
| Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer | Phase 2 | Matthew Galsky | <1 mi |
| Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 Alone and in Combination in Patients With Selected Solid Tumors | Phase 1/2 | Everest Medicines (Beijing) Co., Ltd. | <1 mi |
| A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas | Phase 1 | Weill Medical College of Cornell University | <1 mi |
| Alpha Radiation Emitters Device for the Treatment of Pancreatic Cancer With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer | N/A | Alpha Tau Medical LTD. | <1 mi |
| Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | Phase 2 | SWOG Cancer Research Network | <1 mi |
| Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies | — | National Cancer Institute (NCI) | <1 mi |
| A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies | Phase 1/2 | CRISPR Therapeutics | <1 mi |
| Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma | Phase 1/2 | Neonc Technologies, Inc. | <1 mi |
| A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1) | Phase 1 | Nuvalent Inc. | <1 mi |
| Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer | Phase 2/3 | Panbela Therapeutics, Inc. | <1 mi |
| Study of ORIC-944 in Patients With Metastatic Prostate Cancer | Phase 1 | ORIC Pharmaceuticals | <1 mi |
| Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers | N/A | Memorial Sloan Kettering Cancer Center | <1 mi |
| Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015) | Phase 2 | Merck Sharp & Dohme LLC | <1 mi |
| Defining TRPV4 Contribution of Schwann Cells to Oral Cancer Pain | N/A | New York University | <1 mi |
| ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer | Phase 2 | Zenith Epigenetics | <1 mi |
| AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia | Phase 1/2 | AstraZeneca | <1 mi |
| Adapting for Latinx Populations an Intervention That Involves Discussing and Sharing Patients' Health-Related Values | N/A | Memorial Sloan Kettering Cancer Center | <1 mi |
| Rapid Sequencing of Approved Therapies in Patients with Metastatic or Unresectable Clear Cell Renal Cell Carcinoma | Early 1 | Icahn School of Medicine at Mount Sinai | <1 mi |
| A Study of JNJ-87189401 Plus JNJ-78278343 for Advanced Prostate Cancer | Phase 1 | Janssen Research & Development, LLC | <1 mi |
| Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy | Phase 2 | Academic and Community Cancer Research United | <1 mi |
| Seattle Biopsy Protocol Versus Wide-Area Transepithelial Sampling in Patients With Barrett's Esophagus Undergoing Surveillance | N/A | University of Colorado, Denver | <1 mi |
| Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment | Phase 3 | Canadian Cancer Trials Group | <1 mi |
| A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors | Phase 1/2 | Hutchmed | <1 mi |
| A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias | Phase 1 | Crossbow Therapeutics, Inc. | <1 mi |
| Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia | Phase 2 | Jonathan Brammer | <1 mi |
| Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer | Phase 3 | AstraZeneca | <1 mi |
| Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer | Phase 1/2 | Imunon | <1 mi |
| A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia | Phase 1 | Enliven Therapeutics | <1 mi |
| A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer | Phase 1/2 | Janssen Research & Development, LLC | <1 mi |
| A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas | Phase 1 | CStone Pharmaceuticals | <1 mi |
| Discovering New Targets for Colorectal and Endometrial Cancer Risk Reduction | — | Weill Medical College of Cornell University | <1 mi |
| A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases | Phase 2 | Pierre Fabre Medicament | <1 mi |
| A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103) | Phase 1 | Amgen | <1 mi |
| Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma | Phase 3 | AbbVie | <1 mi |
| Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma | Phase 1 | Weill Medical College of Cornell University | <1 mi |
| Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA | Phase 1/2 | Northwell Health | <1 mi |
| Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma | — | International Extranodal Lymphoma Study Group (IELSG) | <1 mi |
| A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma | Phase 3 | Aura Biosciences | <1 mi |
| NYC Cancer Outreach Network in Neighborhoods for Equity and Community Translation | N/A | NYU Langone Health | <1 mi |
| Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy | Phase 3 | RayzeBio, Inc. | <1 mi |
| A Study of Narmafotinib Given in Combination With Modified FOLFIRINOX in Patients With Metastatic Pancreatic Cancer | Phase 1/2 | Amplia Therapeutics Limited | <1 mi |
| Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors | Phase 1/2 | Vivace Therapeutics, Inc | <1 mi |
| A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051) | Phase 1/2 | Merck Sharp & Dohme LLC | <1 mi |
| DALY II USA/ MB-CART2019.1 for DLBCL | Phase 2 | Miltenyi Biomedicine GmbH | <1 mi |
| A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies | Phase 1/2 | Deciphera Pharmaceuticals, LLC | <1 mi |
| ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL | N/A | Hua-Jay J Cherng, MD | <1 mi |
| First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors | Phase 1 | Daiichi Sankyo | <1 mi |
| A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies | Phase 1 | Seagen, a wholly owned subsidiary of Pfizer | <1 mi |
| A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms | Phase 1 | Incyte Corporation | <1 mi |
| A Study of ASP3082 in Adults With Advanced Solid Tumors | Phase 1 | Astellas Pharma Inc | <1 mi |
| Imetelstat Combinations in Relapsed AML | Phase 1 | Douglas Tremblay | <1 mi |
| Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT) | Phase 2 | Columbia University | <1 mi |
| Radiofrequency Ablation Study in LatinX Patients | N/A | Northwell Health | <1 mi |
| Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer. | Phase 1/2 | TILT Biotherapeutics Ltd. | <1 mi |
| Avapritinib With Decitabine in Patients With SM-AHN | Phase 1 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS) | Phase 2 | Swedish Orphan Biovitrum | <1 mi |
| Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII | Phase 2 | Black Diamond Therapeutics, Inc. | <1 mi |
| ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies | Phase 1 | Beijing InnoCare Pharma Tech Co., Ltd. | <1 mi |
| A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma | Phase 1/2 | ModernaTX, Inc. | <1 mi |
| Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer | Phase 1 | Weill Medical College of Cornell University | <1 mi |
| Candida Therapeutic Vaccine in Head and Neck Cancer Patients to Reduce Recurrence | Phase 2 | University of Arkansas | <1 mi |
| A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer | Phase 2 | Cybrexa Therapeutics | <1 mi |
| A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell Sarcoma | Phase 2 | Sarcoma Alliance for Research through Collaboration | <1 mi |
| TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas | Phase 1 | Treeline Biosciences, Inc. | <1 mi |
| Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial | Phase 2 | Alliance for Clinical Trials in Oncology | <1 mi |
| A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases | Phase 1 | Arcellx, Inc. | <1 mi |
| EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors | Phase 1/2 | Eikon Therapeutics | <1 mi |
| Collection and Storage of Tissue and Blood Samples From Patients With Cancer | — | National Cancer Institute LAO | <1 mi |
| A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer | Phase 3 | AstraZeneca | <1 mi |
| A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients | Phase 3 | Merus B.V. | <1 mi |
| Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate Cancer | Phase 2 | Weill Medical College of Cornell University | <1 mi |
| A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors | Phase 3 | BeOne Medicines | <1 mi |
| Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation | Phase 1 | Institut de Recherches Internationales Servier | <1 mi |
| Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma | — | Case Western Reserve University | <1 mi |
| A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7) | Phase 1 | ADC Therapeutics S.A. | <1 mi |
| Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma | Phase 2/3 | Daiichi Sankyo | <1 mi |
| Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial) | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma | Phase 1/2 | Northwell Health | <1 mi |
| Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC | Phase 3 | Novartis Pharmaceuticals | <1 mi |
| Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis | Phase 1/2 | Nexcella Inc. | <1 mi |
| Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects | Phase 1/2 | VBI Vaccines Inc. | <1 mi |
| Retinoblastoma Phase II Expanded Access Clinical Trial | Phase 2 | Targeted Therapy Technologies, LLC | <1 mi |
| First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors | Phase 1 | IDRx Inc. - A GSK Company | <1 mi |
| Universal Genetic Testing for Cancer Risk Reduction | N/A | NYU Langone Health | <1 mi |
| SAFE Nerve Sparing Guided by Micro-ultrasound (MUS) | Phase 3 | Icahn School of Medicine at Mount Sinai | <1 mi |
| Retrospective Review of Esophageal Cancer at MSKCC | — | Memorial Sloan Kettering Cancer Center | <1 mi |
| Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03) | Phase 1/2 | Merck Sharp & Dohme LLC | <1 mi |
| A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma | Phase 1 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | <1 mi |
| A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism | Phase 3 | Rezolute | <1 mi |
| ARCTIC: Liquid Biomarkers in the Prospective Androgen Receptor Signaling Inhibitors (ARSI) Resistance Clinical Trials | — | Duke University | <1 mi |
| A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM | Phase 1 | Boston Scientific Corporation | <1 mi |
| A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1) | Phase 1/2 | Nuvalent Inc. | <1 mi |
| A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29) | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| Patient-Reported Outcomes and Quality of Life in Adult and Pediatric Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL) | — | St. Jude Children's Research Hospital | <1 mi |
| Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma | Phase 2 | NYU Langone Health | <1 mi |
| Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma | Phase 1 | Orbus Therapeutics, Inc. | <1 mi |
| A Study of CHS-114 in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors | Phase 1 | Coherus Oncology, Inc. | <1 mi |
| Chronic CED of TPT for Recurrent Malignant Glioma | Phase 1 | Jeffrey N. Bruce | <1 mi |
| Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors | Phase 2/3 | Exelixis | <1 mi |
| A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer | Phase 3 | Eli Lilly and Company | <1 mi |
| Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors | Phase 1/2 | AstraZeneca | <1 mi |
| A Study to Investigate ANS03 in Participants With Locally Advanced or Metastatic Solid Tumors | Phase 1 | Avistone Biotechnology Co., Ltd. | <1 mi |
| A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas | Phase 1/2 | Dren Bio | <1 mi |
| Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia | Phase 1/2 | Leland Metheny | <1 mi |
| CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL) | Phase 1 | Vittoria Biotherapeutics | <1 mi |
| A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma | Phase 1/2 | AstraZeneca | <1 mi |
| Blue Light Cystoscopy With Cysview® Registry | — | Photocure | <1 mi |
| Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL | Phase 2 | Etan Orgel | <1 mi |
| A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer | Phase 2 | Eli Lilly and Company | <1 mi |
| Excision of Lymph Node Trial (EXCILYNT) (Mel69) | N/A | Craig L Slingluff, Jr | <1 mi |
| First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia | Phase 1/2 | Kura Oncology, Inc. | <1 mi |
| Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer | Phase 1 | National Cancer Institute (NCI) | <1 mi |
| MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas | Phase 1/2 | Ann & Robert H Lurie Children's Hospital of Chicago | <1 mi |
| A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer | Phase 1 | NYU Langone Health | <1 mi |
| Brentuximab Vedotin in Early Stage Hodgkin Lymphoma | Phase 3 | University College, London | <1 mi |
| Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma | Phase 1 | AIDS Malignancy Consortium | <1 mi |
| Fitness and Nutrition in Glioma | N/A | NYU Langone Health | <1 mi |
| A Study of ASKG915 in Patients With Selected Advanced Solid Tumors. | Phase 1/2 | AskGene Pharma, Inc. | <1 mi |
| Epco, Zanu, Ritux for R/R FL or MZL | Phase 2 | Reid Merryman, MD | <1 mi |
| Interrogation of Exosome-mediated Intercellular Signaling in Patients With Pancreatic Cancer | — | Memorial Sloan Kettering Cancer Center | <1 mi |
| Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia | Phase 1 | Kura Oncology, Inc. | <1 mi |
| Helping Men Adhere to Sexual Rehabilitation Following Prostate Cancer Surgery | N/A | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib | Phase 1/2 | AbbVie | <1 mi |
| Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors | Phase 1/2 | ModernaTX, Inc. | <1 mi |
| Community Health Workers United to Reduce Colorectal Cancer and Cardiovascular Disease Among People at Higher Risk | N/A | Columbia University | <1 mi |
| Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma | Phase 2 | Divaya Bhutani | <1 mi |
| Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01) | Phase 1 | Janux Therapeutics | <1 mi |
| A Study of ASP1002 in Adults for Treatment of Solid Tumors | Phase 1 | Astellas Pharma Global Development, Inc. | <1 mi |
| Miro3D Wound Matrix Study for Diabetic Foot Ulcers and Wound Healing | N/A | Reprise Biomedical, Inc. | <1 mi |
| Reducing Diabetes Distress Using Cognitive Behavioral Therapy in Young Adults With Type 1 Diabetes | N/A | Albert Einstein College of Medicine | <1 mi |
| Transformative Research in Diabetic Nephropathy | — | University of Pennsylvania | <1 mi |
| Medically Tailored Meals for Cardiovascular Health | N/A | Columbia University | <1 mi |
| A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes | Phase 3 | Sanofi | <1 mi |
| Fenofibrate for Prevention of DR Worsening | Phase 3 | Jaeb Center for Health Research | <1 mi |
| Novel Digital Patient-Reported Outcomes Tool for Diabetes Management | N/A | NYU Langone Health | <1 mi |
| CHIME: Comparing Health Interventions for Maternal Equity | N/A | Stanford University | <1 mi |
| Texts for Diabetes Control Among Homeless Persons | N/A | George Washington University | <1 mi |
| Implementing an Effective Diabetes Intervention Among Low-Income Immigrants | N/A | NYU Langone Health | <1 mi |
| PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes | Phase 4 | Brigham and Women's Hospital | <1 mi |
| Different Doses of Naronapride Vs. Placebo in Gastroparesis | Phase 2 | Dr. Falk Pharma GmbH | <1 mi |
| A Study of GNTI-122 in Adults Recently Diagnosed With T1D | Phase 1 | GentiBio, Inc | <1 mi |
| PRenatal and Obstetric Maternal Exposures and ISlet Autoantibodies in Early Life | — | University of Colorado, Denver | <1 mi |
| Bionic Pancreas in CFRD | Phase 3 | Jaeb Center for Health Research | <1 mi |
| DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes | Phase 4 | Ohio State University | <1 mi |
| CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D) | Phase 1/2 | COUR Pharmaceutical Development Company, Inc. | <1 mi |
| A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin | Phase 3 | Eli Lilly and Company | <1 mi |
| RESET System Pivotal Trial (Rev F) | N/A | Morphic Medical Inc. | <1 mi |
| A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight | Phase 3 | Eli Lilly and Company | <1 mi |
| Cholesterol Lowering and Residual Risk in Diabetes, Type 1 | Phase 4 | NYU Langone Health | <1 mi |
| Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease | Phase 3 | Prokidney | <1 mi |
| Inhaled Insulin vs Rapid-acting Injections for Post-meal Glucose Control in Women With Gestational Diabetes | Phase 2/3 | Jaeb Center for Health Research | <1 mi |
| T1D Pregnancy & Me | — | Jaeb Center for Health Research | <1 mi |
| CGM for the Early Detection and Management of Hyperglycemia in Pregnancy | N/A | Jaeb Center for Health Research | <1 mi |
| Cleaner Air for Lower Cardiometabolic Risk | N/A | NYU Langone Health | <1 mi |
| Graded Insulin Suppression Test P&F | Phase 1 | Columbia University | <1 mi |
| Diazoxide Suppression Test P&F Study | Phase 1 | Columbia University | <1 mi |
| Studying the Presence of CFRD Complications With Thoughtful Recruitment (SPeCTRuM) | — | Jaeb Center for Health Research | <1 mi |
| TrialNet Pathway to Prevention of T1D | — | University of South Florida | <1 mi |
| A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes | Phase 3 | Novo Nordisk A/S | <1 mi |
| HLA Demographics Study in Adults With Type 1 Diabetes | — | GentiBio, Inc | <1 mi |
| Leveraging Videos and Community Health Workers to Address Social Determinants of Health in Immigrants | N/A | NYU Langone Health | <1 mi |
| ED Diabetes Screening and Outpatient Care | N/A | NYU Langone Health | <1 mi |
| Real World Evidence Clinical Utility Study of KidneyIntelX | — | Renalytix AI, Inc. | <1 mi |
| Pregnancy and Postpartum CGM in GDM | — | Icahn School of Medicine at Mount Sinai | <1 mi |
| Study of N-acetylcysteine in the Treatment of Patients With the m.3243A>G Mutation and Low Brain Glutathione Levels | Phase 1 | Michio Hirano, MD | <1 mi |
| Lifestyle Patterns and Glycemic Control | N/A | Columbia University | <1 mi |
| Biomarker-guided rTMS for Treatment Resistant Depression | Phase 3 | Weill Medical College of Cornell University | <1 mi |
| A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder | Phase 2 | AbbVie | <1 mi |
| Invasive Decoding and Stimulation of Altered Reward Computations in Depression Patients | N/A | Icahn School of Medicine at Mount Sinai | <1 mi |
| Telephone-Based Support Programs for People With Epilepsy | N/A | NYU Langone Health | <1 mi |
| A Digital Intervention for Post-Stroke Depression and Executive Dysfunction | Phase 2 | Weill Medical College of Cornell University | <1 mi |
| ROSE in Sunset Park | N/A | NYU Langone Health | <1 mi |
| Psilocybin With Pimavanserin Compared to Psilocybin Alone for the Treatment of Major Depressive Disorder | Phase 2 | Icahn School of Medicine at Mount Sinai | <1 mi |
| A Study to Evaluate Sleep Electroencephalogram (EEG) Features (Brain Activity While Sleeping) in Participants With Major Depressive Disorder (MDD) | — | Janssen Research & Development, LLC | <1 mi |
| Feasibility of Home-Based Intermittent 60Hz Light Therapy for Major Depressive Disorder (MDD) | N/A | NYU Langone Health | <1 mi |
| Maintenance rTMS for Depression (Maitr-De) | N/A | University of California, San Diego | <1 mi |
| Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder | Phase 3 | Intra-Cellular Therapies, Inc. | <1 mi |
| Accelerated TMS for MDD | N/A | Neuronetics | <1 mi |
| Heart Rate Variability (HRV)-Guided Transcranial Direct Current Stimulation (tDCS) | N/A | NYU Langone Health | <1 mi |
| Ketamine-Assisted Psychotherapy (KAP) Compared to Ketamine Alone for the Treatment of Depression | Phase 2 | Icahn School of Medicine at Mount Sinai | <1 mi |
| A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression | Phase 2 | Draig Therapeutics Ltd | <1 mi |
| A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder | Phase 3 | Cybin IRL Limited | <1 mi |
| Brain Changes During Social Reward Psychotherapy for Mid- and Late-Life Suicidality | N/A | Weill Medical College of Cornell University | <1 mi |
| Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2) in Major Depressive Disorder (MDD) | Phase 2 | NYU Langone Health | <1 mi |
| WeCare: A System of Care for Black Youth | N/A | New York University | <1 mi |
| Improving the Mental Health of Home Health Aides | N/A | Weill Medical College of Cornell University | <1 mi |
| Mindfulness-Based fMRI Neurofeedback for Depression | N/A | Columbia University | <1 mi |
| Neutralizing Interleukin (IL)-6 | Phase 2 | Icahn School of Medicine at Mount Sinai | <1 mi |
| A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder | Phase 2 | AbbVie | <1 mi |
| Tele-PROTECT Therapy: Effectiveness, Empowerment, and Implementation | N/A | Weill Medical College of Cornell University | <1 mi |
| Accelerated TMS for Depression and OCD | N/A | Weill Medical College of Cornell University | <1 mi |
| DBS for TRD With the Medtronic Percept PC | N/A | Helen Mayberg, MD | <1 mi |
| A Digitally Assisted Risk Reduction Platform for Youth at High Risk for Suicide | N/A | Ksana Health | <1 mi |
| Network Neurofeedback Using 7-Tesla MRI to Reduce Rumination Levels in Depression | N/A | Icahn School of Medicine at Mount Sinai | <1 mi |
| WellPATH-PREVENT: A Mobile Intervention for Middle-Aged and Older Adults Hospitalized for Suicidal Ideation or Attempt | N/A | Weill Medical College of Cornell University | <1 mi |
| SAINT in Postpartum Depression (PPD) | N/A | Magnus Medical | <1 mi |
| Safe Mothers, Safe Children Initiative | N/A | New York University | <1 mi |
| Transcranial Near Infrared Radiation and Cerebral Blood Flow in Depression - R33 | N/A | NYU Langone Health | <1 mi |
| A Study of Brenipatide in Adult Participants With Major Depressive Disorder | Phase 3 | Eli Lilly and Company | <1 mi |
| Engage & Connect: A Psychotherapy for Postpartum Depression | N/A | Weill Medical College of Cornell University | <1 mi |
| Longitudinal Early-onset Alzheimer's Disease Study Protocol | — | Indiana University | <1 mi |
| Late Onset Alzheimer's Disease | — | Columbia University | <1 mi |
| ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease | N/A | InSightec | <1 mi |
| Triage Survey for Neurology Research Eligibility | — | Adams Clinical | <1 mi |
| Evaluating the Efficacy of the Pain Identification and Communication Toolkit | N/A | Weill Medical College of Cornell University | <1 mi |
| Dominantly Inherited Alzheimer Network (DIAN) | — | Washington University School of Medicine | <1 mi |
| Genetic Studies of Early-onset Dementia | — | Columbia University | <1 mi |
| Longitudinal Imaging of Microglial Activation in Different Clinical Variants of Alzheimer's Disease | Phase 2 | Patrick Lao | <1 mi |
| Phase 2 - Rhythmic Light Therapy for Alzheimer's Disease Patients | N/A | Icahn School of Medicine at Mount Sinai | <1 mi |
| Discovery and Validation of Genetic Variants Affecting Microglial Activation in Alzheimer's Disease | Phase 2 | Columbia University | <1 mi |
| Dementia Caregivers' Link to Assistance and Resources | N/A | Visiting Nurse Service of New York | <1 mi |
| Aβ Dynamics in LLMD | Phase 4 | NYU Langone Health | <1 mi |
| Innate Immunity Stimulation Via TLR9 in Early AD | Phase 1 | NYU Langone Health | <1 mi |
| Early Age-Related Hearing Loss Investigation (EARHLI) | N/A | Columbia University | <1 mi |
| A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation | Phase 2/3 | Washington University School of Medicine | <1 mi |
| A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease | Phase 3 | Bristol-Myers Squibb | <1 mi |
| The Effects of Successful OSA Treatment on Memory and AD Biomarkers in Older Adults Study | N/A | California Pacific Medical Center Research Institute | <1 mi |
| A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation | Phase 2/3 | Washington University School of Medicine | <1 mi |
| Chronic Widespread Pain After Rapid Weight Loss in Non-Hispanic Black and Hispanic/Latino/a/x Adults | — | New York University | <1 mi |
| VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2) | Phase 3 | Viking Therapeutics, Inc. | <1 mi |
| A Study to Investigate Why Overweight People Regain Weight After Losing Weight in a Behavioral Weight Loss Program | N/A | University of Pittsburgh | <1 mi |
| Time Restricted Eating for WeIght LoSs MainTenance-2 | N/A | NYU Langone Health | <1 mi |
| Comparing the Efficacy and Safety of the EndoZip System and Apollo ESG in Obese Patients | N/A | Nitinotes Surgical Ltd. | <1 mi |
| Family COMIDA (Consumo de Opciones Más Ideales De Alimentos) (Eating More Ideal Food Options) | N/A | Memorial Sloan Kettering Cancer Center | <1 mi |
| Weight Loss Study: Genetics and Response to Naltrexone/Bupropion | Phase 4 | Columbia University | <1 mi |
| AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight | Phase 3 | Novo Nordisk A/S | <1 mi |
| Endoscopic Bariatric Therapies (EBTs): A Retrospective and Prospective Multicenter Registry | — | Weill Medical College of Cornell University | <1 mi |
| Reducing Obesity Using Social Ties Program | N/A | Weill Medical College of Cornell University | <1 mi |
| Randomized Study on Transoral Outlet Reduction and Lifestyle Changes for Weight Regain After Gastric Bypass | N/A | Boston Scientific Corporation | <1 mi |
| Non-invasive Vagal Stimulation for Frequent Premature Ventricular Complexes | N/A | Northwell Health | <1 mi |
| A Patient Activation Approach to Implementing Depression Treatment in Cardiac Patients | N/A | Columbia University | <1 mi |
| Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia | Phase 3 | Novartis Pharmaceuticals | <1 mi |
| AGENT DCB STANCE: Safety and Effectiveness Study of AGENT Drug-Coated Balloon Compared to Standard of Care Percutaneous Coronary Intervention (PCI) Treatment for de Novo Coronary Lesions | N/A | Boston Scientific Corporation | <1 mi |
| A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy | Phase 3 | Lexicon Pharmaceuticals | <1 mi |
| XVIVO Heart Box (XHB) With Supplemented XVIVO Heart Solution (SXHS) Continued Access Protocol (CAP) | N/A | XVIVO Perfusion | <1 mi |
| Perioperative Anticoagulant Use for Surgery Evaluation -2 (PAUSE-2) Study Patients Receiving a Direct Oral Anticoagulant (DOACs-Dabigatran, Rivaroxaban, Apixaban or Edoxaban) and Needing Elective High-Bleed-Risk Surgery or an Invasive Procedure | N/A | McMaster University | <1 mi |
| The Peri-OPerative COlchicine to Reduce Negative Events (POPCORN) Trial | Phase 4 | VA Office of Research and Development | <1 mi |
| Intravascular Lithotripsy With or Without Rotational Atherectomy for Coronary Calcified Nodule Treatment | N/A | Annapoorna Kini | <1 mi |
| The Half Moon Transcatheter Mitral Valve Repair (TMVr) Pilot Study | N/A | Half Moon Medical | <1 mi |
| Beta-blocker Administration for Cardiomyocyte Division | Phase 1 | Weill Medical College of Cornell University | <1 mi |
| EFS of the DUO System for Tricuspid Regurgitation | N/A | CroiValve Limited | <1 mi |
| Open-label, Dose Escalation Study of Safety and Preliminary Efficacy of TN-401 in Adults With PKP2 Mutation-associated ARVC | Phase 1 | Tenaya Therapeutics | <1 mi |
| CardioFocus HeartLight Post-Approval Study | N/A | CardioFocus | <1 mi |
| Physical Activity and Cognitive Development in Children | — | Columbia University | <1 mi |
| Evaluating the Relationship Between Skin Color and Pulse Oximeter Accuracy in Children | — | University of Pennsylvania | <1 mi |
| AN INTERNATIONAL, OBSERVATIONAL, BLINDED STUDY TO ASSESS THE PERFORMANCE OF THE CORDIO HEARO SYSTEM | — | Cordio Medical | <1 mi |
| Implementation of IVS3 for Upper Limb Motor Recovery | N/A | Weill Medical College of Cornell University | <1 mi |
| Reducing Risk for Infective Endocarditis | N/A | Wake Forest University Health Sciences | <1 mi |
| The TRICURE EFS Study | N/A | TRiCares | <1 mi |
| National Collaborative to Improve Care of Children With Complex Congenital Heart Disease | — | Children's Hospital Medical Center, Cincinnati | <1 mi |
| Trial of the F2 Filter and Delivery System for Embolic Protection During TAVR | N/A | EnCompass Technologies, Inc. | <1 mi |
| Clinical and Healthcare Outcomes From Real-World Use in the United States of a Companion AI During AF Ablation | — | Volta Medical | <1 mi |
| Horizon 360 Protocol for the Treatment of Paroxysmal Atrial Fibrillation With the Sphere-360™ Catheter and Affera™ Mapping and Ablation System (Horizon 360) | N/A | Medtronic Cardiac Ablation Solutions | <1 mi |
| SPHERE Per-AF Post-Approval Study | — | Medtronic Cardiac Ablation Solutions | <1 mi |
| LIVEBETTER: A Trial Comparing Medications in Older Adults With Stable Angina and Multiple Chronic Conditions | Phase 4 | Yale University | <1 mi |
| North American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC) | — | Columbia University | <1 mi |
| Sudden Unexplained Death in Childhood (SUDC) Registry | — | NYU Langone Health | <1 mi |
| LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF | Phase 3 | Tenax Therapeutics, Inc. | <1 mi |
| A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Understanding and Management of Coronary Calcium (The Optimal Trial) | N/A | Fundación EPIC | <1 mi |
| SELUTION 4 De Novo Small Vessel IDE Trial | N/A | M.A. Med Alliance S.A. | <1 mi |
| An Early Feasibility Study of the HighLife 28mm Trans-Septal Transcatheter Mitral Valve Replacement System | N/A | HighLife SAS | <1 mi |
| Propranolol Treatment for Postoperative Chylothorax | Phase 1/2 | June Wu | <1 mi |
| Women's Heart Attack Research Program: Stress Ancillary Study | N/A | NYU Langone Health | <1 mi |
| Safety and Effectiveness of the Orsiro Mission 48-mm Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions | N/A | Teleflex | <1 mi |
| Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy | Phase 4 | Dennis M. McNamara, MD, MS | <1 mi |
| Early Feasibility Study of the NORM™ System in Heart Failure Patients (FUTURE-HFII) | N/A | Foundry Innovation & Research 1, Limited (FIRE1) | <1 mi |
| Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure | N/A | Abbott Medical Devices | <1 mi |
| J-Valve Transfemoral Pivotal Study | N/A | JC Medical, Inc., an affiliate of Edwards Lifesciences LLC | <1 mi |
| PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III | N/A | Endotronix, Inc. | <1 mi |
| Quantifying New Heart Muscle Cells | N/A | Weill Medical College of Cornell University | <1 mi |
| Adult Congenital Heart Disease International EValuation of the Effectiveness of SGLT2i Registry | — | Leiden University Medical Center | <1 mi |
| Early Feasibility Study (EFS) Evaluating Percutaneous Repair of the Atrial Septum With a Novel PFO Occluder: The PROTEA-PFO Study | N/A | Recross Cardio, Inc. | <1 mi |
| Innoventric Trillium™ Stent Graft Early Feasibility Study (EFS) | N/A | Innoventric LTD | <1 mi |
| Safety and Effectiveness of Left Bundle Branch Area Pacing Versus Conventional Cardiac Resynchronization Therapy in Heart Failure | N/A | Boston Scientific Corporation | <1 mi |
| COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction | N/A | Edwards Lifesciences | <1 mi |
| Defining the Basis of Fibromuscular Dysplasia (FMD) | — | Icahn School of Medicine at Mount Sinai | <1 mi |
| Prevail Global Study | N/A | Medtronic Vascular | <1 mi |
| An Open-Label Pilot Study of VTX2735 in Recurrent Pericarditis | Phase 2 | Zomagen Biosciences Ltd. | <1 mi |
| TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy | Phase 3 | Alnylam Pharmaceuticals | <1 mi |
| mHealth-CArdiac REhabilitation for INOCA | N/A | NYU Langone Health | <1 mi |
| EFS of the CardioMech MVRS | N/A | CardioMech AS | <1 mi |
| Impella Reverse Remodeling in End-Stage Heart Failure | — | Columbia University | <1 mi |
| Post-CA Neuroprotection With Magnesium | Phase 1 | NYU Langone Health | <1 mi |
| International Spontaneous Coronary Artery Dissection (SCAD) "iSCAD" Registry | — | SCAD Alliance | <1 mi |
| Percutaneous Intervention Versus Observational Trial of Arterial Ductus in Low Weight Infants | N/A | Nationwide Children's Hospital | <1 mi |
| Phase IA and IB Study of AAVrh.10hFXN Gene Therapy for the Cardiomyopathy of Friedreich's Ataxia | Phase 1 | Weill Medical College of Cornell University | <1 mi |
| MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM) | Phase 3 | Intellia Therapeutics | <1 mi |
| The JenaValve ALIGN-AR LVAD Registry | N/A | JenaValve Technology, Inc. | <1 mi |
| A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM) | — | Bristol-Myers Squibb | <1 mi |
| Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure | N/A | BrioHealth Solutions, Inc. | <1 mi |
| A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction | Phase 3 | Bayer | <1 mi |
| Medtronic Cardiac Surgery PMCF Registry | — | Medtronic Cardiac Surgery | <1 mi |
| PARTNER 3 Trial - Aortic Valve-in-Valve | N/A | Edwards Lifesciences | <1 mi |
| Natural History Study in Pediatric Patients With MYBPC3 Mutation-associated Cardiomyopathy | — | Tenaya Therapeutics | <1 mi |
| Transfusion Requirements in Younger Patients Undergoing Cardiac Surgery | N/A | Unity Health Toronto | <1 mi |
| AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Assessment Using COR ECG Wearable Monitor | — | Peerbridge Health, Inc | <1 mi |
| Global Multicenter Registry on Transcatheter TRIcuspid Valve RePLACEment | — | Montefiore Medical Center | <1 mi |
| Staged Complete Revascularization for Coronary Artery Disease vs Medical Management Alone in Patients With AS Undergoing Transcatheter Aortic Valve Replacement | N/A | University of British Columbia | <1 mi |
| Trial in Arrhythmia Radioablation for Ventricular Tachycardia: Single Fraction vs Three Fractions | N/A | Weill Medical College of Cornell University | <1 mi |
| The PIVATAL Study -Study of Ventricular Arrhythmia (VTA) Ablation in Left Ventricular Assist Device (LVAD) Patients | Phase 4 | University of Rochester | <1 mi |
| CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3) | Phase 3 | Cardiol Therapeutics Inc. | <1 mi |
| Skin Pigment/Pulse Oximeter in Congenital Heart Disease (CHD) | — | Icahn School of Medicine at Mount Sinai | <1 mi |
| Use of GeriKit to Better Phenotype Older Adults With Ischemic Heart Disease | N/A | NYU Langone Health | <1 mi |
| Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF) | N/A | Weill Medical College of Cornell University | <1 mi |
| Characterization of the Cardiac Phenotype of Friedreich's Ataxia (FRDA) | — | Weill Medical College of Cornell University | <1 mi |
| Rectus Sheath Block in Cardiac Surgery | N/A | Icahn School of Medicine at Mount Sinai | <1 mi |
| Cephea Early Feasibility Study | N/A | Abbott Medical Devices | <1 mi |
| Multicenter Trial of ECMO in Children With Severe Cardiac Failure Using the Cardiohelp System | Phase 2 | Stanford University | <1 mi |
| Patient-Centered Approach for Treatment Decisions in Mitral Valve Prolapse | — | Northwell Health | <1 mi |
| Examining Genetic Factors That Affect the Severity of 22q11.2 Deletion Syndrome | — | Albert Einstein College of Medicine | <1 mi |
| Randomized Trial of the Neochord DS1000 System Versus Open Surgical Repair | N/A | NeoChord | <1 mi |
| LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2 | Phase 3 | Tenax Therapeutics, Inc. | <1 mi |
| Pragmatic Evaluation of a Pentaspline Pulsed Field Ablation System to Treat Atrial Fibrillation and Related Arrhythmias | Phase 4 | Vivek Reddy | <1 mi |
| Use of Adenosine to Determine the Electrophysiological Mechanism of Premature Ventricular Contractions | Phase 4 | Weill Medical College of Cornell University | <1 mi |
| A Global Study Comparing Pulsed Field Ablation With Electrographic Flow Mapping Versus Posterior Wall Ablation for Persistent Atrial Fibrillation | N/A | Boston Scientific Corporation | <1 mi |
| Implementing Models for Mechanical Circulatory Support Presurgical Assessment in Congenital Heart Disease Treatment | N/A | Columbia University | <1 mi |
| REvascularization CHoices Among Under-Represented Groups Evaluation: The RECHARGE Trial - Women | Phase 3 | Weill Medical College of Cornell University | <1 mi |
| Clinical Safety and Efficacy of the VDyne Transcatheter Tricuspid Valve Replacement System for the Treatment of Tricuspid Regurgitation ( VISTA-US) | N/A | VDyne, Inc. | <1 mi |
| Registry of Patients With Takotsubo Syndrome | — | NYU Langone Health | <1 mi |
| A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study) | Phase 2 | Tectonic Therapeutic | <1 mi |
| Slow Heart Registry of Fetal Immune-mediated High Degree Heart Block | — | The Hospital for Sick Children | <1 mi |
| Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease | N/A | Population Health Research Institute | <1 mi |
| Left vs Left Randomized Clinical Trial | N/A | Baylor College of Medicine | <1 mi |
| One-Month DAPT in CABG Patients | Phase 3 | Weill Medical College of Cornell University | <1 mi |
| A Study to Learn About The COVID-19 (Study) Vaccine (Called COMIRNATY) in People That Are Less Than 21 Years Old. | Phase 4 | Pfizer | <1 mi |
| Trial of Acceptance and Mindfulness-based Exposure Therapy (AMBET) and Present Centered Therapy (PCT) | N/A | Columbia University | <1 mi |
| BoxX-NoAF Clinical Trial | N/A | AtriCure, Inc. | <1 mi |
| Evaluating Fluid Responsiveness in ICU Patients Using VTI and Trendelenburg Positioning | N/A | Lenox Hill Hospital | <1 mi |
| A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis | Phase 2 | Novartis Pharmaceuticals | <1 mi |
| Cardiogenic Shock Working Group Registry | — | Tufts Medical Center | <1 mi |
| MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions | N/A | Concept Medical Inc. | <1 mi |
| Packed Red Blood Cell Transfusion During Cardiac Arrest | Phase 1 | NYU Langone Health | <1 mi |
| PULSED AF Post-Approval Study | — | Medtronic Cardiac Ablation Solutions | <1 mi |
| Real-world Experience of Catheter Ablation for the Treatment of Paroxysmal and Persistent Atrial Fibrillation | — | Heart Rhythm Clinical and Research Solutions, LLC | <1 mi |
| ULTRA-HFIB-Redo: Ultrasound-based Renal Sympathetic Denervation vs Control in Redo Ablation Patients | N/A | Vivek Reddy | <1 mi |
| Psychosocial Support for Patients With Takotsubo Syndrome | N/A | Weill Medical College of Cornell University | <1 mi |
| Subclinical Transthyretin Cardiac Amyloidosis in V122I TTR Carriers | — | University of Texas Southwestern Medical Center | <1 mi |
| The WiSE®-UP Registry (The WiSE System Utilization & Performance Registry) | — | EBR Systems, Inc. | <1 mi |
| Trisol System EFS Study | N/A | Trisol Medical | <1 mi |
| Enhanced Valves Interventions and Safe AI Generated End Results | — | Montreal Heart Institute | <1 mi |
| Cardiac Sarcoidosis Randomized Trial | Phase 3 | Ottawa Heart Institute Research Corporation | <1 mi |
| CTSN Embolic Protection Trial | N/A | Icahn School of Medicine at Mount Sinai | <1 mi |
| ViewFlex X ICE First-in-Human Study | — | Abbott Medical Devices | <1 mi |
| Fontan Udenafil Exercise Longitudinal Assessment Trial - 2 | Phase 3 | Mezzion Pharma Co. Ltd | <1 mi |
| Percutaneous or Surgical Repair In Mitral Prolapse And Regurgitation for ≥60 Year-olds (PRIMARY) | N/A | Annetine Gelijns | <1 mi |
| The CardioClip Study | N/A | Columbia University | <1 mi |
| Danon Disease Natural History Study | — | Rocket Pharmaceuticals Inc. | <1 mi |
| RADIQAL Study (Radiation Dose and Image Quality Trial) | N/A | Philips Clinical & Medical Affairs Global | <1 mi |
| Use of ReDS Technology in Patients With Acute Heart Failure | N/A | Icahn School of Medicine at Mount Sinai | <1 mi |
| FORWARD CAD IDE Study | N/A | Shockwave Medical, Inc. | <1 mi |
| Enhanced Nutritional Optimization in LVAD Trial | N/A | Columbia University | <1 mi |
| PIvotal Trial of the KARDION Cory P4 MechANical Circulatory SupporT SystEm | N/A | Kardion Inc | <1 mi |
| Assessment of Safety and Accuracy of the Microtech System in Patients Undergoing Left Ventricular Assist Device Implantation | N/A | Microtech Medical Technologies, Ltd | <1 mi |
| His-Bundle Corrective Pacing in Heart Failure | N/A | University of Rochester | <1 mi |
| Safety and Performance Assessment of the Sphere-9™ Catheter and Affera™ Ablation System for the Treatment of Ventricular Tachycardia (Sphere-9 VT EFS) | N/A | Medtronic Cardiac Ablation Solutions | <1 mi |
| Ultrafiltration Versus IV Diuretics in Worsening Heart Failure | N/A | Nuwellis, Inc. | <1 mi |
| Analysis of Lumbar Spine Stenosis Specimens for Identification of Transthyretin Cardiac Amyloidosis | — | Columbia University | <1 mi |
| Phase 2/3 Study of KPL-387 in Recurrent Pericarditis | Phase 2/3 | Kiniksa Pharmaceuticals International, plc | <1 mi |
| A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation | Phase 3 | Novo Nordisk A/S | <1 mi |
| Use of Phenylephrine for Assessment of Mitral Regurgitation Severity | Phase 1/2 | Montefiore Medical Center | <1 mi |
| Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036) | Phase 2/3 | Merck Sharp & Dohme LLC | <1 mi |
| Hospital Airway Resuscitation Trial | N/A | Montefiore Medical Center | <1 mi |
| A Prospective Research Investigation of Ischemia Using MCG | — | SB Technology, Inc. | <1 mi |
| PRIMARY Ancillary Substudy | N/A | Annetine Gelijns | <1 mi |
| CorMatrix Cor TRICUSPID ECM Valve Replacement - Pivotal Study | N/A | Corvivo Cardiovascular, Inc. | <1 mi |
| Pericardiotomy in Cardiac Surgery | N/A | Population Health Research Institute | <1 mi |
| Improving the Heart Health of Home Health Aides | N/A | Weill Medical College of Cornell University | <1 mi |
| Evaluation of the Jarvik 2000 Left Ventricular Assist System With Post-Auricular Connector--Destination Therapy Study | N/A | Jarvik Heart, Inc. | <1 mi |
| AMEND TS Early Feasibility Study | N/A | Valcare Medical Ltd. | <1 mi |
| A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation | Phase 2 | Novartis Pharmaceuticals | <1 mi |
| TTVR Early Feasibility Study | N/A | Medtronic Cardiovascular | <1 mi |
| ARIADNE Clinical Trial | N/A | Stavros E Mountantonakis | <1 mi |
| Heart Attack Research Program: Platelet Sub-Study (HARP) | — | NYU Langone Health | <1 mi |
| Optimal Pediatric Heart Transplant Immunosuppression With MicroRNAs | — | Inova Health Care Services | <1 mi |
| The MITRAL II Pivotal Trial (Mitral Implantation of TRAnscatheter vaLves). | N/A | Mayra Guerrero | <1 mi |
| The Fourth Left Atrial Appendage Occlusion Study | N/A | Hamilton Health Sciences Corporation | <1 mi |
| Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes | Phase 4 | VA Office of Research and Development | <1 mi |
| AltaValve Pivotal Trial | N/A | 4C Medical Technologies, Inc. | <1 mi |
| TVMR With the INNOVALVE System Trial - Early Feasibility Study | N/A | Edwards Lifesciences | <1 mi |
| A Basket Study of Vosoritide in Children With Turner Syndrome, Short Stature Homeobox-Containing Gene Deficiency, and Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone Treatment | Phase 2 | BioMarin Pharmaceutical | <1 mi |
| The CONFORM Pivotal Trial | N/A | Conformal Medical, Inc | <1 mi |
| ARTIST: Aortic Regurgitation Trial Investigating Surgery Versus Trilogy™ | N/A | JenaValve Technology, Inc. | <1 mi |
| A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy | Phase 2 | Novo Nordisk A/S | <1 mi |
| REvascularization CHoices Among Under-Represented Groups Evaluation: The RECHARGE Trial - Minorities | Phase 3 | Weill Medical College of Cornell University | <1 mi |
| Surveillance and Treatment to Prevent Fetal Atrioventricular Block Likely to Occur Quickly (STOP BLOQ) | Phase 3 | NYU Langone Health | <1 mi |
| AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF | Phase 2 | Cytokinetics | <1 mi |
| Exercise Activity Intervention With Sensor-Based Engagement in Patients With Atrial Fibrillation | N/A | Icahn School of Medicine at Mount Sinai | <1 mi |
| Non-interventional Study of Seroprevalence of Pre-existing Antibodies Against Adenovirus-associated Virus Vector (AAV9) and the Progression of Disease in Patients With Plakophilin 2 (PKP2)-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) | — | Tenaya Therapeutics | <1 mi |
| Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II | N/A | Shockwave Medical, Inc. | <1 mi |
| Aspirin and Hemocompatibility Events in Chronic Advanced Heart Failure Patients With Assist Device | Phase 4 | Columbia University | <1 mi |
| A Study of Assessment on Safety and Effectiveness of BWI Pulsed Field Ablation With OMNYPULSE Catheter for the Treatment of Paroxysmal Atrial Fibrillation (PAF) | N/A | Biosense Webster, Inc. | <1 mi |
| Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023) | Phase 2 | Merck Sharp & Dohme LLC | <1 mi |
| Pediatric Influence of Cooling Duration on Efficacy in Cardiac Arrest Patients (P-ICECAP) | N/A | University of Michigan | <1 mi |
| Transition to KPL-387 Monotherapy Dosing & Administration Study | Phase 2 | Kiniksa Pharmaceuticals International, plc | <1 mi |
| The Prevent Coronary Artery Disease Trial | Phase 3 | Icahn School of Medicine at Mount Sinai | <1 mi |
| Intestinal Microbiota Transplantation in Patients With Chronic Heart Failure | Phase 1 | Melana Yuzefpolskaya, MD | <1 mi |
| Imaging Coronary Microvascular Dysfunction (CMD) Study | N/A | Icahn School of Medicine at Mount Sinai | <1 mi |
| Treatment of Pulmonary Arterial Hypertension Using the Aria CV Pulmonary Hypertension System | N/A | Aria CV, Inc | <1 mi |
| A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma | Phase 2 | Eli Lilly and Company | <1 mi |
| Patient Reported Outcomes for Acute Asthma Care Treatment | — | Stanford University | <1 mi |
| Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma | Phase 2 | Sanofi | <1 mi |
| Asthma Symptom Perception Study | N/A | Icahn School of Medicine at Mount Sinai | <1 mi |
| Allergy and Immunology Natural History Study | — | Columbia University | <1 mi |
| Protocol CAUSE-03 / CHEETAH | — | National Institute of Allergy and Infectious Diseases (NIAID) | <1 mi |
| Registry of Asthma Characterization and Recruitment 3 (RACR3) | — | National Institute of Allergy and Infectious Diseases (NIAID) | <1 mi |
| A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma | Phase 2 | Incyte Corporation | <1 mi |
| Biologics And Clinical Immunology Cohort at Sinai | — | Icahn School of Medicine at Mount Sinai | <1 mi |
| Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma | Phase 4 | Regeneron Pharmaceuticals | <1 mi |
| Return to Golf After Orthopaedic Surgery | — | Hospital for Special Surgery, New York | <1 mi |
| Healthier: Health Coaching for People With Rheumatoid Arthritis to Improve Mental Well-Being | N/A | Weill Medical College of Cornell University | <1 mi |
| Chronic Pain in Rheumatoid Arthritis | — | Northwestern University | <1 mi |
| Safety and Feasibility of Umbilical Cord Wharton's Jelly Allograft Injections for Lumbar Pain | Phase 1 | R3 Stem Cell | <1 mi |
| Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients | Phase 3 | University of Pennsylvania | <1 mi |
| Multi-Center PAMPA Study | Phase 4 | NYU Langone Health | <1 mi |
| Navio Robotic Versus Conventional Total Knee Arthroplasty | N/A | Columbia University | <1 mi |
| Oral Steroid Taper After Total Knee Arthroplasty | Phase 1 | Columbia University | <1 mi |
| Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare | Phase 2/3 | Olatec Therapeutics LLC | <1 mi |
| Impact of Bone-Marrow Aspirate Injections in Knee Arthroscopy | N/A | Hospital for Special Surgery, New York | <1 mi |
| Persona OsseoTi Keel Compatibility Study (Total Knee Arthroplasty) | — | Zimmer Biomet | <1 mi |
| MOTION Clinical Trial | N/A | Moximed | <1 mi |
| Analysis of T and B Cell Repertoire Changes in Response to Orencia® (Abatacept) in Rheumatoid Arthritis | — | Hospital for Special Surgery, New York | <1 mi |
| The KinematX Midcarpal Total Wrist Arthroplasty Registry | — | Extremity Medical | <1 mi |
| Alpha-Defensin and Synovial Proteins to Improve Detection of Pediatric Septic Arthritis | N/A | Hospital for Special Surgery, New York | <1 mi |
| Cannabidiol (CBD) in Pain Reduction for Knee Osteoarthritis | Phase 2/3 | NYU Langone Health | <1 mi |
| Primary Subtalar Arthrodesis for Calcaneal Fractures | N/A | Wake Forest University Health Sciences | <1 mi |
| Oral Nutritional Optimization in Total Joint Arthroplasty | N/A | NYU Langone Health | <1 mi |
| Evaluate the Safety and Effectiveness of the Polymotion Hip Resurfacing (PHR) System Compared to Total Hip Arthroplasty | N/A | JointMedica Inc. | <1 mi |
| Safety and Feasibility of Umbilical Cord Wharton's Jelly Allograft Injections for Knee Osteoarthritis | Early 1 | R3 Medical Research | <1 mi |
| Exactech Shoulder Post Market Clinical Follow-up Study | — | Exactech | <1 mi |
| A Study to Investigate the Treatment Effect of Subcutaneous Injections of Pentosan Polysulfate Sodium Compared With Placebo in Adult Participants With Knee Osteoarthritis Pain. | Phase 3 | Paradigm Biopharmaceuticals Ltd. | <1 mi |
| Preventing Injured Knees From osteoArthritis: Severity Outcomes | Phase 2 | Brigham and Women's Hospital | <1 mi |
| RA-PRO PRAGMATIC TRIAL | Phase 3 | University of Alabama at Birmingham | <1 mi |
| Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout | Phase 4 | Massachusetts General Hospital | <1 mi |
| Persona MC vs PS RCT With ROSA | N/A | NYU Langone Health | <1 mi |
| A Phase 1/2a to Evaluate the Safety and Efficacy of Adipose Tissue Allograft (BRC-OA) in Patients With Osteoarthritis of the Knee | Phase 1/2 | Britecyte | <1 mi |
| Evaluation Of The Lung Microbiome In NTM Bronchiectasis | — | NYU Langone Health | <1 mi |
| SPIROMICS Study of Early COPD Progression (SOURCE) | — | University of Massachusetts, Worcester | <1 mi |
| Collection of Airway, Blood and/or Urine Specimens From Subjects for Research Studies | — | Weill Medical College of Cornell University | <1 mi |
| Lung Microbiome and Inflammation in Early COPD | — | NYU Langone Health | <1 mi |
| Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD | Phase 2 | Johns Hopkins University | <1 mi |
| A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) | Phase 3 | Hoffmann-La Roche | <1 mi |
| PRagmatic EVAluation of a Quality Improvement Program for People Living With Modifiable High-risk COPD. | N/A | Observational and Pragmatic Research Institute | <1 mi |
| Comprehensive Patient-Centered Home-based Care Coaching for COPD Self-management | N/A | Icahn School of Medicine at Mount Sinai | <1 mi |
| Closed Loop Oxygen Control in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Nasal High Flow in the Hospital | N/A | Fisher and Paykel Healthcare | <1 mi |
| A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease | Phase 3 | Hoffmann-La Roche | <1 mi |
| Readiness and Progress in Emotion Regulation Therapy | N/A | Teachers College, Columbia University | <1 mi |
| Anxiety During Abstinence in AUD | Early 1 | Columbia University | <1 mi |
| Mobile CBT for Middle Aged and Older Adults | N/A | Weill Medical College of Cornell University | <1 mi |
| Feasibility and Acceptability of a Novel Cognitive Behavioral Skills Mobile App for Pregnant and Postpartum Individuals | N/A | Weill Medical College of Cornell University | <1 mi |
| Study of Cannabidiol and Neuroimaging on Stress | Phase 1/2 | Icahn School of Medicine at Mount Sinai | <1 mi |
| Prediction of Anxiety and Memory State | N/A | Columbia University | <1 mi |
| A Study Comparing Music Therapy and Cognitive Behavioral Therapy for Anxiety in Cancer Survivors | Phase 4 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Brief Interventions for Coping with Distress | N/A | Teachers College, Columbia University | <1 mi |
| Effect of an Educational Nail Biopsy Video on Pre-operative Anxiety, Health Literacy, and Patient Satisfaction | N/A | Weill Medical College of Cornell University | <1 mi |
| An Exploratory Study Examining Biopsychosocial Markers of Anxiety and Depression | — | Singula Institute | <1 mi |
| Harlem Strong Mental Health Coalition | N/A | City University of New York, School of Public Health | <1 mi |
| A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Voyage) | Phase 3 | Definium Therapeutics US, Inc. | <1 mi |
| Personalized Mobile Cognitive Behavioral Therapy Application | N/A | Weill Medical College of Cornell University | <1 mi |
| REstoring Mental Health Through COmmUnity-based Psychological Services in New York City | N/A | George Washington University | <1 mi |
| Neural Circuit Effects of Ketamine in Depression | Phase 4 | Icahn School of Medicine at Mount Sinai | <1 mi |
| ERP to Improve Functioning in Veterans With OCD | N/A | VA Office of Research and Development | <1 mi |
| Prevention of Psychological Health Problems Via Integrated Operational Support | N/A | New York University | <1 mi |
| Connectomic Deep Brain Stimulation for Obsessive Compulsive Disorder | N/A | Icahn School of Medicine at Mount Sinai | <1 mi |
| Virtual Reality for Pain Control in US-Guided Obstetric Needle Procedures | N/A | Icahn School of Medicine at Mount Sinai | <1 mi |
| Precision Analytic Research Methods in OCD | N/A | Icahn School of Medicine at Mount Sinai | <1 mi |
| Mobile Cognitive Behavioral Therapy for Stroke | N/A | Weill Medical College of Cornell University | <1 mi |
| Stress and Anxiety Effects on Valuation | N/A | NYU Langone Health | <1 mi |
| Virtual Reality for Pain Management in Burn Patients | N/A | Weill Medical College of Cornell University | <1 mi |
| Assessment of Music Experiences in Navigating Depression Part 2 | N/A | Icahn School of Medicine at Mount Sinai | <1 mi |
| Psilocybin-Assisted Therapy for Intergenerational Trauma | Phase 2 | Rachel Yehuda | <1 mi |
| Pramipexole to Enhance Social Connections | Phase 2 | University of California, San Diego | <1 mi |
| MBSR Mechanisms in GAD | N/A | NYU Langone Health | <1 mi |
| Randomized Controlled Trial of a Behavioral Training App | N/A | New York University | <1 mi |
| Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4) | Phase 3 | VistaGen Therapeutics, Inc. | <1 mi |
| A Study of Buntanetap in Participants With PD | Phase 2/3 | Annovis Bio Inc. | <1 mi |
| Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD) | Phase 2 | Denali Therapeutics Inc. | <1 mi |
| A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Pallidotomy for the Treatment of Advanced, Idiopathic Parkinson's Disease With Medication-refractory Moderate to Severe Motor Complications | — | InSightec | <1 mi |
| A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease | Phase 3 | BlueRock Therapeutics | <1 mi |
| Autoimmune Features of Neurodegenerative Disorders | — | Columbia University | <1 mi |
| Drug Discovery for Parkinson's With Mutations in the GBA Gene | — | New York Stem Cell Foundation Research Institute | <1 mi |
| PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort | — | Michael J. Fox Foundation for Parkinson's Research | <1 mi |
| A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease | Phase 3 | Hoffmann-La Roche | <1 mi |
| Novel Shoe Device NUSHU to Measure Gait Analysis in Parkinson's Patients | N/A | Weill Medical College of Cornell University | <1 mi |
| Parkinson's Disease Biomarkers in Nerve Cells in the Gut | — | Weill Medical College of Cornell University | <1 mi |
| A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease | Phase 2/3 | Biohaven Therapeutics Ltd. | <1 mi |
| A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease | Phase 2 | Neuron23 Inc. | <1 mi |
| Rehabilitation of Airway Protection in Parkinson's Disease | Phase 2 | Teachers College, Columbia University | <1 mi |
| Noise-augmented Automatic Speech Recognition for Speech Treatment in Parkinson's Disease | Early 1 | Teachers College, Columbia University | <1 mi |
| A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Thalamotomy for the Treatment of Medication-Refractory Tremor Dominant Idiopathic Parkinson's Disease | — | InSightec | <1 mi |
| A Multicenter Study to Evaluate Safety, Tolerability, and Clinical Responses of DSP-1083 Into Subjects With Parkinson's Disease | Phase 1/2 | Sumitomo Pharma America, Inc. | <1 mi |
| This Clinical Trial is Designed to Evaluate the Safety, Tolerability, Feasibility and Preliminary Efficacy of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in Patients With Parkinson's Disease. | Phase 1 | iRegene Therapeutics Co., Ltd. | <1 mi |
| A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus | Phase 1 | Cullinan Therapeutics Inc. | <1 mi |
| RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus | Phase 1/2 | Cabaletta Bio | <1 mi |
| A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases | Phase 2 | Amgen | <1 mi |
| Safety of the Herpes Zoster Subunit Vaccine in Lupus | Phase 4 | NYU Langone Health | <1 mi |
| IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy | Phase 2 | David Ware Branch | <1 mi |
| A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1) | Phase 1/2 | Nkarta, Inc. | <1 mi |
| A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE) | Phase 2 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | <1 mi |
| VIBRANT: VIB4920 for Active Lupus Nephritis | Phase 2 | National Institute of Allergy and Infectious Diseases (NIAID) | <1 mi |
| Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS) | — | Hospital for Special Surgery, New York | <1 mi |
| A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease | Phase 1 | Fate Therapeutics | <1 mi |
| Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease | Phase 3 | NYU Langone Health | <1 mi |
| Repository of Novel Analytes Leading to Autoimmune, Inflammatory and Diabetic Nephropathies (RENAL AID) | — | The Rogosin Institute | <1 mi |
| Safety and Efficacy of ONT01 in Lupus | Early 1 | Hospital for Special Surgery, New York | <1 mi |
| A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1) | Phase 1 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | <1 mi |
| The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study | Phase 2 | Children's Hospital Medical Center, Cincinnati | <1 mi |
| An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants | Phase 3 | AstraZeneca | <1 mi |
| A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132 | Phase 4 | Bristol-Myers Squibb | <1 mi |
| A Study to Investigate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986326 in Adult Participants With Different Forms of Lupus | Phase 1 | Bristol-Myers Squibb | <1 mi |
| Lupus Landmark Study: A Prospective Registry and Biorepository | — | Lupus Research Alliance | <1 mi |
| Alnuctamab for Refractory SLE (LATTE Study) | Phase 1 | Icahn School of Medicine at Mount Sinai | <1 mi |
| Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine | Phase 2 | State University of New York - Upstate Medical University | <1 mi |
| A Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus | Phase 1 | Columbia University | <1 mi |
| A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE | Phase 1/2 | AstraZeneca | <1 mi |
| Relationship Between Data Obtained With the LuGENE® Multiparameter Transcriptomics Blood Test and Clinical and Standard Laboratory Features of Patients With SLE (ReLATE) | — | Ampel BioSolutions, LLC | <1 mi |
| Home-Based Transcranial Direct Current Stimulation (tDCS) for Depression in Multiple Sclerosis (MS) | Phase 2 | NYU Langone Health | <1 mi |
| Task Specific Training for Advanced Multiple Sclerosis | N/A | Hunter College of City University of New York | <1 mi |
| Noninvasive Vagal Nerve Stimulation | N/A | NYU Langone Health | <1 mi |
| Vancomycin Study in Multiple Sclerosis (MS) | Phase 1 | Icahn School of Medicine at Mount Sinai | <1 mi |
| A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders | Phase 1 | TG Therapeutics, Inc. | <1 mi |
| A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients | Phase 2 | Tiziana Life Sciences LTD | <1 mi |
| A Palliative Care Model Impact on Knowledge and Attitudes | N/A | Hunter College of City University of New York | <1 mi |
| TSC Biosample Repository and Natural History Database | — | National Tuberous Sclerosis Association | <1 mi |
| Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis | Phase 4 | National Institute of Allergy and Infectious Diseases (NIAID) | <1 mi |
| PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS | Phase 2 | PhenoNet, Inc. | <1 mi |
| NYSCF Scientific Discovery Biobank | — | New York Stem Cell Foundation Research Institute | <1 mi |
| A Study of the MIND Diet for Persons With Multiple Sclerosis | N/A | Icahn School of Medicine at Mount Sinai | <1 mi |
| Effect of Cooling on Balance Performance in Multiple Sclerosis | — | Hunter College of City University of New York | <1 mi |
| Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS) | Phase 3 | National Institute of Allergy and Infectious Diseases (NIAID) | <1 mi |
| A Study of AZD0120 in Autoimmune Diseases | Phase 1 | AstraZeneca | <1 mi |
| Genes and Environment in Multiple Sclerosis | — | Columbia University | <1 mi |
| An Open-label Study of AZD0120 in Adults With Multiple Sclerosis | Phase 1 | AstraZeneca | <1 mi |
| Study of COYA 302 for the Treatment of ALS | Phase 2 | Coya Therapeutics | <1 mi |
| Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab | Phase 3 | TG Therapeutics, Inc. | <1 mi |
| Eccentric Exercise and Fatigue in Multiple Sclerosis | — | Hunter College of City University of New York | <1 mi |
| A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2) | Phase 1 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | <1 mi |
| A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors | Phase 1 | Alterome Therapeutics, Inc. | <1 mi |
| A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors | Phase 1 | Bristol-Myers Squibb | <1 mi |
| Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial | Phase 1 | National Cancer Institute (NCI) | <1 mi |
| Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer | Phase 2 | BicycleTx Limited | <1 mi |
| A Study of LY4257496 in Participants With Cancer (OMNIRAY) | Phase 1 | Eli Lilly and Company | <1 mi |
| A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies | Phase 1/2 | 858 Therapeutics, Inc. | <1 mi |
| BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia | Phase 1 | SillaJen, Inc. | <1 mi |
| A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer | Phase 1/2 | BioNTech SE | <1 mi |
| Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy | Phase 3 | Proton Collaborative Group | <1 mi |
| A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer | Phase 3 | AstraZeneca | <1 mi |
| PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer | Phase 2 | MedSIR | <1 mi |
| Converting HR+ Breast Cancer Into an Individualized Vaccine | Phase 2 | Weill Medical College of Cornell University | <1 mi |
| S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer | N/A | SWOG Cancer Research Network | <1 mi |
| Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer | Phase 2 | Proton Collaborative Group | <1 mi |
| Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases | Phase 1/2 | Colette Shen | <1 mi |
| A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| Study of INCB123667 in Subjects With Advanced Solid Tumors | Phase 1 | Incyte Corporation | <1 mi |
| Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation | Phase 1 | Senhwa Biosciences, Inc. | <1 mi |
| Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE) | N/A | University Health Network, Toronto | <1 mi |
| De-convoluting Interactions Between Genes, the Cancer Environment, and the Immune System to Develop Therapies That Work for You | — | Weill Medical College of Cornell University | <1 mi |
| Clinical Validation of Early Detection Blood Test for Universal Large-scale Breast Cancer Screening | — | Syantra Inc. | <1 mi |
| DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment | Phase 2 | QuantumLeap Healthcare Collaborative | <1 mi |
| A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01) | Phase 2/3 | Bristol-Myers Squibb | <1 mi |
| A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer | Phase 3 | AstraZeneca | <1 mi |
| Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients | Phase 1/2 | Weill Medical College of Cornell University | <1 mi |
| An Ophthalmic Safety Study in Patients With Breast Cancer | — | AstraZeneca | <1 mi |
| Breast Elasticity Imaging During Neoadjuvant Chemotherapy | N/A | Columbia University | <1 mi |
| First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors | Phase 1/2 | Eli Lilly and Company | <1 mi |
| Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer | Phase 1/2 | Icahn School of Medicine at Mount Sinai | <1 mi |
| Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer | Phase 1 | Olema Pharmaceuticals, Inc. | <1 mi |
| Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors | N/A | The New York Proton Center | <1 mi |
| The Cancer of the Pancreas Screening-5 CAPS5)Study | Phase 3 | Johns Hopkins University | <1 mi |
| Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| A Formative Evaluation For Improving Breast Cancer Hormone Receptor Testing in Tanzania | — | Memorial Sloan Kettering Cancer Center | <1 mi |
| Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors | Phase 1 | MOMA Therapeutics | <1 mi |
| MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles | — | Agendia | <1 mi |
| Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies | Phase 1/2 | AstraZeneca | <1 mi |
| A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy | Phase 3 | AstraZeneca | <1 mi |
| Two Versus One Week Breast Radiotherapy (RT) | Phase 3 | Weill Medical College of Cornell University | <1 mi |
| Exercise Therapy to Improve Cardiovascular Health in Post-Menopausal Women After Treatment for Early Stage Breast Cancer | N/A | Memorial Sloan Kettering Cancer Center | <1 mi |
| Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial | Phase 2 | Massachusetts General Hospital | <1 mi |
| A Study of XMT-1660 in Participants With Solid Tumors | Phase 1 | Mersana Therapeutics | <1 mi |
| Pancreatic Cancer Genetics | — | Columbia University | <1 mi |
| A Study of Changes in Ki67 Expression in People With Breast Cancer Receiving Endocrine Therapy Before Surgery | N/A | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours | Phase 1 | Avacta Life Sciences Ltd | <1 mi |
| Combined Immunotherapies in Metastatic ER+ Breast Cancer | Phase 2 | Weill Medical College of Cornell University | <1 mi |
| Tablet-based Mobile Health Ultrasound for Point-of-care Breast Cancer Diagnosis in Nigeria (Mobile Health: Technology and Outcomes in Low and Middle-Income Countries) | — | Memorial Sloan Kettering Cancer Center | <1 mi |
| DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE) | Phase 2 | Criterium, Inc. | <1 mi |
| A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV) | Phase 1 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer | Early 1 | Rima Patel | <1 mi |
| Generation of Heart Muscle Cells From Blood or Skin Cells of Breast Cancer Patients | — | Memorial Sloan Kettering Cancer Center | <1 mi |
| Enhancing Access to Supportive Services for Women of Color With Metastatic Breast Cancer | N/A | Icahn School of Medicine at Mount Sinai | <1 mi |
| Women Informed to Screen Depending on Measures of Risk (Wisdom Study) | N/A | University of California, San Francisco | <1 mi |
| Optimizing Surgical Decisions in Young Adults With Breast Cancer | N/A | Weill Medical College of Cornell University | <1 mi |
| AVI Didactic Experience for Latinx Patient Treatment Adherence and Non-English Speaker Trial Enrollment Study in Rad Onc | N/A | Columbia University | <1 mi |
| Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration | Phase 1/2 | ORIC Pharmaceuticals | <1 mi |
| OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer | Phase 3 | Olema Pharmaceuticals, Inc. | <1 mi |
| Study of AVZO-021 in Patients With Advanced Solid Tumors | Phase 1/2 | Avenzo Therapeutics, Inc. | <1 mi |
| A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) | Phase 3 | Eli Lilly and Company | <1 mi |
| Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread | Phase 1/2 | Boehringer Ingelheim | <1 mi |
| First in Human Study of TUB-030 in Patients With Advanced Solid Tumors | Phase 1/2 | Tubulis GmbH | <1 mi |
| Medical Imaging and Thermal Treatment for Breast Tumors Using Harmonic Motion Imaging (HMI) | N/A | Columbia University | <1 mi |
| Brain [18F]-FES PET/CT in Patients With Estrogen-Receptor Positive Breast Cancer | Phase 4 | Weill Medical College of Cornell University | <1 mi |
| Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors | Phase 1/2 | Novartis Pharmaceuticals | <1 mi |
| A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs | Phase 1 | Mabwell (Shanghai) Bioscience Co., Ltd. | <1 mi |
| A Study of Multiparametric MRI and pHLIP® ICG in Breast Cancer Imaging During Surgery | Phase 1/2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2) | Phase 3 | Celcuity Inc | <1 mi |
| A Study of LY4337713 in Participants With FAP-Positive Solid Tumors | Phase 1 | Eli Lilly and Company | <1 mi |
| A Study of Breast Cancer Risk Factors and Outcomes of People in Florida | — | Memorial Sloan Kettering Cancer Center | <1 mi |
| Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer | Phase 1 | OncoTherapy Science, Inc. | <1 mi |
| Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer | Phase 1 | National Cancer Institute (NCI) | <1 mi |
| Long-term Safety of Nipple Sparing Mastectomy in Women With High Penetrance Breast Cancer Susceptibility Genes in Breast Cancer | — | Sir Mortimer B. Davis - Jewish General Hospital | <1 mi |
| Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts | N/A | American College of Radiology | <1 mi |
| IMPACT Trial: Intervention to iMProve AdherenCe Equitably | N/A | Columbia University | <1 mi |
| Prospective Study of Sensation and Satisfaction in Cancer and Transgender Mastectomy Patients | — | Weill Medical College of Cornell University | <1 mi |
| Opioid Dispensing Device for Post-Operative Pain in Cancer Patients | N/A | Columbia University | <1 mi |
| Mammography and Breast Arterial Calcification: An Information-Sharing Trial | N/A | Icahn School of Medicine at Mount Sinai | <1 mi |
| Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer | Phase 1 | Eileen Connolly | <1 mi |
| ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors | Phase 1/2 | Avenzo Therapeutics, Inc. | <1 mi |
| Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects | Phase 3 | Greenwich LifeSciences, Inc. | <1 mi |
| Leflunomide in Patients With PTEN-Altered Advanced Solid Malignancies and HER2 Negative Breast Cancer | Phase 1 | Deborah Doroshow | <1 mi |
| SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells | Phase 1 | General Oncology, Inc. | <1 mi |
| A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors | Phase 1 | IDEAYA Biosciences | <1 mi |
| Empathic Communication Skills (ECS) Training | N/A | Memorial Sloan Kettering Cancer Center | <1 mi |
| First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors | Phase 1 | Plexium, Inc. | <1 mi |
| Comprehensive Outcomes for After Cancer Health | N/A | Pack Health | <1 mi |
| A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types | Phase 1/2 | Eisai Inc. | <1 mi |
| A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer | Phase 1/2 | IDEAYA Biosciences | <1 mi |
| A Long-term Extension Study of PCI-32765 (Ibrutinib) | Phase 3 | Janssen Research & Development, LLC | <1 mi |
| Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy | Phase 1 | Abdera Therapeutics Inc. | <1 mi |
| Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors | Phase 1 | Innate Pharma | <1 mi |
| Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment | Phase 3 | Boehringer Ingelheim | <1 mi |
| DRP-104 in Patients With NFE2L2/KEAP1-altered Non-Small Cell Lung Cancer | Phase 2 | NYU Langone Health | <1 mi |
| Phase I/IIa Study of H002 in NSCLC With Active EGFR Mutation | Phase 1/2 | RedCloud Bio | <1 mi |
| A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS | Phase 3 | AstraZeneca | <1 mi |
| Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors | Phase 1 | Bicara Therapeutics | <1 mi |
| Testing Tumor Tissue and Blood to Help Select Personalized Treatments for Patients With Suspected Lung Cancers | — | Lung Cancer Mutation Consortium | <1 mi |
| Lung Cancer Biomarkers and Screening | — | NYU Langone Health | <1 mi |
| A First-in-human Study to Learn How Safe BAY 3713372 is and How it Works in Participants With MTAP-deleted Solid Tumors | Phase 1/2 | Bayer | <1 mi |
| Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss | Phase 1/2 | Tango Therapeutics, Inc. | <1 mi |
| Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC | Phase 3 | Nuvalent Inc. | <1 mi |
| A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors | Phase 1/2 | Marengo Therapeutics, Inc. | <1 mi |
| GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2 | Phase 1 | Y-mAbs Therapeutics | <1 mi |
| MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors | Phase 1 | Eli Lilly and Company | <1 mi |
| The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | Phase 1/2 | PMV Pharmaceuticals, Inc | <1 mi |
| BBO-11818 in Adult Subjects With KRAS Mutant Cancer | Phase 1 | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | <1 mi |
| Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors | Phase 1 | AstraZeneca | <1 mi |
| Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer | Phase 1 | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | <1 mi |
| LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC | Phase 3 | NovoCure GmbH | <1 mi |
| Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment | Phase 2 | BioNTech SE | <1 mi |
| A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) | Phase 3 | Amgen | <1 mi |
| Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors | Phase 1/2 | Tango Therapeutics, Inc. | <1 mi |
| A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Phase 3 | AstraZeneca | <1 mi |
| Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01) | Phase 2/3 | Bristol-Myers Squibb | <1 mi |
| LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia | — | University of Rochester | <1 mi |
| A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | Phase 1 | Incyte Corporation | <1 mi |
| Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients | Phase 1/2 | Tango Therapeutics, Inc. | <1 mi |
| A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors | Phase 1 | Aktis Oncology, Inc. | <1 mi |
| Patient-Generated Health Data Collection During Chemoradiotherapy for Lung Cancer | — | The New York Proton Center | <1 mi |
| A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas | Phase 1/2 | Novartis Pharmaceuticals | <1 mi |
| Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC | Phase 1 | AstraZeneca | <1 mi |
| A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1) | Phase 1 | Dizal Pharmaceuticals | <1 mi |
| Phase II Trial of Lung Chemoemobolization | Phase 2 | City of Hope Medical Center | <1 mi |
| Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors | Phase 2 | Iovance Biotherapeutics, Inc. | <1 mi |
| Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet® | Phase 2 | CivaTech Oncology | <1 mi |
| A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection | Phase 3 | Taiho Oncology, Inc. | <1 mi |
| A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer | Phase 1/2 | Regeneron Pharmaceuticals | <1 mi |
| A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations | Phase 1/2 | Daiichi Sankyo | <1 mi |
| A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer | Phase 1 | Ankyra Therapeutics, Inc | <1 mi |
| A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression | Phase 1/2 | A2 Biotherapeutics Inc. | <1 mi |
| A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies | Phase 1/2 | AstraZeneca | <1 mi |
| A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer | Phase 1 | BeiGene | <1 mi |
| Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC | Phase 1/2 | Icahn School of Medicine at Mount Sinai | <1 mi |
| A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors | Phase 2 | Daiichi Sankyo | <1 mi |
| Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab | Phase 1/2 | Linnaeus Therapeutics, Inc. | <1 mi |
| A Multicenter Study in Bronchoscopy Combining Stimulated Raman Histology With Artificial Intelligence for Rapid Lung Cancer Detection - The ON-SITE Study | — | Invenio Imaging Inc. | <1 mi |
| Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing | — | A2 Biotherapeutics Inc. | <1 mi |
| Pembrolizumab for Advanced NSCLC and PS 2-3 | Phase 2 | Icahn School of Medicine at Mount Sinai | <1 mi |
| Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer | Phase 2 | Iovance Biotherapeutics, Inc. | <1 mi |
| Confocal Laser Endomicroscopy VERification | N/A | Amsterdam University Medical Centers (UMC), Location Academic Medical Center (AMC) | <1 mi |
| Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers | Phase 1/2 | Synthekine | <1 mi |
| National Cancer Institute "Cancer Moonshot Biobank" | — | National Cancer Institute (NCI) | <1 mi |
| KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A) | Phase 1/2 | Merck Sharp & Dohme LLC | <1 mi |
| Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities | Phase 1/2 | Taiho Pharmaceutical Co., Ltd. | <1 mi |
| A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | Johnson & Johnson Enterprise Innovation Inc. | <1 mi |
| GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors | Phase 1/2 | GI Innovation, Inc. | <1 mi |
| A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors | Phase 1 | Cogent Biosciences, Inc. | <1 mi |
| A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies | Phase 1/2 | GV20 Therapeutics | <1 mi |
| VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma | Phase 1/2 | VM Oncology, LLC | <1 mi |
| Inpatient Capture: A Mixed Methods Study to Develop an Inpatient Lung Cancer Screening Program in a Safety Net Hospital. | N/A | Physician Affiliate Group of New York | <1 mi |
| A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies | Phase 1 | Janux Therapeutics | <1 mi |
| Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations | Phase 3 | ArriVent BioPharma, Inc. | <1 mi |
| A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors | Phase 1/2 | Verastem, Inc. | <1 mi |
| A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors | Phase 1 | Astellas Pharma Inc | <1 mi |
| Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability | Phase 3 | NRG Oncology | <1 mi |
| Multilevel Intervention for Precision Oncology | N/A | VA Office of Research and Development | <1 mi |
| Longitudinal Evaluation of Microbial and Host Signatures During Immunotherapy for Lung Cancer | — | NYU Langone Health | <1 mi |
| Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors | Phase 1 | Calico Life Sciences LLC | <1 mi |
| GEMINI-NSCLC: NSCLC Biomarker Study | — | Tempus AI | <1 mi |
| A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation | Phase 1/2 | Hoffmann-La Roche | <1 mi |
| A Study of Mental Health Care in People With Cancer | N/A | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of LY4170156 in Participants With Selected Advanced Solid Tumors | Phase 1 | Eli Lilly and Company | <1 mi |
| A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors | Phase 1 | Eli Lilly and Company | <1 mi |
| A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression | Phase 1/2 | A2 Biotherapeutics Inc. | <1 mi |
| A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer | Phase 1/2 | BioNTech SE | <1 mi |
| Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer | Phase 3 | Canadian Cancer Trials Group | <1 mi |
| Surgery Versus Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer | — | Washington University School of Medicine | <1 mi |
| A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC) | Phase 2 | Genentech, Inc. | <1 mi |
| A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer | Phase 1/2 | Janssen Research & Development, LLC | <1 mi |
| M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors | Phase 1 | EMD Serono Research & Development Institute, Inc. | <1 mi |
| A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors | Phase 1 | Eli Lilly and Company | <1 mi |
| Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) | Phase 1/2 | Eli Lilly and Company | <1 mi |
| A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors | Phase 1/2 | Bristol-Myers Squibb | <1 mi |
| DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers | Phase 2 | Boehringer Ingelheim | <1 mi |
| Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS | Phase 1/2 | Revolution Medicines, Inc. | <1 mi |
| Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies | Phase 1 | TopAlliance Biosciences | <1 mi |
| PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56 | Phase 1/2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation | Phase 1/2 | Arvinas Inc. | <1 mi |
| WTC Chest CT Imaging Archive | — | Icahn School of Medicine at Mount Sinai | <1 mi |
| Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion | Phase 1 | IDEAYA Biosciences | <1 mi |
| A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas | Phase 1 | EvolveImmune United, Inc | <1 mi |
| Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV) | Phase 3 | Nuvation Bio Inc. | <1 mi |
| A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer | Phase 1 | Avistone Biotechnology Co., Ltd. | <1 mi |
| A Study of BMS-986504 in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9) | Phase 2 | Bristol-Myers Squibb | <1 mi |
| Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors | Phase 1 | Revolution Medicines, Inc. | <1 mi |
| RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses | Phase 2 | Reunion Neuroscience Inc | <1 mi |
| A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation | Phase 1 | Clasp Therapeutics, Inc. | <1 mi |
| Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer | Phase 3 | Eli Lilly and Company | <1 mi |
| Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC | Phase 1/2 | Revolution Medicines, Inc. | <1 mi |
| A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2 | Phase 1 | Mersana Therapeutics | <1 mi |
| Safety and Efficacy of OBX-115 in Advanced Solid Tumors | Phase 1/2 | Obsidian Therapeutics, Inc. | <1 mi |
| A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer | Phase 1/2 | Iovance Biotherapeutics, Inc. | <1 mi |
| Ladarixin With Sotorasib in Advanced NSCLC | Phase 1 | NYU Langone Health | <1 mi |
| Genomic and Methylation Markers in SCLC and LCNEC for Chemo-Immunotherapy Resistance Prediction (STRATUS) | — | Oncology Center of Biochemical Education And Research | <1 mi |
| First in Human Study of AZD9592 in Solid Tumors | Phase 1 | AstraZeneca | <1 mi |
| A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors | Phase 1 | Eli Lilly and Company | <1 mi |
| A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations | Phase 1 | Alterome Therapeutics, Inc. | <1 mi |
| KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01) | — | Merck Sharp & Dohme LLC | <1 mi |
| Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients | Phase 3 | Summit Therapeutics | <1 mi |
| A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer | Phase 1 | Johnson & Johnson Enterprise Innovation Inc. | <1 mi |
| AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104). | Phase 1 | Amgen | <1 mi |
| Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors | Phase 1 | SystImmune Inc. | <1 mi |
| Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors | Phase 1 | SystImmune Inc. | <1 mi |
| A Study of LY4175408 in Participants With Advanced Cancer | Phase 1 | Eli Lilly and Company | <1 mi |
| Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors | Phase 1 | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | <1 mi |
| Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC) | Phase 3 | Amgen | <1 mi |
| Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders | Phase 2 | Carl Allen | <1 mi |
| A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer | Phase 1/2 | Volastra Therapeutics, Inc. | <1 mi |
| A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC | Phase 2 | Teligene US | <1 mi |
| Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors | Phase 1/2 | Revolution Medicines, Inc. | <1 mi |
| Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT) | Phase 1 | Tr1X, Inc. | <1 mi |
| Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC | Phase 2 | Weill Medical College of Cornell University | <1 mi |
| Analysis of RATS, VATS and Open Lung Resections After Neoadjuvant Chemo-immunotherapy in Patients Performed in Five Referred Centers | — | Scientific Institute San Raffaele | <1 mi |
| A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC | Phase 1/2 | TRIANA Biomedicines, Inc. | <1 mi |
| Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301) | Phase 3 | Revolution Medicines, Inc. | <1 mi |
| A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors | Phase 1/2 | BioNTech SE | <1 mi |
| A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201) | Phase 3 | Bristol-Myers Squibb | <1 mi |
| A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1% | Phase 3 | Bristol-Myers Squibb | <1 mi |
| A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies | Phase 1/2 | Institut de Recherches Internationales Servier | <1 mi |
| FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC | Phase 1/2 | Tubulis GmbH | <1 mi |
| Impact of Behavior Modification Interventions and Lung Cancer Screening on Smoking Cessation in People Living With HIV: A Feasibility Study | N/A | AIDS Malignancy Consortium | <1 mi |
| A Study of NST-6179 in Subjects With Intestinal Failure-Associated Liver Disease (IFALD). | Phase 2 | NorthSea Therapeutics B.V. | <1 mi |
| Project I Test: Implementing HIV Testing in Opioid Treatment Programs | N/A | Columbia University | <1 mi |
| An Open-label Study to Investigate ECUR-506 in Male Babies Less Than 9 Months of Age With Neonatal Onset OTC Deficiency | Phase 1/2 | iECURE, Inc. | <1 mi |
| Persuasive Health Communication Intervention for HIV/HCV | N/A | Icahn School of Medicine at Mount Sinai | <1 mi |
| Gene Therapy for Alpha 1- Antitrypsin Deficiency | Phase 1 | Weill Medical College of Cornell University | <1 mi |
| TReatment for ImmUne Mediated PathopHysiology | Phase 2 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | <1 mi |
| Affect of Melatonin on Sleep and Cognition in Cirrhosis | N/A | Weill Medical College of Cornell University | <1 mi |
| Evaluating Alcohol Use in Alcoholic Liver Disease | — | Nicole T Shen | <1 mi |
| A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition | Phase 2 | Regeneron Pharmaceuticals | <1 mi |
| Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs | — | European Foundation for Study of Chronic Liver Failure | <1 mi |
| Non-Invasive Quantification of Liver Health in NASH (N-QUAN) | N/A | Perspectum | <1 mi |
| Long-term Safety and Efficacy of Odevixibat in Patients With Alagille Syndrome | Phase 3 | Albireo, an Ipsen Company | <1 mi |
| A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis | Phase 3 | Ipsen | <1 mi |
| Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis) | Phase 3 | Takeda | <1 mi |
| FXR Effect on Severe Alcohol-Associated Hepatitis (FRESH) Study | Phase 2 | Intercept Pharmaceuticals | <1 mi |
| Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | Phase 3 | Gilead Sciences | <1 mi |
| HBV Vaccination of Healthy Volunteers to Evaluate the Composition of Germinal Centers | Phase 4 | Rockefeller University | <1 mi |
| Study of Choline Chloride for Injection in Adolescent and Adult Patients With Intestinal Failure Receiving Long Term Parenteral Support | Phase 2/3 | Protara Therapeutics | <1 mi |
| A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH) | Phase 2 | Boehringer Ingelheim | <1 mi |
| A Prospective Database of Infants With Cholestasis | — | Arbor Research Collaborative for Health | <1 mi |
| Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND) | Phase 3 | Mirum Pharmaceuticals, Inc. | <1 mi |
| A Study of SIPLIZUMAB in AILD and LT Patients | Phase 1 | Elizabeth C. Verna | <1 mi |
| Functional Assessment in Liver Transplantation | — | University of California, San Francisco | <1 mi |
| RESTORE TRIAL: A Phase 2 Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD) | Phase 2 | Altimmune, Inc. | <1 mi |
| ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP) | — | Alnylam Pharmaceuticals | <1 mi |
| A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME) | Phase 2 | Aligos Therapeutics | <1 mi |
| Liver Transplant CGM | — | Icahn School of Medicine at Mount Sinai | <1 mi |
| High Fructose Diet, the Gut Microbiome, and Metabolic Health | N/A | Icahn School of Medicine at Mount Sinai | <1 mi |
| Study of Bitopertin in Participants With EPP or XLP (APOLLO) | Phase 3 | Disc Medicine, Inc | <1 mi |
| PiMZ Longitudinal Cohort (PiMZ Logic) | — | Columbia University | <1 mi |
| Identification of Acute Intermittent Porphyria Modifying Genes | — | Icahn School of Medicine at Mount Sinai | <1 mi |
| Human Models of Selective Insulin Resistance: Alpelisib, Part I | Phase 1 | Columbia University | <1 mi |
| A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH | Phase 3 | Akero Therapeutics, Inc | <1 mi |
| Droxidopa to Increase Mean Arterial Pressure in Decompensated Cirrhosis Patients With Acute Kidney Injury | Phase 2 | Giuseppe Cullaro, MD | <1 mi |
| Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States | Phase 2 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | <1 mi |
| A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 65 Years With Alcohol-related Liver Disease | Phase 2 | GlaxoSmithKline | <1 mi |
| Diet and Meal Timing in Patients With Metabolic Dysfunction Associated Steatoic Liver Disease | N/A | Weill Medical College of Cornell University | <1 mi |
| A Study Observing the Long-term, Effectiveness and Safety of Odevixibat (Bylvay) in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing Treatment | — | Ipsen | <1 mi |
| Longitudinal Study of the Porphyrias | — | Icahn School of Medicine at Mount Sinai | <1 mi |
| Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein | Phase 3 | Takeda | <1 mi |
| HepB mAb19 in Individuals With Chronic Hepatitis B Infection | Phase 1 | Rockefeller University | <1 mi |
| A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH | Phase 3 | 89bio, Inc. | <1 mi |
| Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema | Phase 2 | Sanofi | <1 mi |
| A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma | Phase 2 | Coherus Oncology, Inc. | <1 mi |
| A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma | Phase 1/2 | Tvardi Therapeutics, Incorporated | <1 mi |
| National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer | — | National Cancer Institute (NCI) | <1 mi |
| Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant | Phase 4 | Icahn School of Medicine at Mount Sinai | <1 mi |
| A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC) | Phase 1 | AbbVie | <1 mi |
| Durvalumab With Gemcitabine and Cisplatin for the Treatment of High-Risk Resectable Liver Cancer Before Surgery | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Diversity and Inclusion in Research Underpinning Prevention and Therapy Trials | N/A | Icahn School of Medicine at Mount Sinai | <1 mi |
| A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02) | Phase 2 | Daiichi Sankyo | <1 mi |
| Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors | Phase 1/2 | Children's Oncology Group | <1 mi |
| A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08) | Phase 1/2 | GI Innovation, Inc. | <1 mi |
| A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors | Phase 1/2 | DualityBio Inc. | <1 mi |
| Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations | Phase 1 | Tyra Biosciences, Inc | <1 mi |
| Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors | Phase 1/2 | Tango Therapeutics, Inc. | <1 mi |
| The Dragon PLC Trial (DRAGON-PLC) | N/A | Maastricht University | <1 mi |
| A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma | Phase 1 | Alnylam Pharmaceuticals | <1 mi |
| Biopsy After Radioembolization to Identify Changes in Tumor Cells From the Radiation | — | Memorial Sloan Kettering Cancer Center | <1 mi |
| DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors | Phase 2 | DualityBio Inc. | <1 mi |
| Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer | Phase 2 | AstraZeneca | <1 mi |
| A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-011 in Patients With Advanced Solid Tumor | Phase 1 | Abbisko Therapeutics Co, Ltd | <1 mi |
| A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy | Phase 3 | Pierre Fabre Medicament | <1 mi |
| Brodalumab in the Treatment of Immune-Related Adverse Events | Phase 1 | Brian Henick, MD | <1 mi |
| Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen | Phase 3 | Crinetics Pharmaceuticals Inc. | <1 mi |
| HOPE Against Cancer Recurrence in HCC | Phase 4 | Philipp Dutkowski | <1 mi |
| Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study) | — | HistoSonics, Inc. | <1 mi |
| A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies | Phase 1 | SEED Therapeutics, Inc. | <1 mi |
| A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors | Phase 1 | BeOne Medicines | <1 mi |
| A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors | Phase 1/2 | DualityBio Inc. | <1 mi |
| Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma | Phase 1 | Nammi Therapeutics Inc | <1 mi |
| Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases | Phase 2 | Weill Medical College of Cornell University | <1 mi |
| Tissue Analysis After Tumor Ablation for Liver Metastases Leading to Immediate Retreatment | Phase 2/3 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes | Phase 3 | Eli Lilly and Company | 4 mi |
| A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation. | Phase 2 | Taiho Oncology, Inc. | 4 mi |
| Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight | Phase 3 | Eli Lilly and Company | 4 mi |
| First-in-human Study of 7MW4911 in GI Cancer | Phase 1/2 | Mabwell (Shanghai) Bioscience Co., Ltd. | 4 mi |
| A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies | Phase 1 | Kumquat Biosciences Inc. | 4 mi |
| MiniMed Fit Payload Wear Study | — | Medtronic Diabetes | 4 mi |
| A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes | Phase 2 | Zucara Therapeutics Inc. | 4 mi |
| GATEWAY: Safety Evaluation of the MiniMed™ NMX8-AID System in Children and Adults Living With Diabetes | N/A | Medtronic Diabetes | 4 mi |
| Targeted Genomic Analysis of Blood and Tissue Samples From Patients With Cancer | — | Rutgers, The State University of New Jersey | 4 mi |
| Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial) | Phase 2 | National Cancer Institute (NCI) | 4 mi |
| Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer | Phase 2 | Rutgers, The State University of New Jersey | 4 mi |
| Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted | Phase 2 | Rutgers, The State University of New Jersey | 4 mi |
| ATATcH Alternating Treatment Plans for Advanced Cancer | Phase 2 | Rutgers, The State University of New Jersey | 4 mi |
| DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment | Phase 4 | Rutgers, The State University of New Jersey | 4 mi |
| Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis | Phase 2/3 | CSL Behring | 4 mi |
| Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer | Phase 2 | National Cancer Institute (NCI) | 4 mi |
| SuperSaturated Oxygen Comprehensive Observational Registry | — | TherOx | 4 mi |
| Innovations in Genicular Outcomes Registry | — | Pacira Pharmaceuticals, Inc | 4 mi |
| A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | Phase 3 | Teva Branded Pharmaceutical Products R&D, Inc. | 4 mi |
| Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma | Phase 4 | Sanofi | 4 mi |
| Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment | Phase 3 | AstraZeneca | 5 mi |
| Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids | Phase 2 | AstraZeneca | 5 mi |
| A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants | — | Bristol-Myers Squibb | 5 mi |
| Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder | Phase 2 | AbbVie | 5 mi |
| A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | Phase 3 | AbbVie | 5 mi |
| Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer | Phase 4 | Pfizer | 5 mi |
| Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) | Phase 3 | National Cancer Institute (NCI) | 5 mi |
| A Culturally-Tailored Mobile Health and Social Media Physical Activity Intervention for Improving Physical Activity in Hispanic or Latino/Latina Adolescent and Young Adult Childhood Cancer Survivors, Walking Juntos Study | Phase 2 | Children's Oncology Group | 5 mi |
| SilverCloud as a School-Based Intervention for Vulnerable Youth | N/A | NYU Langone Health | 5 mi |
| A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder | Phase 3 | Xenon Pharmaceuticals Inc. | 5 mi |
| Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder | Phase 2 | Intra-Cellular Therapies, Inc. | 5 mi |
| LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis | Phase 3 | Boehringer Ingelheim | 5 mi |
| A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression) | Phase 3 | Xenon Pharmaceuticals Inc. | 5 mi |
| A Study to Assess Safety and Tolerability of PCRX-201 in Subjects With Painful Osteoarthritis of the Knee | Phase 2 | Pacira Pharmaceuticals, Inc | 5 mi |
| Prevention of Cardiovascular Disease and Mortality in Patients With Psoriasis or Psoriatic Arthritis | N/A | University of Pennsylvania | 5 mi |
| Phase 2A Pilot C3 Trial of Recurrent/Refractory Metastatic Advanced Pancreatic Cancer | Phase 1/2 | State University of New York - Downstate Medical Center | 5 mi |
| Pilot Trial of Spiritual Care Interventions for Patients With Cancer | N/A | Weill Medical College of Cornell University | 5 mi |
| Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01) | Phase 3 | AstraZeneca | 5 mi |
| Transgenerational Metabolic-Immune Biomarkers of Neurological and Neurodevelopmental Disorders | — | Southwest Autism Research & Resource Center | 5 mi |
| Triage Survey for Cardiovascular, Obesity, and Related Endocrine Trial Eligibility | — | Brooklyn Clinical Research | 5 mi |
| In-Person Lifestyle Program for Black Adolescent Girls at Risk for Type 2 Diabetes | N/A | Cornell University | 5 mi |
| Non-interventional Pre-screening Protocol Aims to Evaluate Participants for Potential Trial Eligibility in Future Clinical Trials/Studies Focusing on Metabolic and Psychiatric Health. | — | Clindove Research LLC | 5 mi |
| Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol | Phase 3 | Axsome Therapeutics, Inc. | 5 mi |
| ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response | Phase 2 | ACADIA Pharmaceuticals Inc. | 5 mi |
| A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder | Phase 2 | Janssen Research & Development, LLC | 5 mi |
| Tracking Results of Ablations to Combat AF Registry Generation 2 | — | AtriCure, Inc. | 5 mi |
| Comparative Effectiveness of Carvedilol Versus Metoprolol Succinate in Heart Failure Patients With an Implantable Cardioverter Defibrillator | Phase 4 | University of Rochester | 5 mi |
| Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76) | Phase 3 | Anthos Therapeutics, Inc. | 5 mi |
| BREATHE: An Efficacy-implementation Trial Among Black Adults With Uncontrolled Asthma | N/A | Columbia University | 5 mi |
| A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines | Phase 3 | Takeda | 5 mi |
| ConsideRAte Study - Splenic Stimulation for RA | N/A | Galvani Bioelectronics | 5 mi |
| Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response | Phase 3 | MoonLake Immunotherapeutics AG | 5 mi |
| Nebulized Ketamine for the Treatment of Major Depressive Disorder in an Inpatient Setting | Phase 3 | Theresa Jacob, PhD, MPH | 5 mi |
| Clinical Trial on Agitation in Alzheimer's Dementia | Phase 2 | IGC Pharma, LLC | 5 mi |
| Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder | Phase 2 | Intra-Cellular Therapies, Inc. | 5 mi |
| Testing Adapted Self-Help Plus (SH+) for Stress and Well-Being in International Students at a U.S. University | N/A | The New School | 5 mi |
| A Study of NTX-1472 in Social Anxiety Disorder | Phase 2 | Newleos Therapeutics, Inc. | 5 mi |
| A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE) | Phase 4 | GlaxoSmithKline | 5 mi |
| Effectiveness of Task Specific Home Exercise Program | N/A | New York Presbyterian Brooklyn Methodist Hospital | 5 mi |
| Mobile Health for Adherence in Breast Cancer Patients | N/A | ECOG-ACRIN Cancer Research Group | 5 mi |
| The PREDICT Registry: | — | PreludeDx | 5 mi |
| A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis | Phase 3 | Sumitomo Pharma Switzerland GmbH | 5 mi |
| Efficacy and Safety Evaluation of VS-101 in Combination With Chemoradiotherapy in Patients With Head and Neck Cancer | Phase 2 | VSPharmTech Co.,Ltd. | 5 mi |
| Leveraging the Emergency Department (LEAD) Study | N/A | Hackensack Meridian Health | 6 mi |
| A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations | Phase 3 | Teva Branded Pharmaceutical Products R&D LLC | 6 mi |
| A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | Phase 3 | BeiGene | 6 mi |
| A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer. | Phase 2 | AbbVie | 8 mi |
| sFOLFOXIRI in Advanced Gastroesophageal Cancer, (SAGE) | Phase 2 | Rutgers, The State University of New Jersey | 9 mi |
| Microbiotic Product to Promote Microbiome Health and Improve Chemotherapy Delivery | Phase 2 | Howard S. Hochster, MD | 9 mi |
| A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC) | Phase 2 | National Cancer Institute (NCI) | 9 mi |
| Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer | Phase 2 | Rutgers, The State University of New Jersey | 9 mi |
| A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer | Phase 3 | National Cancer Institute (NCI) | 9 mi |
| A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer | Phase 2 | Jazz Pharmaceuticals | 9 mi |
| Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer | Phase 1 | National Cancer Institute (NCI) | 9 mi |
| Exercise to Improve Brain Health in Older African Americans | Phase 2 | Rutgers, The State University of New Jersey | 9 mi |
| Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk | Phase 3 | Population Health Research Institute | 9 mi |
| SDM POSSIBLE: A Breast Cancer Treatment Decision Aid for Women 70+ With Low-Risk Stage I Breast Cancers | N/A | Beth Israel Deaconess Medical Center | 9 mi |
| Liver Transplantation in Intrahepatic Cholangiocarcinoma | — | Rutgers, The State University of New Jersey | 9 mi |
| A Clinical Study to Assess the Efficacy and Safety of Alpha DaRT224 for the Treatment of Patients With Recurrent Cutaneous Squamous Cell Carcinoma | N/A | Alpha Tau Medical LTD. | 9 mi |
| DBS for Depression | Phase 1 | Northwell Health | 9 mi |
| A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004) | Phase 2 | Merck Sharp & Dohme LLC | 9 mi |
| DBS for Obsessive-Compulsive Disorder | N/A | Northwell Health | 9 mi |
| A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants | Phase 2 | Hoffmann-La Roche | 9 mi |
| Pivotal Trial of Automated Artificial Intelligence (AI) Based System for Early Diagnosis of Diabetic Retinopathy | — | iHealthScreen Inc | 9 mi |
| Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 | Phase 2/3 | Mirati Therapeutics Inc. | 9 mi |
| RADIANT: Pre-op Radiation With Abemaciclib and Letrozole | Phase 1 | Mridula George, MD | 9 mi |
| TEMPUS ARIES: A Biobank Registry Platform Study in Oncology | — | Tempus AI | 9 mi |
| A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC) | Phase 3 | Pfizer | 9 mi |
| Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer | — | Mayo Clinic | 10 mi |
| Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype | Phase 3 | Sanofi | 11 mi |
| Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics | — | Wake Forest University Health Sciences | 11 mi |
| A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) | Phase 3 | Hoffmann-La Roche | 11 mi |
| Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients | Phase 3 | Alliance for Clinical Trials in Oncology | 11 mi |
| The REBALANCE Study - a Prospective, Multicenter, Randomized, Pivotal Study of the May Health System | N/A | May Health | 11 mi |
| Mosaic Trial for Stem Cell Transplant Recipients | N/A | Northwestern University | 11 mi |
| A Postmarketing Study of Lecanemab in South Korean Participants With Alzheimer's Disease | — | Eisai Korea Inc. | 11 mi |
| A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer | Phase 3 | AstraZeneca | 11 mi |
| A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1) | Phase 3 | Bristol-Myers Squibb | 11 mi |
| A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA) | Phase 3 | AstraZeneca | 12 mi |
| TECTONIC CAD IVL IDE Study | N/A | Abbott Medical Devices | 12 mi |
| Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer | Phase 3 | Alliance for Clinical Trials in Oncology | 12 mi |
| Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations | Phase 3 | Daiichi Sankyo | 12 mi |
| Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors | — | ECOG-ACRIN Cancer Research Group | 12 mi |
| Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial | Phase 3 | National Cancer Institute (NCI) | 12 mi |
| RSSearch Patient Registry-Long Term Study of Use of SRS/SBRT | — | The Radiosurgery Society | 12 mi |
| Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors | Phase 1 | Radiopharm Theranostics, Ltd | 12 mi |
| A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | AbbVie | 12 mi |
| Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer | Phase 3 | Bayer | 12 mi |
| Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial) | Phase 2 | SWOG Cancer Research Network | 12 mi |
| Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial) | Phase 2/3 | SWOG Cancer Research Network | 12 mi |
| Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma | Phase 3 | Children's Oncology Group | 12 mi |
| Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) | Phase 3 | Merck Sharp & Dohme LLC | 12 mi |
| Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis | Phase 3 | Sanofi | 12 mi |
| Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma | Phase 2 | Rutgers, The State University of New Jersey | 12 mi |
| Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving Immunotherapy | N/A | Wake Forest University Health Sciences | 12 mi |
| Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer | Phase 2 | Protara Therapeutics | 12 mi |
| A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer | Phase 3 | Hoffmann-La Roche | 12 mi |
| A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer | Phase 3 | Ferring Pharmaceuticals | 12 mi |
| EMPHASYS Cup Positioning in THA With Non-Invasive Navigation (Velys Hip Navigation (VHN)) | N/A | DePuy Orthopaedics | 12 mi |
| Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment | Phase 3 | Boehringer Ingelheim | 12 mi |
| A Study of DF6002 Alone and in Combination With Nivolumab | Phase 1 | Dragonfly Therapeutics | 12 mi |
| Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study | Phase 2/3 | Kardigan, Inc. | 12 mi |
| TRIcvalve biCAVal Valve System for Severe Tricuspid Regurgitation (TRICAV-I) | N/A | P+F Products + Features USA Inc. | 12 mi |
| ALT-FLOW II Trial of the Edwards APTURE Transcatheter Shunt System | N/A | Edwards Lifesciences | 12 mi |
| Abbott Cephea Mitral Valve Disease Registry | — | Abbott Medical Devices | 12 mi |
| ADSTILADRIN Early Utilization and Outcomes in the Real World Setting | — | Ferring Pharmaceuticals | 12 mi |
| Investigating Dupilumab's Effect in Asthma by Genotype | Phase 4 | Boston Children's Hospital | 12 mi |
| Virtual Reality Goggle Utilization for Venipuncture Distraction | N/A | Montefiore Medical Center | 12 mi |
| Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients | Phase 2 | National Cancer Institute (NCI) | 12 mi |
| Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide | Phase 3 | Novo Nordisk A/S | 12 mi |
| Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) | Phase 1/2 | Curis, Inc. | 12 mi |
| Alexithymia Intervention for Suicide | Phase 1 | VA Office of Research and Development | 12 mi |
| Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer | Phase 1 | National Cancer Institute (NCI) | 12 mi |
| Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML | Phase 2 | Montefiore Medical Center | 12 mi |
| DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors | Phase 1 | DynamiCure Biotechnology | 12 mi |
| Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer | Phase 4 | Novartis Pharmaceuticals | 12 mi |
| Genomics in Michigan to AdJust Outcomes in Prostate canceR (G-MAJOR) for Men With Newly Diagnosed Favorable Risk Prostate Cancer | N/A | University of Michigan Rogel Cancer Center | 12 mi |
| Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML. | Phase 1 | Huda Salman | 12 mi |
| Phase I Study of Fractionated Stereotactic Radiation Therapy | Phase 1 | Albert Einstein College of Medicine | 12 mi |
| This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve. | Phase 3 | Pfizer | 12 mi |
| Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response | Phase 3 | Canadian Cancer Trials Group | 12 mi |
| A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss | Phase 2 | VA Office of Research and Development | 12 mi |
| A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1). | Phase 3 | Pfizer | 12 mi |
| Reduced Intensity Haploidentical BMT for High Risk Solid Tumors | Phase 2 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 12 mi |
| First in Human, Dose Escalation Study of AN4005 | Phase 1 | Adlai Nortye Biopharma Co., Ltd. | 12 mi |
| FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia | Phase 1 | Montefiore Medical Center | 12 mi |
| Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma | Phase 1/2 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 12 mi |
| Molecular and Genomic Profiling of Head and Neck Tumors | — | Montefiore Medical Center | 12 mi |
| Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes | Phase 1 | H. Lee Moffitt Cancer Center and Research Institute | 12 mi |
| AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer | Phase 3 | AstraZeneca | 12 mi |
| Treatment of Radiation and Cisplatin Induced Toxicities with Tempol | Phase 2 | Matrix Biomed, Inc. | 12 mi |
| Phase 1 Study of ACR-2316 in Specific Advanced Solid Tumors | Phase 1 | Acrivon Therapeutics | 12 mi |
| A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors | Phase 1 | Genentech, Inc. | 12 mi |
| Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1) | Phase 1 | Ichnos Sciences SA | 12 mi |
| Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML | Phase 1 | Montefiore Medical Center | 12 mi |
| Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S04) | N/A | National Cancer Institute (NCI) | 12 mi |
| A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma | Phase 1 | Johnson & Johnson Enterprise Innovation Inc. | 12 mi |
| A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors | Phase 2 | Nationwide Children's Hospital | 12 mi |
| Upfront Surgical Resection for Osteosarcoma | — | Montefiore Medical Center | 12 mi |
| Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS | Phase 1 | Montefiore Medical Center | 12 mi |
| Study of LYL314 in Aggressive Large B-Cell Lymphoma | Phase 1/2 | Lyell Immunopharma, Inc. | 12 mi |
| A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer | Phase 1 | Aura Biosciences | 12 mi |
| DFMO Maintenance for Patients With Relapsed/Refractory Ewing Sarcoma or Osteosarcoma | Phase 1/2 | Montefiore Medical Center | 12 mi |
| Digoxin Medulloblastoma Study | Phase 2 | H. Lee Moffitt Cancer Center and Research Institute | 12 mi |
| Use of a Comprehensive, Mobile Application to Assist Cancer Patients With Diet, Nutrition and Activity | N/A | Montefiore Medical Center | 12 mi |
| Testing the Addition of an Anti-Cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (5-Fluorouracil) for Metastatic, Refractory Colorectal Cancer | Phase 1 | National Cancer Institute (NCI) | 12 mi |
| Outcomes in Pediatric and Young Adult B-Cell Malignancies After Commercially Available Immunotherapy | — | Stanford University | 12 mi |
| Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis | Phase 1 | National Cancer Institute (NCI) | 12 mi |
| PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC | Early 1 | Presage Biosciences | 12 mi |
| Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer | Phase 2 | NRG Oncology | 12 mi |
| ZZ06 in Adult Patients With Advanced Solid Tumor Malignancies | Phase 1 | Changchun Intellicrown Pharmaceutical Co. LTD | 12 mi |
| A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2 | Phase 1 | NextPoint Therapeutics, Inc. | 12 mi |
| Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S01) | N/A | National Cancer Institute (NCI) | 12 mi |
| A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer. | Phase 3 | Pfizer | 12 mi |
| Fresh Takes!: An Evaluation of the Impact of Receiving Fresh Food Boxes | N/A | Montefiore Medical Center | 12 mi |
| Evaluating the Efficacy of GPT-based Nutrition and Diabetic Counseling in Gestational Diabetes Management: A Randomized Controlled Trial (AIM-GDM) | N/A | Montefiore Medical Center | 12 mi |
| Regulation of Endogenous Glucose Production by Central KATP Channels | Phase 2 | Meredith Hawkins | 12 mi |
| Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes | Phase 3 | vTv Therapeutics | 12 mi |
| Hybrid Closed Loop Effectiveness Trial in Adults With Type 1 Diabetes | N/A | Boston Medical Center | 12 mi |
| A Mental Health Services Engagement Program for Racial and Ethnic Minority Young Adults | N/A | New York University | 12 mi |
| Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) | Phase 3 | Neurocrine Biosciences | 12 mi |
| Orexin Antagonism for Suicide Risk: A Proof-of-Concept Clinical Trial | Phase 2 | Marianne Goodman | 12 mi |
| NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) | Phase 3 | Neurocrine Biosciences | 12 mi |
| Suicide Specific Rumination in Veterans | N/A | VA Office of Research and Development | 12 mi |
| ACP-204 in Adults With Alzheimer's Disease Psychosis | Phase 2/3 | ACADIA Pharmaceuticals Inc. | 12 mi |
| Assessment of Transcatheter Edge-to-Edge Repair in Atrial Functional Mitral Regurgitation (ATRIAL-MR) | — | University Hospital of Cologne | 12 mi |
| Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease | Phase 3 | Alessandro Doria | 12 mi |
| Cardiovascular Multimodality Imaging Study | — | Montefiore Medical Center | 12 mi |
| A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma | Phase 3 | GlaxoSmithKline | 12 mi |
| AeviceMD for Detection of Wheeze in Pediatric and Adult Populations | — | Aevice Health Pte. Ltd. | 12 mi |
| A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR) | Phase 2 | Upstream Bio Inc. | 12 mi |
| ASTHMAXcel Voice Study | N/A | Montefiore Medical Center | 12 mi |
| Psychiatric Outcomes of Unruptured Intracranial Aneurysms (POUIA) | N/A | Montefiore Medical Center | 12 mi |
| Telemedicine-Delivered Unified Protocol for Cognitive Behavioral Therapy for Anxiety and Depression | N/A | Albert Einstein College of Medicine | 12 mi |
| Transforming Care for Individuals With Childhood-onset Systemic Lupus Erythematosus | N/A | Michigan State University | 12 mi |
| A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus | Phase 3 | Viatris Innovation GmbH | 12 mi |
| Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials | N/A | Eastern Cooperative Oncology Group | 12 mi |
| TMEM-MRI: A Pilot Feasibility Study of MRI for Imaging of TMEM in Patients With Operable Breast Cancer | N/A | Montefiore Medical Center | 12 mi |
| CDK and Body Composition Study | — | Montefiore Medical Center | 12 mi |
| Reiki Breast Surgery QOL Project for Women Undergoing Breast Surgery | N/A | Albert Einstein College of Medicine | 12 mi |
| TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd | Phase 2 | Ana C Garrido-Castro, MD | 12 mi |
| Intra-Operative Radiation Registry | — | Albert Einstein College of Medicine | 12 mi |
| QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer | — | Abramson Cancer Center at Penn Medicine | 12 mi |
| ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab | Phase 3 | Alliance for Clinical Trials in Oncology | 12 mi |
| Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies | Early 1 | Presage Biosciences | 12 mi |
| ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer | Phase 3 | BioNTech SE | 12 mi |
| Circulating Tumor DNA | Phase 2 | Yale University | 12 mi |
| Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial | Phase 3 | National Cancer Institute (NCI) | 12 mi |
| Cough Capture as a Portal Into the Lung | — | Albert Einstein College of Medicine | 12 mi |
| Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer | Phase 2 | Nitin Ohri | 12 mi |
| Centralized Screening Unit (CSU) at Montefiore-Einstein | N/A | Albert Einstein College of Medicine | 12 mi |
| EXoPERT EMERALD Clinical Study | — | EXoPERT | 12 mi |
| Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection | Phase 2 | Gilead Sciences | 12 mi |
| Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors | Phase 2 | SWOG Cancer Research Network | 12 mi |
| Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial | Phase 3 | NRG Oncology | 12 mi |
| Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC | Phase 2 | Replimune Inc. | 12 mi |
| HepQuant: Study to Assess the Role of Blood-based Biomarkers and Quantitative MR Imaging for Patients Receiving Radiation Therapy for Liver Cancer | N/A | Montefiore Medical Center | 12 mi |
| Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI | N/A | VA Office of Research and Development | 12 mi |
| Fludarabine and Intermediate-dose TBI Followed by PTCy in Patients Undergoing Allo Transplant for Heme Malignancies | Phase 2 | Hackensack Meridian Health | 12 mi |
| Study to Evaluate the Usability and Value of Integrated Digital Solutions in Medical Care of Participants With Multiple Sclerosis | — | Hoffmann-La Roche | 12 mi |
| Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy | Phase 2 | Hackensack Meridian Health | 12 mi |
| Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) | Phase 2 | Merck Sharp & Dohme LLC | 12 mi |
| Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001) | Phase 1 | Merck Sharp & Dohme LLC | 12 mi |
| A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head) | Phase 3 | Regeneron Pharmaceuticals | 12 mi |
| Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer | Phase 2/3 | National Cancer Institute (NCI) | 12 mi |
| AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy | Phase 1/2 | UniQure Biopharma B.V. | 12 mi |
| A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) | Phase 3 | Merck Sharp & Dohme LLC | 12 mi |
| EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD) | — | Exact Sciences Corporation | 12 mi |
| A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016) | Phase 3 | Merck Sharp & Dohme LLC | 12 mi |
| A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer | Phase 2 | Janssen Research & Development, LLC | 12 mi |
| Shield Post-Approval Study Protocol | — | Guardant Health, Inc. | 12 mi |
| A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder. | Phase 3 | AbbVie | 12 mi |
| Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment | — | Children's Oncology Group | 12 mi |
| A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors | Phase 1/2 | Astellas Pharma Global Development, Inc. | 12 mi |
| A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors | Phase 1/2 | Bristol-Myers Squibb | 12 mi |
| Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial | Phase 3 | SWOG Cancer Research Network | 12 mi |
| A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011) | Phase 3 | Merck Sharp & Dohme LLC | 12 mi |
| Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL) | Phase 2 | AbbVie | 12 mi |
| A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206) | Phase 1/2 | Bristol-Myers Squibb | 12 mi |
| A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy | Phase 2 | Eli Lilly and Company | 12 mi |
| Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors | Phase 1/2 | Milton S. Hershey Medical Center | 12 mi |
| A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002) | Phase 1/2 | Merck Sharp & Dohme LLC | 12 mi |
| Neoadjuvant Lu-177-PSMA-617 in Patients With High Risk Localized Prostate Cancer Undergoing Radical Prostatectomy | Phase 2 | Hackensack Meridian Health | 12 mi |
| Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer | Phase 1/2 | Janssen Research & Development, LLC | 12 mi |
| Pembrolizumab and Lenvatinib in Advanced Cervical Cancer | Phase 2 | Georgetown University | 12 mi |
| Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies | Phase 1 | Vanda Pharmaceuticals | 12 mi |
| Utility of 18F-rhPSMA-7.3 in the Diagnosis of Prostate Cancer After Focal Gland Treatment | N/A | Hackensack Meridian Health | 12 mi |
| NOURISH-T+: Promoting Healthy Eating and Exercise Behaviors | N/A | University of South Florida | 12 mi |
| Phase IB/II of CPX-351 for Relapse Prevention in AML | Phase 1/2 | Georgetown University | 12 mi |
| A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours) | Phase 1 | Boehringer Ingelheim | 12 mi |
| A Study of BG-C477 in Participants With Advanced Solid Tumors | Phase 1 | BeOne Medicines | 12 mi |
| A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012) | Phase 3 | Merck Sharp & Dohme LLC | 12 mi |
| A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy | Phase 3 | Lyell Immunopharma, Inc. | 12 mi |
| Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults | Phase 1 | Sabine Mueller, MD, PhD | 12 mi |
| Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome | Phase 2 | Orca Biosystems, Inc. | 12 mi |
| A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers | Phase 1 | Regeneron Pharmaceuticals | 12 mi |
| The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL | Phase 2 | Pediatric Transplantation & Cellular Therapy Consortium | 12 mi |
| Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma | Phase 1/2 | Hackensack Meridian Health | 12 mi |
| AMNIOX CORD Study - Radical Prostatectomy With and Without Cryopreserved Umbilical Cord Allograft | Phase 2/3 | Hackensack Meridian Health | 12 mi |
| A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma | Phase 1/2 | Celgene | 12 mi |
| ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome | — | Stanford University | 12 mi |
| Intra-Tumoral Injections of Natural Killer Cells for Recurrent Malignant Pediatric Brain Tumors | Phase 1 | Sabine Mueller, MD, PhD | 12 mi |
| Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma | Phase 2 | Giselle Sholler | 12 mi |
| A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015) | Phase 2 | Merck Sharp & Dohme LLC | 12 mi |
| A Clinical Study of V940 and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012) | Phase 2 | Merck Sharp & Dohme LLC | 12 mi |
| XTX301 in Patients With Advanced Solid Tumors | Phase 1/2 | Xilio Development, Inc. | 12 mi |
| ETMR One: An International Registry and Research Platform for Children With Embryonal Tumor With Multilayer Rosettes | — | Hackensack Meridian Health | 12 mi |
| Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors | Phase 1 | BeiGene | 12 mi |
| DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma | Phase 2 | Giselle Sholler | 12 mi |
| A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1) | Phase 3 | Merus B.V. | 12 mi |
| DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers | Phase 1 | Boehringer Ingelheim | 12 mi |
| Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma | Phase 1 | Hackensack Meridian Health | 12 mi |
| A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors | Phase 2 | Georgetown University | 12 mi |
| A Global Study of the PETAL Consortium | — | Massachusetts General Hospital | 12 mi |
| PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV) | Phase 2 | Pulmotect, Inc. | 12 mi |
| A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors | Phase 1/2 | Eikon Therapeutics | 12 mi |
| Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma | Phase 1 | SIRPant Immunotherapeutics, Inc. | 12 mi |
| Pediatric Precision Laboratory Advanced Neuroblastoma Therapy | Phase 2 | Giselle Sholler | 12 mi |
| A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon, Rectum, Stomach, or Pancreas | Phase 1 | Boehringer Ingelheim | 12 mi |
| Clinical Application of Stem Cell Educator Therapy in Type 1 Diabetes | Phase 2/3 | Throne Biotechnologies Inc. | 12 mi |
| OBWELL: Innovative Psychotherapeutic Intervention to Treat Postpartum Depression | N/A | Hackensack Meridian Health | 12 mi |
| Pulsed Electromagnetic Field Treatment In Patients With Alzheimer's Disease | N/A | Herrick Medical LLC | 12 mi |
| The HEARTFELT Study | N/A | Heartfelt Technologies | 12 mi |
| A Study About How Blood Cell Growth Patterns Relate to Heart Health After Treatment for Hodgkin Lymphoma | — | Children's Oncology Group | 12 mi |
| Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis | Phase 3 | Duke University | 12 mi |
| A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer | Phase 3 | Hoffmann-La Roche | 12 mi |
| RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer | Phase 1/2 | Georgetown University | 12 mi |
| Post-operative Urinary Retention (POUR) Following Thoracic Surgery | Phase 1/2 | Hackensack Meridian Health | 12 mi |
| A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors | Phase 1/2 | Alentis Therapeutics AG | 12 mi |
| A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC) | Phase 1 | Astellas Pharma Global Development, Inc. | 12 mi |
| Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors | Phase 1 | Whitehawk Therapeutics, Inc. | 12 mi |
| Iscador® P (Mistletoe) Immunotherapy for Recurrent Osteogenic Sarcoma | Phase 2 | Hackensack Meridian Health | 12 mi |
| CT-95 in Advanced Cancers Associated With Mesothelin Expression | Phase 1 | Context Therapeutics Inc. | 12 mi |
| A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors | Phase 1/2 | Alentis Therapeutics AG | 12 mi |
| A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors. | Phase 1 | Bristol-Myers Squibb | 12 mi |
| A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002) | Phase 1/2 | Merck Sharp & Dohme LLC | 12 mi |
| RAPA-201 Therapy of Solid Tumors | Phase 1/2 | Rapa Therapeutics LLC | 12 mi |
| A Phase 1 Study of LNCB74 in Advanced Solid Tumors | Phase 1 | NextCure, Inc. | 12 mi |
| A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors | Phase 1/2 | Bristol-Myers Squibb | 12 mi |
| A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors | Phase 1/2 | Bristol-Myers Squibb | 12 mi |
| Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer | Phase 2 | Georgetown University | 12 mi |
| A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors | Phase 1 | NiKang Therapeutics, Inc. | 12 mi |
| Support for Cancer Patients Awaiting News | N/A | Hackensack Meridian Health | 12 mi |
| A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma | Phase 1 | Pfizer | 12 mi |
| A Study of ZL-1310 in Subjects With Small Cell Lung Cancer | Phase 1 | Zai Lab (Shanghai) Co., Ltd. | 12 mi |
| First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours | Phase 1/2 | AstraZeneca | 12 mi |
| Evaluating Novel Therapies in ctDNA Positive GI Cancers | Phase 3 | Georgetown University | 12 mi |
| A Study of ZW251 in Participants With Advanced Solid Tumors | Phase 1 | Zymeworks BC Inc. | 12 mi |
| Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform | — | Elephas | 12 mi |
| A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) | Phase 3 | Bristol-Myers Squibb | 13 mi |
| A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02) | Phase 3 | DualityBio Inc. | 13 mi |
| Testing RG1-VLP Vaccine to Prevent HPV-related Cancers | Phase 1 | National Cancer Institute (NCI) | 13 mi |
| A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide | Phase 2 | Eli Lilly and Company | 13 mi |
| Registry for Stage 2 Type 1 Diabetes | — | Sanofi | 13 mi |
| Study of ALTO-300 in MDD | Phase 2 | Alto Neuroscience | 13 mi |
| Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease | Phase 2 | Celgene | 13 mi |
| A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2) | Phase 3 | Bristol-Myers Squibb | 13 mi |
| Trial-Ready Cohort-Down Syndrome (TRC-DS) | — | University of Southern California | 13 mi |
| Open-label Extension Study in Participants With Early Alzheimer's Disease | Phase 2 | GlaxoSmithKline | 13 mi |
| A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma | Phase 3 | AstraZeneca | 13 mi |
| A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007) | Phase 3 | AstraZeneca | 13 mi |
| Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors | N/A | NRG Oncology | 13 mi |
| Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004) | Phase 3 | Merck Sharp & Dohme LLC | 13 mi |
| Ultralow Dose PET Imaging of 18F-FDG Uptake | Phase 2 | Akiva Mintz | 13 mi |
| Ultralow Dose PET Imaging for PSMA Expression | Phase 2 | Akiva Mintz | 13 mi |
| Ultralow Dose PET Imaging of SSTR2 Radiotracer Uptake | Phase 2 | Akiva Mintz | 13 mi |
| Outcomes of Ablation of Unresectable Pancreatic Cancer Using the NanoKnife Irreversible Electroporation System- | — | Englewood Hospital and Medical Center | 13 mi |
| Ultralow Dose PET Imaging for 18F-NaF Uptake | Phase 2 | Akiva Mintz | 13 mi |
| Tempus Sculptor Study: Small Cell Lung Cancer (SCLC) Observational Study | — | Tempus AI | 13 mi |
| Novel Method to Assess Hepatic Regeneration and Predict Hepatic Related Morbidity After Partial Hepatectomy | N/A | Englewood Hospital and Medical Center | 13 mi |
| Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis | Phase 3 | Celgene | 13 mi |
| A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy | Phase 2 | Boehringer Ingelheim | 13 mi |
| A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies | Phase 2 | AbbVie | 13 mi |
| A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression | Phase 2 | AbbVie | 13 mi |
| Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis. | Phase 3 | Novartis Pharmaceuticals | 13 mi |
| Barrigel® PPRT (Post-Prostatectomy Radiation Therapy) Trial | N/A | Palette Life Sciences, Inc. | 13 mi |
| Brain Activity Changes After Cognitive Behavioral Therapy for Anxiety in Autistic Youth From High-Need Communities | N/A | Montclair State University | 13 mi |
| Examining Effects of Ocrevus on Cognitive Fatigue Using fMRI | — | Kessler Foundation | 14 mi |
| An Examination of Cognitive Fatigue Using Functional Neuroimaging | — | Kessler Foundation | 14 mi |
| Examining Effects of Tysabri on Cognitive Fatigue Using fMRI | — | Kessler Foundation | 14 mi |
| Focused Extracorporeal Shockwave Therapy for Knee Arthritis | N/A | Kessler Foundation | 14 mi |
| Investigating the Effects of Wearable Robotic Exoskeleton for Improving Mobility and Cognition in Persons With MS | N/A | Kessler Foundation | 14 mi |
| A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec | Phase 2 | Candel Therapeutics, Inc. | 14 mi |
| A Study to Evaluate Solriktug in Adult Participants With Asthma | Phase 2 | Uniquity One (UNI) | 14 mi |
| A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2) | Phase 3 | Bristol-Myers Squibb | 16 mi |
| Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies | Phase 1 | AbbVie | 16 mi |
| American Hepato-Pancreato-Biliary Association (AHPBA) Pancreatic Irreversible Electroporation (IRE) Registry | — | University of Louisville | 16 mi |
| MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) | Phase 3 | Pfizer | 16 mi |
| A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer | Phase 2/3 | Bristol-Myers Squibb | 16 mi |
| Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Colorectal Liver Metastasis | Early 1 | Northwell Health | 16 mi |
| Electroconvulsive Therapy (ECT) for Agitation in Dementia (AD) | N/A | Brent Forester | 16 mi |
| A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine | Phase 2 | Boehringer Ingelheim | 16 mi |
| A Modified Platform Trial of Multiple CAMPs for the Management of Diabetic Foot Ulcers and Venous Leg Ulcers | N/A | Integra LifeSciences Corporation | 16 mi |
| Geriatric Evaluation and Management With Survivorship Health Education for Older Survivors of Cancer, GEM-S Trial | Phase 3 | University of Rochester | 16 mi |
| Utility of Biparametric MRI (Magnetic Resonance Imaging) as a Screening Tool for Prostate Cancer in a High-Risk Cohort | N/A | Northwell Health | 16 mi |
| A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV) | Phase 3 | Xynomic Pharmaceuticals, Inc. | 16 mi |
| A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors | Phase 1/2 | Artios Pharma Ltd | 16 mi |
| PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC) | Phase 1 | PanTher Therapeutics | 16 mi |
| A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease | Phase 2 | AbbVie | 16 mi |
| Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma | Phase 2 | Corcept Therapeutics | 16 mi |
| A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body | Phase 1/2 | Regeneron Pharmaceuticals | 16 mi |
| The ME&MG Digital Solution for Autonomous Assessment of Myasthenia Gravis | N/A | Ad scientiam | 16 mi |
| DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma | Phase 1/2 | University of California, San Francisco | 16 mi |
| Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants With Advanced Solid Tumors | Phase 1 | Genmab | 16 mi |
| A Study of GEN1106 in Participants With Solid Tumors | Phase 1 | Genmab | 16 mi |
| A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors | Phase 1 | GlaxoSmithKline | 16 mi |
| Trial to Evaluate the Safety and Effectiveness of Treatment With COMS One Device in Subjects With Diabetic Foot Ulcers | N/A | Piomic Medical | 16 mi |
| DFC 004 Biomarkers for Active Diabetic Foot Ulcers | — | University of Michigan | 16 mi |
| Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson's Disease | — | AbbVie | 16 mi |
| A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study | Phase 2 | GlaxoSmithKline | 16 mi |
| Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors | Phase 1/2 | Aminex Therapeutics, Inc. | 16 mi |
| IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE) | Phase 2 | Innate Pharma | 16 mi |
| STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers | Phase 1/2 | STORM Therapeutics LTD | 16 mi |
| INFINITIVE: ImmuNotherapy For PatIeNts wIth colorecTal LIVer MEtastases | Early 1 | Northwell Health | 16 mi |
| A Study of MGC026 in Participants With Advanced Solid Tumors | Phase 1 | MacroGenics | 16 mi |
| Perioperative Anticoagulant Use for Surgery Evaluation -Virtual Visit (PAUSE-Virtual) | — | McMaster University | 16 mi |
| Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry | — | Boston Scientific Corporation | 16 mi |
| A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes | Phase 2 | Hoffmann-La Roche | 16 mi |
| Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder | Phase 2 | Syndeio Biosciences, Inc | 16 mi |
| Assessing the Fertility Status of Men With Spinal Muscular Atrophy (SMA) | — | Bar-Chama, Natan, M.D. | 16 mi |
| A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease | Phase 3 | Hoffmann-La Roche | 16 mi |
| Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer | Phase 2/3 | BioNTech SE | 16 mi |
| Comparison Between ABP 692 and Ocrevus® (Ocrelizumab) | Phase 3 | Amgen | 16 mi |
| A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | Phase 3 | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | 16 mi |
| A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL) | Phase 3 | BeOne Medicines | 16 mi |
| Determine Safety & Recommended Phase 2 Dosing of Zeaxanthin Alone or in Combination w/Pembrolizumab in Patients With Metastatic Cancer | Phase 1 | Valley Health System | 16 mi |
| Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study | Phase 2 | NRG Oncology | 16 mi |
| A Study of V940/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013) | Phase 2 | Merck Sharp & Dohme LLC | 16 mi |
| Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib | Phase 1/2 | Genprex, Inc. | 16 mi |
| A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis | Phase 3 | Bristol-Myers Squibb | 17 mi |
| Maturation of Arteriovenous Fistula With Automated Sonography Assessments Trial | N/A | Sonavex, Inc. | 17 mi |
| A Study to Evaluate Solrikitug in Participants With COPD (ZION) | Phase 2 | Uniquity One (UNI) | 17 mi |
| A BCT Intervention for an Hourly Activity Habit Among Caregivers for Persons With AD/ADRD | N/A | Northwell Health | 17 mi |
| BCT Intervention For Walking Habit Among Caregivers of People With AD/ADRD | N/A | Northwell Health | 17 mi |
| Assessment of a Minimally Invasive Collection Device for Molecular Analysis of Esophageal Samples | N/A | Mayo Clinic | 17 mi |
| Minimally Invasive Molecular Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Adenocarcinoma | N/A | Mayo Clinic | 17 mi |
| Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs) | — | Alexion Pharmaceuticals, Inc. | 17 mi |
| Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma | Phase 2 | H. Lee Moffitt Cancer Center and Research Institute | 17 mi |
| Evaluation of Circulating Immune Response After Histosonics in Colorectal Cancer (ECHO-CRC) | Phase 1 | Northwell Health | 17 mi |
| First in Human Phase1/2a Clinical Trial of Anti-PAUF Monoclonal Antibody PBP1510 in Patients With Pancreatic Cancer | Phase 1/2 | Prestige Biopharma Limited | 17 mi |
| Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Pancreatic Cancer | Early 1 | Northwell Health | 17 mi |
| Determinates of Atrial Tracking and Prevalence of Atrial Fibrillation in the Micra AV2 (DANCE AFIB) | — | Northwell Health | 17 mi |
| Optimal Ventilation for Cardiac Arrest | N/A | Children's Hospital of Philadelphia | 17 mi |
| Implanted Loop Recorders for Detection and Management of Arrhythmia With Bruton Tyrosine Kinase Inhibitors | N/A | Northwell Health | 17 mi |
| Virtual Personalized Exercise Program for Lung Cancer Patients | N/A | Northwell Health | 17 mi |
| A Study to Learn More About How Well Sevabertinib (BAY 2927088) Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) | Phase 3 | Bayer | 17 mi |
| Renal Denervation + PVI vs PVI Alone for Persistent AF | N/A | University of Rochester | 17 mi |
| CanScan; Community-based Registry to Assess, Address and advaNce SCreening for cANcer Prevention and Management | — | Hackensack Meridian Health | 17 mi |
| Identification of Breast Cancer in Breath Samples Using Trained Detection Dogs | — | SpotitEarly | 17 mi |
| (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma | Phase 2 | IDEAYA Biosciences | 17 mi |
| Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT) | Phase 1/2 | Plus Therapeutics | 17 mi |
| A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer | Phase 2 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | 17 mi |
| Tau Networks in Psychotic Alzheimer's Disease | — | Northwell Health | 17 mi |
| Repeat Ablation of Persistent Atrial Fibrillation, Including Mitral Isthmus Catheter Ablation, With the FARAPULSE Pulsed Field Ablation System | N/A | Boston Scientific Corporation | 17 mi |
| Factor VIII Inhibitor Bypass Activity (FEIBA) Versus Fresh Frozen Plasma As First Line Therapy For Bleeding After Cardiac Surgery | Phase 2 | Northwell Health | 17 mi |
| Clinical Study of the inQB8 TTVR System | N/A | inQB8 Medical Technologies, LLC | 17 mi |
| Trans-arterial Embolization for the Treatment of Facet Pain Due to Facet Arthropathy | N/A | Northwell Health | 17 mi |
| Electroencephalogram Recording in Patients With Systemic Lupus Erythematosus | — | Northwell Health | 17 mi |
| Trial of Belimumab in Early Lupus | Phase 4 | Northwell Health | 17 mi |
| A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment | — | Ipsen | 17 mi |
| National Liver Cancer Screening Trial | Phase 4 | University of Texas Southwestern Medical Center | 17 mi |
| Study to Assess EN3835 in the Treatment of Plantar Fibromatosis (Also Known as Ledderhose Disease) | Phase 3 | Endo Pharmaceuticals | 17 mi |
| Amnio-Maxx in Patients With Diabetic Foot Ulcers Unresponsive to Standard of Care Treatment Alone | N/A | Capsicure, LLC | 17 mi |
| Evaluation of ELU42 Topical Spray for the Treatment of Diabetic Foot Ulcers | Phase 1/2 | Eluciderm Inc | 17 mi |
| Observational Study to Evaluate the Efficacy of Sustained QUTENZA® Use in Painful Diabetic Peripheral Neuropathy | — | Averitas Pharma, Inc. | 17 mi |
| Palliative Dose Escalated Radiation for Painful Non-Spine Bone Metastases and Painful Non-Bone Metas | Phase 2 | Rutgers, The State University of New Jersey | 17 mi |
| Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial) | Phase 2 | National Cancer Institute (NCI) | 17 mi |
| Investigating Targetable Metabolic Pathways Sustaining Pancreatic Cancer | N/A | Rutgers, The State University of New Jersey | 17 mi |
| Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula | Phase 3 | SWOG Cancer Research Network | 17 mi |
| mHealth Mindfulness With Patients With Serious Illness and Their Caregivers | N/A | Rutgers, The State University of New Jersey | 17 mi |
| Peritoneal Carcinomatosis Leveraging ctDNA Guided Treatment in GI Cancer Study (PERICLES Study) | N/A | Rutgers, The State University of New Jersey | 17 mi |
| Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T | Phase 2 | Dendreon | 18 mi |
| Transcranial Direct Current Stimulation for Depression | N/A | Soterix Medical | 18 mi |
| An Internet-based Program to Help Cancer Survivors Manage Pain | N/A | Wake Forest University Health Sciences | 19 mi |
| DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM) | Phase 2 | Diakonos Oncology Corporation | 19 mi |
| Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial | Phase 3 | ECOG-ACRIN Cancer Research Group | 19 mi |
| A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome | Phase 3 | Bristol-Myers Squibb | 19 mi |
| Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer | Phase 3 | Daiichi Sankyo | 19 mi |
| Collection of Sputum and Labeling for Lung Cancer | — | bioAffinity Technologies Inc. | 19 mi |
| Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01) | Phase 3 | AstraZeneca | 19 mi |
| Measuring Surgical Recovery After Radical Cystectomy | — | M.D. Anderson Cancer Center | 19 mi |
| Effect of 2-Week Continuous Glucose Monitoring on Glycemic Management in Patients New-to-Insulin on Hospital Discharge | N/A | NYU Langone Health | 19 mi |
| ELUCIDATE FFRct Study | — | Elucid Bioimaging Inc. | 19 mi |
| Phase 3 Pivotal Trial Comparing CARTISTEM® and Surgical Comparator for Knee Cartilage Lesions and Osteoarthritis | Phase 3 | Medipost, Inc. | 19 mi |
| A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT) | Phase 2 | Memorial Sloan Kettering Cancer Center | 20 mi |
| Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain | Phase 2 | Dogwood Therapeutics Inc. | 20 mi |
| Detection and Risk Stratification in Veterans Presenting With Microscopic Hematuria | — | Pacific Edge Limited | 20 mi |
| NHLBI and Cook Trans-Atrial Intra-Pericardial Tricuspid Annuloplasty (TRAIPTA) Early Feasibility Study | N/A | National Heart, Lung, and Blood Institute (NHLBI) | 20 mi |
| The Multicenter Stress Cardiac Magnetic Resonance Quantitative Perfusion Imaging in the United States Study | N/A | Brigham and Women's Hospital | 20 mi |
| Virtue® SAB in the Treatment of Coronary ISR Trial | N/A | Orchestra BioMed, Inc | 20 mi |
| Optical Coherence Tomography of the Saphenous Vein Graft | N/A | St. Francis Hospital, New York | 20 mi |
| Testing the Feasibility of Computer-based Cognitive Training in Individuals with Multiple Sclerosis Living in the Community | N/A | Kessler Foundation | 20 mi |
| Meeting an Unmet Need in Multiple Sclerosis | N/A | Kessler Foundation | 20 mi |
| A Novel Combinatory Approach to Maximize Functional Recovery of Learning and Memory in Multiple Sclerosis | N/A | Kessler Foundation | 20 mi |
| Single-Fraction SBRT Versus Standard Palliative Radiation Therapy in Treating Patients With Metastatic Cancer | Phase 2 | Roswell Park Cancer Institute | 21 mi |
| A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC | Phase 3 | AstraZeneca | 21 mi |
| A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia | Phase 2 | Janssen Research & Development, LLC | 21 mi |
| Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies | — | Tempus AI | 21 mi |
| Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors | N/A | Novian Health Inc. | 21 mi |
| A Study of Enasidenib in People With T-Cell Lymphoma | Phase 2 | Memorial Sloan Kettering Cancer Center | 22 mi |
| Effects Of Osteopathic Manipulative Medicine(OMM) On Lower Extremity Muscle Characteristics In Parkinson's Disease(PD) Patients | N/A | New York Institute of Technology | 22 mi |
| Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy | Phase 2 | BioNTech SE | 22 mi |
| A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer | Phase 2 | Processa Pharmaceuticals | 22 mi |
| Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib | Phase 2 | Janssen Research & Development, LLC | 22 mi |
| A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma | Phase 3 | Regeneron Pharmaceuticals | 22 mi |
| AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma | Phase 1 | Carna Biosciences, Inc. | 22 mi |
| Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination With Anti-CD20 Monoclonal Antibody in Mature B-cell Malignancies | Phase 1 | InnoCare Pharma Inc. | 22 mi |
| A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions | Phase 3 | Takeda | 22 mi |
| A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) | Phase 3 | AstraZeneca | 22 mi |
| Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer | Phase 2 | BicycleTx Limited | 22 mi |
| A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC | Phase 3 | AstraZeneca | 22 mi |
| Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer | Phase 3 | Daiichi Sankyo | 22 mi |
| Neural and Psychiatric Consequences of Cannabis Use in Adolescents | N/A | University of Miami | 23 mi |
| The Effects of Daily Polyvagal Exercises on Stress in Students of Physical Therapy | N/A | Dominican University New York | 23 mi |
| A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma | Phase 2 | Pfizer | 25 mi |
| The Impact of CAR-T Cell Therapy on Fertility; A Patient Survey | — | Blood Cancer United | 25 mi |
| A Study Called FINE-REAL to Learn More About the Use of the Drug Finerenone in a Routine Medical Care Setting | — | Bayer | 25 mi |
| Study of LAM561 Acid in Pediatric Patients With Malignant Glioma and Other Advanced Solid Tumors | Phase 1/2 | Laminar Pharmaceuticals | 25 mi |
| Cardiac Rehabilitation of Stroke Survivors (SRP-CROSS) | N/A | Hackensack Meridian Health | 25 mi |
| The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With at Least Mild FMR | N/A | Cardiac Dimensions, Inc. | 25 mi |
| A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma | Phase 1/2 | Janssen Research & Development, LLC | 25 mi |
| Studies of Brain and Body Interaction | — | Rutgers University | 25 mi |
| Rutgers University Study of the Genetics of Pulmonary Hypertension | — | Rutgers, The State University of New Jersey | 25 mi |
| Personalizing Treatment Delivery | N/A | Rutgers, The State University of New Jersey | 25 mi |
| Rutgers University Study of the Genetics of Breast Cancer. | — | Rutgers, The State University of New Jersey | 25 mi |
| Endometrial Cell Collection With the PadKit | N/A | Hackensack Meridian Health | 26 mi |
| realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL | — | Incyte Corporation | 26 mi |
| A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | Regeneron Pharmaceuticals | 26 mi |
| A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005) | Phase 2 | Merck Sharp & Dohme LLC | 26 mi |
| Use of the CA 125 Algorithm for the Early Detection of Ovarian Cancer in Low Risk Women | N/A | M.D. Anderson Cancer Center | 26 mi |
| Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors | Phase 1/2 | Qurient Co., Ltd. | 26 mi |
| A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) | Phase 2/3 | Merck Sharp & Dohme LLC | 26 mi |
| L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML | Phase 2/3 | Moleculin Biotech, Inc. | 26 mi |
| A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer | Phase 1 | Astellas Pharma Global Development, Inc. | 26 mi |
| A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors) | Phase 1 | Boehringer Ingelheim | 26 mi |
| NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies | Phase 1/2 | Novita Pharmaceuticals, Inc. | 26 mi |
| Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors | Phase 2 | Tiago Biachi de Castria | 26 mi |
| Phase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors | Phase 1 | Vaxiion Therapeutics | 26 mi |
| Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma | Phase 2/3 | TuHURA Biosciences, Inc. | 26 mi |
| Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC) | Phase 2 | Stingray Therapeutics | 26 mi |
| Pancreatic Cancer Detection Consortium | — | City of Hope Medical Center | 26 mi |
| Pre-Emptive LAVA-ECMO for Complex High-Risk TAVR | — | Atlantic Health System | 26 mi |
| Assessing the Relationship Between Symptoms and Mitral Regurgitnant. Severity | — | Atlantic Health System | 26 mi |
| A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004) | Phase 3 | Merck Sharp & Dohme LLC | 26 mi |
| A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) | Phase 3 | Merck Sharp & Dohme LLC | 26 mi |
| A Primary Care-Based Psychosocial Intervention To Improve Cognitive & Depression Outcomes in Older Adults With MCI & Early Stage AD | N/A | Weill Medical College of Cornell University | 26 mi |
| Mind-Body Skills Group for Graduate Students | N/A | Weill Medical College of Cornell University | 26 mi |
| Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change | Phase 2 | National Cancer Institute (NCI) | 26 mi |
| BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS) | Phase 2 | SCRI Development Innovations, LLC | 26 mi |
| A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4) | Phase 3 | Mirati Therapeutics Inc. | 26 mi |
| Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer | Phase 3 | BioNTech SE | 26 mi |
| Observational Study Protocol: LIVER-R | — | AstraZeneca | 26 mi |
| A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer | Phase 3 | Pfizer | 27 mi |
| This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1. | Phase 3 | Pfizer | 27 mi |
| A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Phase 3 | Pfizer | 27 mi |
| Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC | Phase 1/2 | Xencor, Inc. | 27 mi |
| The Leukemia and Lymphoma Society (LLS) National Research Registry | — | Blood Cancer United | 27 mi |
| Clinical Utility of WATS3D: A 5-Year Prospective Study | — | CDx Diagnostics | 28 mi |
| CAMP RWE Trial: Amnion Grafts for Healing Hard-to-Heal Ulcers in RW Populations | N/A | Capsicure, LLC | 28 mi |
| Stronger Together Psoriatic Arthritis Wellness Study | — | Global Healthy Living Foundation | 28 mi |
| Study of JK07 in Patients With Chronic Heart Failure | Phase 2 | Salubris Biotherapeutics Inc | 28 mi |
| Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care | Phase 3 | GT Medical Technologies, Inc. | 28 mi |
| MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma | Phase 3 | AstraZeneca | 28 mi |
| A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes | Phase 3 | Eli Lilly and Company | 28 mi |
| Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart Failure | Phase 4 | Electrophysiology Research Foundation | 28 mi |
| Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL | Phase 2 | New York Medical College | 28 mi |
| Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma | Early 1 | New York Medical College | 28 mi |
| Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) | Phase 1/2 | Vironexis Biotherapeutics Inc. | 28 mi |
| EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection | Phase 2 | New York Medical College | 28 mi |
| A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors | Phase 1 | Sapience Therapeutics | 28 mi |
| A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy | Phase 2 | Spectrum Pharmaceuticals, Inc | 28 mi |
| AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion | Phase 2 | Mitchell Cairo | 28 mi |
| A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Phase 3 | Genmab | 28 mi |
| Artificial Intelligence Mapping and Ablation of Non-Pulmonary Vein Electrical Drivers of AF Study | N/A | Vektor Medical | 28 mi |
| Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis. | Phase 3 | AbbVie | 28 mi |
| A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab | Phase 3 | AbbVie | 28 mi |
| Defibrotide Dose-escalation for SOS Post-HSCT | Phase 2 | New York Medical College | 28 mi |
| Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma | Phase 3 | National Cancer Institute (NCI) | 28 mi |
| Behavioral Exposure for Introceptive Tolerance RCT | Phase 2 | Rutgers, The State University of New Jersey | 28 mi |
| A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma | Phase 1/2 | Vaishalee Kenkre | 28 mi |
| A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous Carcinoma | Phase 2 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | 28 mi |
| A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer | Phase 3 | Janssen Research & Development, LLC | 28 mi |
| A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) | Phase 3 | Merck Sharp & Dohme LLC | 28 mi |
| A Youth-led Intervention to Reduce Healthcare Disparities in Cancer Screening | N/A | Rutgers, The State University of New Jersey | 28 mi |
| Bright Ideas - CIN Feasibility Study | N/A | The Hospital for Sick Children | 28 mi |
| To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL | Phase 3 | Acrotech Biopharma Inc. | 28 mi |
| Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma | Phase 2 | Brown University | 28 mi |
| A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001) | Phase 1 | Merck Sharp & Dohme LLC | 28 mi |
| A Study Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer | Phase 3 | AbbVie | 28 mi |
| Effects of Latin Dancing on Sleep Quality in Hispanic Cancer Survivors | N/A | Rutgers, The State University of New Jersey | 28 mi |
| CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer. | Phase 2 | TORL Biotherapeutics, LLC | 28 mi |
| Addressing Genomic Disparities in Cancer Survivors | N/A | Rutgers, The State University of New Jersey | 28 mi |
| A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors | Phase 1 | Exelixis | 28 mi |
| MySmartSkin Online Skin Self-exam Intervention for Melanoma Survivors | N/A | Rutgers, The State University of New Jersey | 28 mi |
| Reducing Urban Cervical Cancer Disparities | N/A | Fox Chase Cancer Center | 28 mi |
| Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC) | Phase 2 | Nataliya Uboha | 28 mi |
| A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer | Phase 1/2 | Janssen Research & Development, LLC | 28 mi |
| Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A) | Phase 1/2 | Merck Sharp & Dohme LLC | 28 mi |
| A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors | Phase 1 | Genentech, Inc. | 28 mi |
| SynKIR-310 for Relapsed/Refractory B-NHL | Phase 1 | Verismo Therapeutics | 28 mi |
| Spine Oncology Registry | — | Ohio State University Comprehensive Cancer Center | 28 mi |
| E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers | Phase 1/2 | Christian Hinrichs | 28 mi |
| A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101) | Phase 1 | GlaxoSmithKline | 28 mi |
| Naltrexone and Propranolol Combined With Immunotherapy | Phase 1 | Sarah Weiss | 28 mi |
| A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With Cemiplimab or REGN5678 for Adult Participants With Advanced Prostate Cancer | Phase 1/2 | Regeneron Pharmaceuticals | 28 mi |
| A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS) | Phase 1 | PureTech | 28 mi |
| E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers | Phase 2 | Christian Hinrichs | 28 mi |
| Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma | Phase 2 | Juan P. Alderuccio, MD | 28 mi |
| Project CARE: CAncer Risk Evaluation | N/A | Anita Y. Kinney, PhD, RN | 28 mi |
| Mindfulness-based Ecological Momentary Intervention for Smoking Cessation Among Cancer Survivors | N/A | Rutgers, The State University of New Jersey | 28 mi |
| A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014) | Phase 2 | Merck Sharp & Dohme LLC | 28 mi |
| Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers | Phase 1 | National Cancer Institute (NCI) | 28 mi |
| A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma | Phase 3 | Hoffmann-La Roche | 28 mi |
| Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma | Phase 1/2 | Cellectis S.A. | 28 mi |
| Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies | Phase 1/2 | Georgiamune Inc | 28 mi |
| A Mobile Health Intervention Among Hispanics | N/A | Rutgers, The State University of New Jersey | 28 mi |
| A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma | Phase 1 | AstraZeneca | 28 mi |
| Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer | Phase 2 | Dustin Deming | 28 mi |
| Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes | N/A | Endogenex, Inc. | 28 mi |
| Extracellular Vesicles, Insulin Action, and Exercise | N/A | Rutgers, The State University of New Jersey | 28 mi |
| Exercise and Time of Day in Type 2 Diabetes | N/A | Rutgers, The State University of New Jersey | 28 mi |
| Bringing Advocacy Via Digital Guide to the Emergency Department (Project BADGE) | N/A | Rutgers, The State University of New Jersey | 28 mi |
| Diabetes Electronic Prompt for Improved Care Coordination and Treatment in the ED | N/A | Rutgers, The State University of New Jersey | 28 mi |
| Single vs Multi-Dose Insulin for Glycemic Control (SUGAR) | N/A | Rutgers, The State University of New Jersey | 28 mi |
| Enhancing Preventative Health Behaviors Among Emergency Department Hyperglycemic Patients | N/A | Rutgers, The State University of New Jersey | 28 mi |
| ALA-enriched Nutrition for Prevention of Cognitive Decline in APOE4 Older Adults | Phase 2 | Michal Schnaider Beeri, Ph.D. | 28 mi |
| Metabolic Health, Bones and Nuts During Weight Loss in Adults | N/A | Rutgers, The State University of New Jersey | 28 mi |
| DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting | — | Alnylam Pharmaceuticals | 28 mi |
| Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009) | Phase 1/2 | Merck Sharp & Dohme LLC | 28 mi |
| A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer | Phase 1/2 | Genentech, Inc. | 28 mi |
| Investigating the Metabolic Pathways in Hormone Receptor Positive/HER2 Negative Breast Cancer | N/A | Rutgers, The State University of New Jersey | 28 mi |
| Adaptive Radiation Planning for the Reduction of Radiation-Induced Toxicity in Patients With Stage II-IV Non-small Cell Lung Cancer | N/A | Rutgers, The State University of New Jersey | 28 mi |
| Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm | Phase 2 | Greg Durm, MD | 28 mi |
| TELESCOPE- TELEhealth Shared Decision-making COaching | N/A | Rutgers, The State University of New Jersey | 28 mi |
| KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors | Phase 1 | Kura Oncology, Inc. | 28 mi |
| KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer | Phase 1 | Christian Hinrichs | 28 mi |
| Cardiopulmonary Monitoring in Lung Cancer Patients Receiving Combined Thoracic Radiotherapy and Immunotherapy | — | Bo Lu | 28 mi |
| TELEhealth Shared Decision-making COaching for Lung Cancer Screening in Primary Care (TELESCOPE) for Hispanics | N/A | Rutgers, The State University of New Jersey | 28 mi |
| A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function | Phase 1 | Epizyme, Inc. | 28 mi |
| A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis | Phase 2 | MapLight Therapeutics | 29 mi |
| A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults | Phase 1 | UCB Biopharma SRL | 29 mi |
| A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period. | Phase 2 | Genentech, Inc. | 29 mi |
| Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination with XELOX or Irinotecan in Patients with Advanced Gastric Cancer | Phase 1/2 | Idience Co., Ltd. | 29 mi |
| Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) | Phase 2 | AstraZeneca | 29 mi |
| A Dose Escalation Study of AV-380 in Cancer Patients With Cachexia | Phase 1 | AVEO Pharmaceuticals, Inc. | 29 mi |
| To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer | Phase 2 | Hoffmann-La Roche | 29 mi |
| Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) | Phase 3 | Merck Sharp & Dohme LLC | 29 mi |
| Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations | Phase 1/2 | AbbVie | 29 mi |
| Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors | Phase 1/2 | MBrace Therapeutics | 29 mi |
| ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors | Phase 3 | OncoC4, Inc. | 29 mi |
| A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC | Phase 1 | EpiBiologics | 29 mi |
| A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer | Phase 2/3 | AbbVie | 29 mi |
| A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors | Phase 1 | BeiGene | 29 mi |
| The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study | Phase 3 | American Society of Clinical Oncology | 29 mi |
| Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer | Phase 3 | National Cancer Institute (NCI) | 29 mi |
| Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer | Phase 3 | ECOG-ACRIN Cancer Research Group | 29 mi |
| Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers | Phase 2 | SWOG Cancer Research Network | 29 mi |
| PRISM: Patient Experiences With PET Imaging in Prostate Cancer | — | Yale University | 29 mi |
| Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation | Phase 2 | SWOG Cancer Research Network | 29 mi |
| A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer | Phase 1/2 | Pfizer | 29 mi |
| A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. | Phase 3 | Pfizer | 29 mi |
| Dose-Deescalated 3-Fraction Stereotactic Body Radiotherapy For Centrally Located Lung Cancer | Phase 1/2 | Yale University | 29 mi |
| Rectal Spacers Use in Prostate Cancer Radiation Therapy | N/A | Princeton ProCure management, LLC. | 29 mi |
| A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee | Phase 3 | Eli Lilly and Company | 29 mi |
| Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS) | Phase 3 | Sanofi | 29 mi |
| A Study to Compare the Combination of BMS-986504 With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion | Phase 2/3 | Bristol-Myers Squibb | 29 mi |
| Liquid Biopsy Based NGS in Newly Diagnosed NSCLC | N/A | Charu Aggarwal | 30 mi |
| Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis | Phase 3 | Sun Pharmaceutical Industries Limited | 30 mi |
| PROton Therapy for Post Surgical Treatment of GYNecologic Cancer | Phase 2 | Abramson Cancer Center at Penn Medicine | 30 mi |
| The Radiation Oncology Registry and Biosample Repository | — | Abramson Cancer Center at Penn Medicine | 30 mi |
| A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer | Phase 3 | Janssen Research & Development, LLC | 30 mi |
| A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) | Phase 3 | Amgen | 30 mi |
| Evaluate Impact of Exercise Program on Fatigue in Breast Cancer During Chemotherapy | N/A | Virtua Health, Inc. | 30 mi |
| Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy | N/A | M.D. Anderson Cancer Center | 30 mi |
| Shortening Adjuvant Photon and Proton Irradiation (SAPPHIRe-II): A 4 Cohort, Randomized, Phase II Multi-center Trial Evaluating Shorter Schedules of Adjuvant Regional Nodal Irradiation Among Women and Men With Node-positive and High-risk Node-negative Invasive Breast Cancer | Phase 2 | M.D. Anderson Cancer Center | 30 mi |
| Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial) | Phase 2 | SWOG Cancer Research Network | 30 mi |
| Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations | Phase 3 | AstraZeneca | 30 mi |
| Video Telehealth Pulmonary Rehabilitation to Reduce Hospital Readmission in Chronic Obstructive Pulmonary Disease | N/A | University of Alabama at Birmingham | 33 mi |
| Clinical Utility of Management of Patients With Pulmonary Nodules Using the Percepta Nasal Swab Classifier | — | Veracyte, Inc. | 34 mi |
| Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations | Phase 3 | SWOG Cancer Research Network | 34 mi |
| Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes | Phase 3 | Kailera | 34 mi |
| Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes | Phase 3 | Kailera | 34 mi |
| Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type | Phase 3 | Suven Life Sciences Limited | 34 mi |
| STOP AF First Post-Approval Study | — | Medtronic Cardiac Ablation Solutions | 34 mi |
| Sustained Acoustic Medicine for Symptomatic Treatment of Knee Pain Related to Osteoarthritis | Phase 2 | ZetrOZ, Inc. | 34 mi |
| Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC | Phase 2 | Dana-Farber Cancer Institute | 34 mi |
| Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening | — | Freenome Holdings Inc. | 34 mi |
| A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007) | Phase 3 | Merck Sharp & Dohme LLC | 34 mi |
| A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer | Phase 1/2 | Hoffmann-La Roche | 34 mi |
| Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype | Phase 3 | Sanofi | 35 mi |
| A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD | Phase 2 | Verona Pharma plc | 35 mi |
| PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer | Phase 1 | City of Hope Medical Center | 35 mi |
| Persona Revision Knee System Outcomes | — | Zimmer Biomet | 37 mi |
| Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer | Phase 2/3 | Kartos Therapeutics, Inc. | 37 mi |
| Clinical Nurse Specialist Led Early Palliative Survivorship Care for Patients With Advanced Cancer | N/A | Good Samaritan Hospital Medical Center, New York | 37 mi |
| Molecular Genetics Studies of Cancer Patients and Their Relatives | — | City of Hope Medical Center | 37 mi |
| Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) | Phase 3 | Neurocrine Biosciences | 37 mi |
| A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease | Phase 2 | AstraZeneca | 37 mi |
| Evaluation of an Online Prostate Cancer Screening Decision Aid | N/A | David Siegel | 37 mi |
| External Trigeminal Nerve Stimulation for Migraine Treatment in Pregnancy | — | Cefaly Technology | 38 mi |
| AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 | Phase 2 | AstraZeneca | 38 mi |
| A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer | Phase 1/2 | AstraZeneca | 38 mi |
| A Phase 2a Multicenter Clinical Trial of TB006 in Participants With Parkinson's Disease | Phase 2 | TrueBinding, Inc. | 38 mi |
| Real-World Patient Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States: | — | Supernus Pharmaceuticals, Inc. | 38 mi |
| A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease | Phase 4 | Impax Laboratories, LLC | 38 mi |
| Caris Biorepository Research Protocol | — | Caris Science, Inc. | 40 mi |
| Foundational Programs to Combat Clinician Stress | N/A | Lancaster General Hospital | 41 mi |
| A Pilot Trial of "Just ASK™" to Increase Discussions About Breast Cancer Clinical Trials | N/A | University of Pennsylvania | 41 mi |
| Cryotherapy in Combination with Red Light PDT for Actinic Keratosis of Full Face | Phase 4 | Psoriasis Treatment Center of Central New Jersey | 42 mi |
| A Pancreatic Cancer Screening Study in Hereditary High Risk Individuals | — | Nuvance Health | 42 mi |
| The Role of MicroRNA in the Diagnosis, Prognosis and Response to Treatment in Pancreatic Cancer | — | Nuvance Health | 42 mi |
| Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation | Phase 3 | Amgen | 42 mi |
| A Pancreatic Cancer Screening Study in Individuals With New-Onset or Deteriorating Diabetes Mellitus | — | Nuvance Health | 42 mi |
| Study of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) | Phase 1 | ARTBIO Inc. | 43 mi |
| Practical Geriatric Assessment (PGA) Implementation Strategies and Correlative Evaluations (PACE-70) | — | Abramson Cancer Center at Penn Medicine | 43 mi |
| A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama) | Phase 3 | Definium Therapeutics US, Inc. | 43 mi |
| A Phase 1 Study of 68Ga-R11228 and 177Lu-R11228 in Breast Cancer | Phase 1 | Radionetics Oncology | 43 mi |
| A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208) | Phase 1/2 | Bristol-Myers Squibb | 43 mi |
| Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D) | Phase 2 | Sparrow Pharmaceuticals | 43 mi |
| Neurologic Stem Cell Treatment Study | N/A | MD Stem Cells | 45 mi |
| A Randomized Comparison of Personalized Therapy Mgmt Based On Coronary Atherosclerotic Plaque Vs. Usual Care for Symptomatic Patients With Suspicion of CAD | N/A | Cleerly, Inc. | 47 mi |
| International Weight Control Registry | — | Tufts University | 47 mi |
| Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck | Phase 3 | ECOG-ACRIN Cancer Research Group | 48 mi |
| A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM) | Phase 3 | GlaxoSmithKline | 48 mi |
| Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors | Phase 2 | AstraZeneca | 48 mi |
| Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT | Phase 3 | Priothera SAS | 48 mi |
| Atezolizumab and Pre-Surgical Brain Radiation Therapy for Glioblastoma Multiforme | Early 1 | Stony Brook University | 48 mi |
| Testing a Brief Motivational Intervention to Increase Physical Activity for Cancer Survivors | N/A | Stony Brook University | 48 mi |
| A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | Phase 2/3 | Karyopharm Therapeutics Inc | 48 mi |
| Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) | Phase 3 | Genelux Corporation | 48 mi |
| A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma | Phase 3 | Regeneron Pharmaceuticals | 48 mi |
| Raman Spectroscopy and Skin Cancer | — | Renee Farrell | 48 mi |
| A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma | Phase 2 | Regeneron Pharmaceuticals | 48 mi |
| Decision Aid and Thyroid Nodules Management | N/A | Stony Brook University | 48 mi |
| Acute Myeloid Leukemia and Markers of Leukemia Stem Cells (CLL1 and CD45RA) | — | Suhu Liu | 48 mi |
| PET Imaging Using the Tracer [18F]VAT to Assess the Antidepressant Effect of Nicotine. | Phase 4 | Stony Brook University | 48 mi |
| The Role of mGluR5 in CBT-I | Phase 4 | Stony Brook University | 48 mi |
| Combination of Novel Therapies for CKD Comorbid Depression | Phase 2 | Stony Brook University | 48 mi |
| The VENTOR Clinical Study | N/A | CoLabs Medical | 48 mi |
| Hydrogen Water Intervention With Heart Rate Variability as an Outcome Biomarker in ME/CFS | N/A | Stony Brook University | 48 mi |
| A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients | Phase 3 | Colorado Prevention Center | 48 mi |
| Randomized Placebo Controlled Study of Triamcinolone Acetonide Extended Release Injection for Thumb (CMC) Osteoarthritis | Phase 2 | Marie Badalamente | 48 mi |
| Impact of Art Therapy on Self-Reported Pain and Anxiety Scores of Patients Waiting to Be Seen in the Emergency Department | N/A | Stony Brook University | 48 mi |
| CtDNA Based MRD Testing for NAC Monitoring in TNBC | — | Personalis Inc. | 48 mi |
| Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer | Early 1 | Alison Stopeck | 48 mi |
| First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer | Phase 1 | OnKure, Inc. | 48 mi |
| A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases | Phase 2 | Biostar Pharma, Inc. | 48 mi |
| Definitive Radiation Therapy for Inoperable Breast Cancer | N/A | Alexander Stessin | 48 mi |
| Definitive Radiation for High-Risk Spine Metastases | Phase 2 | Stony Brook University | 48 mi |
| SBU-RESET: RElaxation, Stress Reduction and Epigenetics Trial in Cancer Survivors | N/A | Barbara Nemesure | 48 mi |
| Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | Phase 2/3 | AbbVie | 48 mi |
| Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V | Phase 2 | Novartis Pharmaceuticals | 50 mi |